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Abstract 
 
Dependence on heroin and other opioids represents a considerable problem worldwide.  
There is a continual need to improve therapy and/ or find more efficacious alternatives 
if these issues are to be addressed.  The most commonly implemented pharmacological 
therapy in treating said dependencies is methadone; however its success is the subject of 
ongoing debate. Certain plasma proteins including alpha1-acid glycoprotein (AGP) bind 
to drugs which causes inactivation and, if low enough, may prevent a therapeutic effect 
being attained.  The hepatic synthesis of AGP increases two- to five-fold during 
numerous physiological and pathophysiological conditions, becoming the most 
prevalent acute phase protein in the blood.  Additionally, the structure of the sugar 
chains (glycans) attached to the surface of underlying polypeptide backbones can differ, 
potentially altering the functions performed.   
 
AGP was isolated from blood samples obtained from patients undergoing various stages 
and types of opioid-replacement therapy and from heparinised blood samples provided 
by the Blood Transfusion Service. Structural analysis of the glycans was undertaken 
primarily through the use of high pH anion-exchange chromatography (HPAEC) and 
intrinsic fluorescence used as a measure of drug binding.  The composition of glycans 
attached to the polypeptide backbone of AGP isolated from patient samples was found 
to markedly differ from that of a ‘normal’ healthy population.  Levels of galactose and 
N-acetyl-glucosamine were amplified in all methadone treatment groups which 
suggested increased branching of glycans; this was supported by HPAEC analysis of 
complete glycan chains. Binding of methadone to all isolated AGP samples was 
elevated at the highest drug concentrations tested; however the degree of quenching 
appeared to be greater in patients.  
 
Therefore, the glycoforms expressed by AGP appear to be associated with the 
subsequent binding of the glycoprotein to methadone. It is possible that altered 
glycosylation could increase affinity for the drug, reducing its bioactive concentration to 
below that required to produce the pharmacological effect. Currently, the doses of 
methadone used in opioid replacement therapy are primarily influenced by the 
expression of physical symptoms, however this preliminary study has indicated that 
determination of the level and glycoform expression of AGP may offer potential use 
when determining the most effective therapy and dosage regimen.   
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Chapter 1 
Introduction 
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1.1 Glycosylation 
 
 
1.1.1 The emergence of Glycobiology 
 
Fundamentally, Glycobiology comprises the study of biological macromolecules, 
namely proteins and lipids, whose surfaces are covalently modified by the enzymatic 
addition of oligosaccharide chains (sugars with the empirical formula (CH2O)n).  
Commonly known as glycosylation, it occurs co- and/or post-translation in the 
endoplasmic reticulum (ER) and Golgi apparatus to produce specific glycoconjugate 
structures belonging to the glycoprotein and glycolipid families respectively.  It is a 
complex, ordered and energy consuming process that has become widely recognised as 
both functionally significant and responsible for providing huge structural diversity 
(Varki et al., 2009; Taylor and Drickamer, 2003).  The presence of oligosaccharide 
chains (known as glycans) had historically been given little credence in the study of 
these biomolecules, considered only as stores of residual energy or an embellishment of 
the macromolecule to which they were attached.  Removal of the glycans was thus 
commonplace during the study of glycoproteins, instead interest focussed on the 
analysis of the protein backbone alone.  
 
Technological developments have caused views regarding the importance of 
glycosylation to change and allowed the field of Glycobiology to grow – so named by 
Rademacher et al. in 1988.  It has now become widely accepted that glycans have 
crucial roles in determining the properties expressed by a glycoconjugate.  Through 
such research, numerous physiological and pathophysiological conditions in which 
glycan structure has huge functional significance have been identified (Varki, 1993). 
 
 
1.1.2  The importance of Glycosylation  
 
Glycosylation takes the form of variable sugar chain structures, the quantity of which is 
dependent on the availability of attachment sites.  Through interactions forged with the 
surfaces of proteins or lipids, glycans affect their stability, conformation and 
consequently the overall function.  These factors may explain why up to 70% of 
proteins are reportedly modified in this way (Wormald and Dwek, 1999). 
3 
 
The glycans expressed by a glycoprotein are determined by the specific enzyme clusters 
- particularly the glycosyltransferases – residing in a cell’s ER and Golgi, thus 
glycosylation is not directly regulated at the genetic level.  Glycosyltransferases catalyse 
the fusion of monomeric building blocks of the carbohydrate complexes 
(monosaccharides), arranging them in specific sequences which then associate with the 
remaining polypeptide fragment (Kobata, 1992; Sasisekharan and Myette, 2003).   
 
If transcription of genes encoding the specific glycosyltransferases involved in glycan 
synthesis is altered during certain physiological and pathophysiological conditions, 
variations in the structure and function of the glycoconjugate is likely to occur. When 
specific to the causative condition, these structural alterations can offer use as 
biomarkers, implemented in their diagnosis and management.  Studies have shown that 
aberrant glycosylation is expressed in various diseases but whether it is due to, or a 
cause of, the disease is unknown.  A recent example suggested that the expression of 
specific glycoforms (glycoproteins with an identical amino acid sequence but variations 
in the surface glycosylation) of α1-acid glycoprotein (AGP) is correlated with the 
inflammatory phases of leprosy (Gupta et al., 2010).  The glycoforms expressed by 
patients with ENL differed to those enduring other stages of the disease and a healthy 
population.   
 
There are a specific group of inherited disorders, known as the congenital disorders of 
glycosylation (CDGs), which arise when the biosynthetic and processing pathways 
involved in glycosylation are not performed correctly (Durand and Seta, 2000; Jaeken 
and Matthijs 2007).  In the absence of correct glycan expression various irregularities 
arise, particularly in neuronal development – reaffirming the importance of the 
structural modification.  Efficiency of infectious agents and cancer progression were 
shown by various groups to be dependent on the presence of glycosylated structures 
(Bertozzi and Kiessling, 2001; Dell and Morris, 2001).  Many pathogens, including 
E.coli and N. Meningitides, display ‘normal’ sugar chains on their surface allowing 
them to evade the immune response of infected hosts.  For example, the occurrence of 
polysialic acids resembling those in normal developing neuronal tissues prevent the 
destruction of these pathogens, allowing subsequent infection of eukaryotic cells (Sears 
and Wong, 1998).   
 
4 
 
The occurrence of a glycocalyx (a 60-100 angstrom extracellular structure) surrounding 
all cells signifies that glycans are likely to function as ligands for receptors; determining 
the intramolecular functions of a glycoconjugate - also promoting interactions with 
signalling molecules and cell-to-cell and cell-to-extracellular matrix communication. 
Intermolecular properties such as circulating half-life and immunogenicity are further 
examples of the influence of glycan expression (Varki, 1993).   
 
 
1.1.3 The components of Glycans 
 
Monosaccharides represent the monomeric units of glycans, comprising two groups - 
the aldoses and ketoses corresponding to the expression of an aldehyde or keto 
functional group which are composed of a carbon covalently linked to an oxygen atom 
by a double bond; situated at the end (-CH=O) or within (>C=O) a chain, respectively.  
Upon polymerisation of eight or fewer monosaccharides, oligosaccharides are formed 
but if more than eight are involved in the structure they are termed polysaccharides 
(Bertozzi and Rabuka, 2009).  Sub-classifications of monosaccharides focus upon the 
number of carbon atoms in the structure; the most common being six (hexose) as found 
in glucose (Glc), galactose (Gal) and mannose (Man).  Fucose (Fuc) is termed a 
deoxyhexose due to the absence of the hydroxyl group (-OH) on C6.  N-acetyl 
neuraminic acid (NeuAc), a nine carbon sugar present at the termini of glycan chains, 
belongs to the sialic acid family (Varki, 1992).  Additionally, the hexosamines form a 
group of monosaccharides expressing an amino group on the second carbon and often 
exist in an N-acetylated form in glycan chains, for example N-acetylglucosamine 
(GlcNAc) and N-acetylgalactosamine (GalNAc). 
 
Simple monosaccharide structural representations use the Fischer projection 
implementing linear structures.  However, these do not depict their existence in nature; 
instead they close into a cyclic hemiacetal ring to acquire increased stability.  The -OH 
of C5 and the aldehyde group (-CHO) of C1 react as demonstrated in figure 1.1a using 
Man.  A summary of the monosaccharides commonly found in glycans is shown in 
figure 1.1b; including Gal, Man, Fuc, GlcNAc and GalNAc which all adopt the chair 
conformation as illustrated for Man in figure 1.1a.  In this more stable conformation, C1 
becomes the anomeric carbon as it is a chiral centre – the –OH group joined to the 
anomeric C may sit below the plane of the ring (termed alpha, α) or above (beta, β).  
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The orientation of the -CHOH group located furthest from the functional -CHO can also 
exist in one of two configurations allowing them to be classed as either D-, which exists 
most commonly in nature, or the L- form.  The monosaccharides composing glycan 
chains are attached through the formation of glycosidic bonds between the -OH 
reducing group of C1 and any other -OH of an adjacent residue (either an α or β 
anomeric configuration, depending on the conformation of the -OH group on C1 of the 
donating monosaccharide).  Bond formation requires a condensation reaction; ergo a 
molecule of H2O is expelled as depicted in figure 1.2, and the resultant oligosaccharide 
chains may be homogenous or heterogeneous in structure, as determined by the 
constituent monosaccharides.   
 
The glycan structures may differ only slightly in sequence, length of chains, type of 
bond or number of chains that are attached, providing a wide diversity of structures 
(heterogeneity) from relatively few monosaccharide units.   Consideration of the ability 
of three amino acids to produce only six tripeptides while three hexoses are capable of 
generating thousands of trisaccharides (27,648), illustrates how the synthesis of long 
glycan chains significantly increases glycoconjugate structural diversity (Maeder, 
2002).  There is enhanced potential for the generation of variable structures as each 
sugar can display different anomeric configurations – α and β.  Additionally linkage 
position may differ thus leading to more complex structures. 
 
These glycan chains have functions both individually important but are also involved in 
determining the physical properties and physiological functions of the various structures 
of which they become a physical component.  Of particular interest to this study is the 
ability of oligosaccharides to covalently attach to proteins, producing glycoproteins, 
discussed in more detail in section 1.2.   
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Figure 1.1. Summary of common glycan monosaccharides.  a)  A demonstration, 
using Mannose, of the reaction which occurs between the -OH of carbon 5 and -CHO of 
carbon 1 (blue) to produce the stable ring conformation.  b) Monosaccharides common 
to glycoprotein oligosaccharide chains represented in their stable cyclic hemiacetal 
configuration.  The lack of an -OH group on C6 of fucose is highlighted – fucose is a 
deoxyhexose.  α and β configurations are represented by          and           respectively. 
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Figure 1.2. The glycosidic linkage. [Adapted from Ferrier and Collins, 1972].  
Two monomeric units have been used to demonstrate the formation of a β1,4 glycosidic 
linkage which leads to the formation of the disaccharide lactose (β-D-galactopyranosyl-
(1    4)-β-D-glucopyranose).  
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1.1.4  Glycoproteins 
 
Glycoproteins are unique biomolecules composed of one or more glycans covalently 
bound to a protein ‘backbone’ and often terminated by sialic acid (SA) residues.  The 
complicated synthesis and modification of glycans takes place co- and/ or post-
translation and is fundamental to the determination of the function and stabilisation of 
the underlying polypeptide.  Although it was thought to be specific to eukaryotes, 
glycosylation of proteins has been reported in eubacteria (Dobos et al., 1996) and 
archaea (Lechner and Wieland, 1989).  In fact those discovered in bacteria display much 
greater variation than those in eukaryotes, some directly affecting the function of the 
underlying protein and others crucial to interactions with the host immune system (Benz 
and Schmid, 2002).  
 
The reducing end of the oligosaccharide chain component becomes attached to the 
polypeptide either through N-linkages (via the amide nitrogen of specific asparagine 
residues) or O-linkages (via the -OH of serine/threonine).  N-glycans are prevalent in 
plasma proteins and do not contain glucose (Glc), while the latter predominate in 
glycoproteins of epithelial origin and may incorporate Glc as a chain constituent (Dell 
and Morris, 2001).   
 
Glycoprotein expression is dependent on the cell type to which the structures are 
integrated.  Certain genes encode information that, once transcribed and translated, 
produce the protein backbone, which is subsequently responsible for directing the sites 
of glycosylation (Freeze, 2001).  Glycoform expression promotes a high degree of 
heterogeneity, essentially a result of different cell types possessing a diverse array of 
enzymes thus catalysing a range of reactions and producing distinct glycans.  Variable 
structures therefore not only reflect the source cell or tissue but also the physiological 
and biochemical conditions present during synthesis (van Dijk et al., 1994).  
Heterogeneity can alter physical properties like stability and solubility thus affecting the 
conformation and ability to perform the typical function of the biomolecule including 
protein-protein or protein-saccharide recognition, intracellular trafficking of enzymes, 
cell-cell recognition, and inhibition of leukocyte rolling during the inflammatory 
response (Durand and Seta, 2000; Sears and Wong, 1998).  
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Glycans are widely distributed on the cell surface potentially linked through various 
combinations of N- and O-linkages, for example erythropoietin (EPO) and coagulation 
factor VIII.  Some glycoproteins however display only one type of linkage; α1-acid 
glycoprotein (AGP), α1-antitrypsin, interferon β, interferon γ, and tissue plasminogen 
activator (TPA) are solely N-linked, whilst Interleukin 2 and GCSF express O-linked 
only (Lis and Sharon, 1993; Durand and Seta, 2000).  The presence of a consensus 
sequence, Asn-X-Ser/Thr, in N-linked glycoproteins often allows predictions to be 
made as to which Asn residues of the protein will become glycosylated - only those 
situated in the sequence have this potential (Gavel and von Heijne, 1990).  Kornfeld and 
Kornfeld (1985) reported that approximately one third of Asn residues become N-
glycosylated, limited by specific requirements including a ‘sufficient pool of completely 
assembled and glycosylated lipid-linked oligosaccharide donor, an adequate activity of 
oligosaccharyltransferase, and a properly oriented and accessible Asn-X-Ser/Thr 
sequence in the acceptor’.  O-linked glycan synthesis is far simpler - numerous core 
structures can be generated, increasing glycan diversity thus making them more difficult 
to characterise than N-linked which share a core structure, GlcNAc2Man3.   
 
Most serum proteins express glycans on their surface, particularly secretory proteins 
and those incorporated into the plasma membrane.  Glycosylation ensures maturation of 
the underlying protein is correct; if absent, the function of the biomolecule may be 
changed or possibly lost.  Some proteins like albumin do not require glycosylation to 
bestow functionality (Sabatini et al., 1982). An example where incomplete 
glycosylation prevents the glycoprotein achieving optimal bioactivity is when 
erythropoietin (EPO), released from the kidney to regulate red blood cell (RBC) 
production, has reduced sialic acid (SA) content - under these circumstances it is rapidly 
cleared by the liver. Ordinarily sialylation prevents elimination, promoting its 
effectiveness in treating anaemia.  For optimal solubility, biosynthesis and circulating 
half-life, EPO must express one O-linked glycosylation site at position 126 and three N-
linked at 24, 38 and 83 (Macdougall and Eckardt, 2006; Paulson and Colley, 1989).  
Van Dijk and colleagues (1994) reported reduced sialylation of certain glycoproteins 
can also arise in rheumatoid arthritis (RA). 
 
Despite their association with disease, the potential for glycoproteins in therapeutics has 
intensified with research.  It has lead to the production of recombinant forms of EPO 
used to treat anaemia and tPA (tissue plasminogen activator - a serine protease 
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inhibitor), which induces fibrinolysis through the conversion of plasminogen to plasmin 
(Williams et al., 1986; Adamson and Eschbach, 1989).  More recently, the potential of 
recombinant glycoproteins in the treatment of Herpes Simplex Virus 2 and 
inflammatory bowel disease (IBD) has been indicated (Hoshino et al., 2005 and Li et 
al., 2009 respectively). 
 
Understanding the pathways involved in the synthesis and modification of N-linked 
glycans, as discussed below, is of paramount importance when studying the 
physiological and pathological states during which these are known to be altered.  
Analysing the levels of glycoproteins has shown use clinically, often correlating with 
numerous physiological and pathophysiological conditions alongside fluctuations in the 
level of inflammatory cells (Fournier et al., 2000).  However, studying the glycan 
structures could offer more accurate and condition-specific markers, important when 
early treatment and monitoring is crucial in tackling diseases. 
 
 
1.1.4.1 N-linked Glycan biosynthesis 
 
N-glycosylation relies on a complex enzyme catalysed synthetic- (within the cytosol 
and ER), and processing- (in the ER and Golgi) pathway. Initially component 
monosaccharides are converted into activated high-energy sugar nucleotides e.g. UDP-
GlcNAc and GDP-Man, and are subsequently transferred to a membrane-bound lipid 
dolichylphosphate (Dol-P), on the cytosolic side of the ER to form Man5GlcNAc2-Dol-
P. GlcNAc-1-phosphotransferase, GlcNAc-transferase and mannosyltransferases are 
required to catalyse the transfer from their donor sugar nucleotide, to the Dol-P.  The 
structure then translocates through the activity of a flippase to the lumenal side of ER.  
A further seven monosaccharides are donated, binding together via glycosidic bonds to 
produce the fourteen residue Glc3Man9(GlcNAc)2 oligosaccharide precursor.   
 
Dennis et al. (1999) effectively summarised N-glycan biosynthesis in four distinct 
phases occurring after the formation of this precursor and associated with different 
compartments of the secretory pathway.  First, transfer of the oligosaccharide precursor 
from a dol-P donor to nascent glycoproteins occurs in the RER lumen; requiring a 
multimeric oligosaccharyltransferase complex (OST; Imperiali and O’Connor, 1999).  
Glycosidases then trim the structure while being transported in the RER and Golgi.  
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Substitution occurs in the medial-Golgi by GlcNAc-transferases and finally elongation 
takes place in the trans-Golgi network.  These stages are encapsulated in figure 1.3.   
 
As illustrated in figure 1.4, N-glycosylation of the Asn amide group requires formation 
of β-turns or loops in the secondary structure of the polypeptide; hydrogen-bonds form 
between the amide (-NH2) group of Asn and the hydroxyl (-OH) group of Ser/Thr 
(Smith et al, 1997).  The amino acid proline (Pro) lacks an α-amide proton; preventing 
the formation of loops/turns thus it is never present in the consensus sequence (Bause, 
1983). A bond is formed between the anomeric -OH group of the terminal 
monosaccharide (GlcNAc) and the -NH group of Asn.  Yet and Wold (1990) reported 
that interactions can occur between N-linked oligosaccharides and aromatic, un-charged, 
amino acid (AA) side chains within the three AAs on either side of the glycosylated Asn.  
The addition of N-glycans bestows protection, stability and solubility to the underlying 
protein.  The glycan structures which are newly attached to Asn can then be processed 
through the competitive action of glycosidases such as glucosidases and mannosidases, 
and glycosyltransferases like galactosyltransferases during passage through the ER and 
Golgi compartments. It is the competition between enzymes for substrates that 
facilitates the expression of increased microheterogeneity; catalysing numerous 
different sets of reactions (Guile et al., 1996; Couldrey and Green, 2000).   
 
Several regulatory steps are in place to prevent the synthesis of incorrect glycoproteins; 
upon trimming of two Glc by α1,2-glucosidase I and α1,3-glucosidase II in the ER, the 
nascent glycoproteins enter the calnexin/calreticulin cycle which ensures only correctly 
folded proteins continue in the pathway. If folding is incorrect, a luminal 
glycosyltransferase adds a Glc residue onto the unfolded/misfolded molecule forcing it 
re-enter the calnexin/calreticulin cycle where it remains until correctly folded and the 
remaining Glc is removed by glucosidase II (Sousa et al., 1992; Deprez et al., 2005).   
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Figure 1.3. The glycosylation pathway of N-linked glycoproteins. [Adapted from 
Rich and Withers (2008) and Varki et al. (2009)].  A summary of the synthetic and 
processing pathways catalysed by enzymes residing in the ER and Golgi; these differ 
depending on the type of N-linked glycans expressed.            
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Figure 1.4. Linkage formation between Asn and the first GlcNAc of the glycan 
pentasaccharide core. [Adapted from Metzler, 2001].   OST catalyses the formation of 
a bond between the side-chain –NH2 group of Asn and the C-1 of the first core GlcNAc 
residue.  The hydrogen bonds formed with the Ser/Thr residue when transfer takes place 
from dolichol to protein are important in forming a loop.  It helps polarise the –NH2 
group of the Asn side chain, making an electrophilic centre as shown in step 1 that can 
participate in a displacement reaction.  
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1.1.4.2 High Mannose, Complex and Hybrid N-linked glycoproteins. 
 
Despite N-linked glycans sharing a common pentasaccharide core (Man3GlcNAc2), the 
overall structures can vary widely - primarily differing by the sequence and quantity of 
monosaccharides of which they are composed (Albani and Plancke, 1999).  Enzymes 
residing in the ER and Golgi trim and process the glycan precursor determining whether 
it will be of high Man, complex or hybrid form.  These structures are illustrated in 
figure 1.5.   
 
Between two and six Man residues may connect to the pentasaccharide core, producing 
the common heptasaccharide core of high Man structures: 
        Man α1    6(Manα1   3)Man α1    6(Man α1   3)Manβ1    4GlcNAcβ1    4GlcNAc 
Only Man is present in the chains of these structures, up to four can bind the Man 
residues at the non-reducing terminal (Kobata, 1992; Imperiali and O’Connor, 1999).  A 
common substitution of these glycans is the addition of one or more phosphate groups 
to the outer Man residue, producing mannose-6-phosphate in lysosomal hydrolases.  It 
can then bind to the Man-6-phosphate receptor (Smith et al., 1997). 
 
For the biosynthesis of complex N-linked glycans more processing is required because, 
although the only Man residues they contain belong to the trimannosyl core, they 
ordinarily express a greater variety of monosaccharides and linkages. The outer 
GlcNAc, Gal, Fuc and SA residues typical of such structures become attached to a 
GlcNAc residue at the reducing end, which in turn binds to the core α-Man residues.  It 
is also possible that a Fuc residue may become linked to the innermost GlcNAc residue, 
further increasing the potential structural variation (Kobata, 1992).  Complex glycan 
structures typically express 4-6 GlcNAc residues and 5-7 neutral sugars while high Man 
may only have 2 GlcNAc but approximately 5-9 Man (Fan et al., 1994).  The complex 
group can be subdivided based on the number of branches present i.e. bi-, tri-, tetra-, 
and penta-antennary chains (figure 1.6).  Neu5Ac - a SA residue - commonly terminates 
these glycan branches allowing them to circulate in the blood (Morell et al., 1971); in 
their absence, the molecules may be targeted by the liver. 
 
When oligosaccharides exhibit features of both high Man and complex type glycans, 
they are categorised as hybrids.  Man residues can join to GlcNAc and core outer Man 
residues; comparable to those observed in the high Man structures.  In similarity to 
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complex glycans, a Fuc residue may bind to the innermost GlcNAc residue (Kobata, 
2000; Durand and Seta, 2000).  Therefore, although they exhibit characteristics of high 
Man glycans with a Man α1,6 branch, they are also similar to complex-type glycans 
with a Man α1,3 branch composed of Gal and further GlcNAc residues. 
 
An important example of a naturally occurring N-linked plasma glycoprotein is α1 – 
acid glycoprotein (AGP, or orosomucoid), secreted by liver parenchymal cells.  It solely 
expresses complex N-linked glycans and although its specific biological role/function 
has yet to be clearly defined it is known to bind steroids, catecholamines and certain 
drugs: transporting them through the plasma.  AGP can also be considered a natural 
anti-inflammatory and immunomodulatory agent, the concentration and/or ‘normal’ 
glycosylation of which may change under various physiological and pathophysiological 
conditions.  During the acute phase response (APR), stimulated during many of these 
conditions, the production of AGP is increased, possibly limiting the activity of certain 
drugs to which it binds (Kremer et al., 1988; Israili and Dayton, 2001). 
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Figure 1.5. The structure of the three types of N-linked glycan. [Adapted from 
Varki et al., 2009]. All share the same pentasaccharide core structure with different 
appendages. 
GlcNAc   Man  Gal          NeuAc 
  
 
  
Asn Asn Asn 
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a) bi-antennary 
 
 
 
               (NeuAcα2,6)Galβ1,4GlcNAcβ1,2Man 
                       α1,2 
                         Manβ1,4GlcNAcβ1,4GlcNAcβ1Asn 
                       α1,3 
               (NeuAcα2,6)Galβ1,4GlcNAcβ1,2Man 
 
 
 
b) tri-antennary 
 
 
               (NeuAcα2,6)Galβ1,4GlcNAcβ1,2Man 
                       α1,2 
                         Manβ1,4GlcNAcβ1,4GlcNAcβ1Asn 
                       α1,3 
               (NeuAcα2,6)Galβ1,4GlcNAcβ1,2Man 
                         β1,4 
               (NeuAcα2,3)Galβ1,4GlcNAc 
                           α1,3 
                         Fuc 
 
 
 
c) tetra-antennary  
 
 
                          Fuc 
                           α1,3 
               (NeuAcα2,3)Galβ1,4GlcNAc 
                             β1,6 
               (NeuAcα2,6)Galβ1,4GlcNAcβ1,2Man 
                       α1,2 
                         Manβ1,4GlcNAcβ1,4GlcNAcβ1Asn 
                       α1,3 
               (NeuAcα2,6)Galβ1,4GlcNAcβ1,2Man 
                         β1,4 
               (NeuAcα2,3)Galβ1,4GlcNAc 
                           α1,3 
                         Fuc 
 
 
 
Figure 1.6. Examples of the branching in complex and hybrid glycans.  [Adapted 
from Hashimoto, 2004].  Different degrees of branching are exemplified with a constant 
core structure and linkages represented in green.  
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1.2  APR: Acute phase response  
 
 
Initiation of the APR (summarised in figure 1.7) occurs upon systemic tissue injury, 
acute and chronic inflammation, and viral or bacterial infection as part of the body’s 
defence system, attempting to regain homeostasis (Kushner and Rzewnicki, 1994).  
Inflammation at the site of injury results from a local immune response.  Cytokine and 
glucocorticoid hormone release - primarily by tissue macrophages (and to a lesser 
degree T-lymphocytes, platelets, fibroblasts and polymorphonuclear leukocytes) - can 
cause a systemic immune response to follow, thereby affecting many organs.  They 
induce the APR, disturbing the vascular system and altering the breakdown of various 
muscle proteins and lipids.  Changes occur to the concentrations of specific plasma 
proteins including α1-acid glycoprotein and albumin (Brinkmann-van der Linden et al., 
1998; Menkes, 1993), collectively known as acute phase proteins (APPs); the majority 
of which are glycoproteins (Ebersole and Cappelli, 2000).  The APR is an extremely 
important but short-lived process, initiated minutes after the stimulus it lasts up to two 
days and is responsible for minimising damage to surrounding tissue and destroying 
foreign molecules.  Anti-inflammatory cytokines are released with subsidence of the 
APR; IL-10 inhibits synthesis of the proinflammatory cytokines interleukin-1α (IL-1α), 
tumour necrosis factor α (TNF-α) and interleukin-6α (IL-6α), representing a natural 
feedback loop alongside the glucocorticoids.  Resolution of the APR involves the 
restoration of membrane integrity, diuresis of excess fluid and a decrease in the 
catabolism of endogenous protein stores (Koj, 1998; Crestani et al., 1998).   
 
The APR reprioritises the hepatic synthesis of export proteins like albumin for an up-
regulation of acute phase reactants like α1-acid glycoprotein; a process thought to be 
primarily under the control of IL-6 activity on hepatocytes which induces acute phase 
protein transcription (Morrone et al., 1988).  The concentration can increase from 2 fold 
- as reported by Voulgari et al. (1982) after surgery, during infections and breast, lung 
and ovarian cancers - to several hundred fold (Johnson and Smith, 2006; Ebersole and 
Cappelli, 2000).  An increase has also been observed in arteriosclerosis and type 1 
diabetes (Gomes et al., 2003).  Fibroblasts and endothelial cells are recruited, further 
increasing the level of cytokines produced - fevers, leukocytosis and increased hormone 
production can also arise (Hochepied et al., 2000).   
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Figure 1.7. Summary of the APR. [Adapted from Koj, 1996]. 
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AGP is a constitutively expressed positive APP i.e. hepatic synthesis is increased during 
the APR, potentially amplifying its concentration by over 25% (Ceciliani and Pocacqua, 
2007).  It has been suggested that a marked increase in AGP concentration may limit 
adverse reactions such as inflammation by providing a form of negative feedback 
(Crestani et al., 1998).  Negative APPs include albumin, α-fetoprotein and transferrin 
whose concentrations are correlated with a diminished hepatic synthesis during the 
APR.  APPs can be grouped by the extent of up-regulation as illustrated in table 1.1. 
Alternatively it has been shown APPs can be separated into two major classes based on 
their response to cytokines. Type I - including AGP and serum amyloid A - are 
regulated by IL-1, IL-6 and glucocorticoids like dexamethasone.  Type II are regulated 
by IL-6-type cytokines, for example the three chains of fibrinogen (Ebersole and 
Cappelli, 2000).  
 
There have been studies indicating that extra-hepatic expression of APPs, although 
generally infrequent and less well understood than hepatic expression, can occur from 
human breast epithelial cells, endothelial cells and lymphocytes including the 
monocytes and granulocytes (Gendler et al., 1982; Adam et al., 2003).  When increased 
production of AGP and other plasma proteins occur, drugs possessing a high affinity for 
them become increasingly bound and inactivated.  Consequently, the plasma level of 
bioactive (unbound) drug available to the target site of action or receptor is reduced, 
alongside its efficacy (Kremer et al., 1988).  The fact that changes in APP concentration 
affect many aspects of health and subsequent treatment is therefore hardly surprising.   
 
Expression of these proteins can be greatly increased in response to numerous factors 
therefore limiting their use as markers of specific diseases.  However, additional 
specific alterations in glycan structure during the APR to tissue injury and inflammation 
can occur. In fact some studies have correlated microheterogeneity with particular 
diseases, therefore offering potential use as biochemical markers.  Minor micro-
heterogeneity for example was shown by De Graaf and colleagues (1993) to be altered 
during acute and chronic inflammation when there is an increase in α1-3 fucosylation of 
AGP; sialylation was also reported to decrease (Moule et al., 1987).  Additionally, 
Adam et al. (2003) reported glycosylation patterns might be useful when determining 
the stage of a patient’s multiple sclerosis (MS); however - despite its sensitivity - they 
were sceptical of its specificity.  The degree of branching (major microheterogeneity) 
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has often been reported to alter during pathological conditions; in RA for example a 
decrease has been detected (Pawlowski et al., 1989). 
 
AGP is one of the APPs which can undergo extensive post-translational modification.  
It is involved in the regulation of inflammation; perhaps through the acquisition of SLe
x
 
containing glycans which help AGP bind to leukocyte and endothelial cell (ETC) 
selectins, suppressing inflammation by preventing the movement of leukocytes, keeping 
the inflammatory response localised (De Graaf et al., 1993). 
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Protein name Class of 
APP 
Sub-class  Function 
 
Ceruloplasmin 
 
 
 
 
 
 
 
 
 
 
Positive 
 
 
I 
(Concentration increases 
by approx. 50%) 
Copper transport 
protein 
 
Complement C3 and 
C4 
 
 
Opsonin 
 
α1-acid glycoprotein 
 
 
 
 
II 
(2-5 fold increase) 
Immunomodulation, 
transport 
 
α1-antitrypsin 
 
 
Antiprotease 
 
Fibrinogen 
 
 
Coagulation 
 
C-reactive protein 
 
 
III 
(up to 1000-fold increase 
in concentration) 
Opsonin, 
immunomodulation 
 
Serum amyloid A 
Leukocyte activation, 
chemotaxis, 
phagocytosis 
 
Albumin 
 
 
 
Negative 
 
- 
 
Transport 
 
Transferrin 
 
 
- 
 
Transport 
 
 
Table 1.1. Classification of acute phase proteins.  Based on information from 
Ceciliani et al. (2002) and Ceciliani and Pocacqua (2007). 
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1.3     α1 -Acid-Glycoprotein (AGP) 
 
 
In 1882, AGP was first identified as a ‘reddish-brown residue that remained in solution’ 
(Chiu et al., 1977) but the protein was not isolated or characterised until 1950 by the 
Weimer and Schmid groups.  It is a constitutively produced glycoprotein, hepatically 
synthesised in parenchymal cells at a rate of 10mg/kg/day with a plasma concentration 
of approximately 0.3-1.46gL
-1 
in healthy young adult humans (Blain et al., 1985; 
Ceciliani and Pocacqua, 2007).  Like other APPs, its mRNA expression is influenced by 
cytokines and steroid hormones.  Levels of AGP, as discussed in the previous section, 
can increase 2- to 5-fold as a result of the APR to pathological and physiological 
stimuli.  Concentrations have been reported to increase during myocardial infarctions 
and stress (Duché, 2000).  It is known that various factors act to influence AGP 
glycosylation including the inflammatory state (Van Dijk et al., 1998), pregnancy 
(Havenaar et al., 1998), drug or glucocorticoid use (Pos et al., 1988), and oral 
contraceptive use (Brinkman-van der Linden et al., 1996).  
 
Being a secondary APP, AGP should reduce the harmful systemic effects induced 
during the initial stages of acute inflammation (Van den Heuvel, 2000).  Its ability to 
inhibit the complement cascade is reliant on the microheterogeneity of its glycans which 
in turn is dependent on the expression of (patho)physiological conditions.  
Microheterogeneity is described as either major, reflecting changes in the number of 
branches on N–linked glycans, or minor which occurs through variation in the SA or 
Fuc content (Kalmovarin et al., 1991). 
 
Transcription of AGP encoding genes can be both endogenous and exogenous.  
Although extra-hepatic expression has been reported, they are most commonly 
hepatically expressed (Adam et al., 2003).  In vivo, the human liver synthesises AGP 
from the information encoded by 3 adjacent genes, namely AGP-A, B and B', which 
form a cluster of 70kb on chromosome 9 (Lögdberg and Wester, 2000).  All three genes 
exhibit six exons and five introns but code for different variants.  The hepatic 
expression of the genes is regulated both transcriptionally and posttranscriptionally 
through the activities of inflammatory cytokines including glucocorticoids, Il-1β, TNF-
α and Il-6 (Chang et al., 1998).  Native (commercial) AGP is reported to consist of more 
AGP-A encoded material than AGP-B/B' but unlike the former gene, AGP-B/B' only 
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encodes a single variant (Eap et al., 1988a).  A study by Van Dijk (1991) found both 
gene products increased during inflammation in burn patients but the contribution made 
by the AGP-A gene was greater.   
  
AGP-A codes for the predominantly monomorphic ORM-1 variant (ORM1 F1 and 
ORM1 S) and the identical AGP-B and AGP-B' genes encode a single ORM-2 variant 
(ORM2 A).  They differ from AGP-A by a 22 base substitution and are expressed 
around 100 times less.  Dente and colleagues (1985) identified the two genes using 
southern blotting showing they were present in normal serum in a ratio of 3:1 
respectively.   AGP-B and B' produce low levels of bi-antennary glycans while AGP-A 
primarily gives rise to tri-/tetra-antennary glycans (Dente et al., 1987; Tomei et al., 
1989; Duché et al., 2000).  Normal pooled serum can contain ORM1 F1, ORM1 S and 
ORM2 A variants; according to Eap and colleagues (1988a) the three main human AGP 
phenotypes depend on whether two or three of the variants are expressed in plasma, 
namely F1S/A (50%), F1/A (35%) and S/A (15%).  
 
 
1.3.1  Structure of AGP 
 
AGP has a chemical nature identical to many serum components which also interact 
with hormones like progesterone, producing dissociable complexes (Albani, 1997).  It 
has a molecular weight between 38.8kDa-48kDa (Israeli and Dayton, 2001); the value 
reported is likely to depend primarily on the method of isolation used.  Unusually, it is 
soluble in both water and polar organic solvents (Fournier et al., 2000).  AGP belongs 
to the subfamily of immunocalins - binding proteins with immunomodulatory functions 
but can also be classed as a mucoprotein, seroglobulin and α-1-globulin (Kremer et al., 
1988).  In 1973, Schmid and colleagues were the first to identify the structure of AGP, 
however they had believed there to be only 181 amino acids constituting the peptide 
backbone.  This was refuted in 1985 when it became widely accepted that an extra Lys 
and Arg resided at positions 173 and 174 respectively, producing a 183 amino acid 
backbone (Dente et al., 1985).  The 22 sites for possible amino acid substitution which 
present the differences between AGP-A and AGP B/B', may lie within the glycosylation 
sites (positions 15, 75 and 85) but whether it causes altered glycosylation of the gene 
products is unknown (Van Dijk, 1991).  The sequence of amino acids is illustrated in 
figure 1.8.  Using homology modelling, Hazai et al., (2006) found that serine (Ser) is 
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located at position 77 and glutamate (Glu) at 92 in ORM2 but not in ORM1.  Also, at 
positions 98 and 115, ORM1 has phenylalanine (Phe) and aspartate (Asp) respectively 
but ORM2 expresses valine (Val) and tyrosine (Tyr). 
   
The human AGP precursor consists of 201 residues; the first 18 residues become 
cleaved during protein processing (Ceciliani and Pocacqua, 2007).  Its protein portion 
constitutes 23kDa of the mass and approximately 59% of the structure (Albani et al., 
2000; Liao et al., 1985).  Polymorphisms can arise; at positions 32 and 47, various 
amino acids can be expressed and substitutions can occur at residues 21 and 181.  
Despite the potential for polymorphisms, the structure of AGP still shows an 80% 
homology with immunoglobulin G (Kremer et al., 1988).  
 
Proportionally, the different secondary structures including α-helix, β-sheet, reverse β-
turns, and unordered structures account for 15%, 41%, 12%, 8% and 24% of the AGP 
molecule respectively – as reported by Kopecký and colleagues (2003) upon analysis by 
infrared and Raman spectroscopy.  The large proportion of β-sheet in the structure is 
common to proteins exhibiting the transport-trafficking function - lipocalins.  These 
molecules consist of a single eight-stranded antiparallel β-sheet closed back on itself to 
form a continuously hydrogen-bonded β-barrel (Flower, 1996).   
 
Four of the five AGP glycan chains are linked to Asn residues within reverse β-turns or 
in regions where charged and polar residues are numerous (Kremer et al., 1988; 
Ceciliani and Pocacqua, 2007); the glycosylation process may force the nascent peptide 
to twist from an Asn turn to a β-turn.  This has been supported by nuclear magnetic 
resonance (NMR) analysis (O’Connor and Imperiali, 1997).  As previously described 
(section 1.1.3.1), proline cannot form part of the consensus sequence Asn-X-Ser(Thr) as 
it prevents the formation of a β-turn which is required for the glycan attachment.  
 
Studies have shown that certain amino acids show particular preferences regarding their 
locations in the folded structure.  There are three tryptophan (Trp) residues; Trp 25 is 
buried in the hydrophobic binding site while the others are closer to the surface; Trp 160 
is exposed and Trp 122 lies between the hydrophobic binding site and the surface 
(figure 1.8).  The closer the Trp residues are to the surface, the more they can rotate 
(Friedman et al., 1985).  Additionally, nearly all the Phe and 5-7 Tyr are completely or 
partially buried in the native state.   
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Glu – Ile – Pro – Leu – Cys – Ala – Asn – Leu – Val – Pro – Val – Pro – Ile – Thr – 
Asn – Ala – Thr – Leu – Asp – Gln/Arg – Ile – Thr – Gly – Lys – Trp – Phe – Tyr – Ile 
– Ala – Aer – Ala – Phe/Ala – Arg – Asn – Glu – Glu – Try – Asn – Lys – Ser – Val – 
Gln – Glu – Ile – Gln – Ala – Thr/Ala – Phe – Phe – Try – Phe – Thr – Pro – Asn – Lys 
– Thr – Glu – Asp – Thr – Ile – Phe – Leu – Arg – Glu – Tyr – Gln – Thr – Arg – Gln- 
Asp/Asn – Gln – Cys – Ile/Phe – Try – Asn – Thr/Ser – Tyr – Leu – Asn- Val – Gln – 
Arg – Glu – Asn – Gly – Thr – Ile/Val – Ser – Arg – Tyr – Val/Glu – Gly – Gly – 
Gln/Arg – Glu – His – Phe/Val – Ala – His – Leu – Leu – Ile – Leu – Arg – Asp – Thr – 
Lys – Thr – Tyr/Leu – Met – Leu/Phe – Ala/Gly – Phe/Ser – Asp/Tyr – Val/Leu – 
Asn/Asp – Asp – Glu – Lys – Asn – Trp – Gly – Leu – Ser – Val/Phe – Tyr – Ala – 
Asp – Lys – Pro – Glu – Thr – Lys – Glu – Gln – Leu – Gly – Phe – Tyr – Glu – Ala – 
Leu – Asp – Cys – Leu – Arg/Cys – Ile – Pro – Lys/Arg – Ser – Asp – Val – Val/Met – 
Tyr – Thr – Asp – Trp – Lys – Lys – Asp – Lys – Cys – Glu – Pro – Leu – Glu – Lys – 
Gln – His – Glu – Lys – Glu – Arg – Lys – Gln – Glu – Glu – Gly – Ser – COOH                         
 
 
Figure 1.8. The amino acid sequence of AGP. [reproduced from Dente et al., 1985] 
The five Asn sites to which glycans attach are labelled in green and the amino acid 
residues where substitution occurs are purple.  Trp 25 (red) indicates the residue buried 
in the hydrophobic pocket, Trp 160 (orange) is exposed and Trp 122 (blue) resides 
between the surface and pocket. 
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Glycan chains account for the remaining 41-45% of the molecule.  Despite such an 
abnormally high content, galactoglycoprotein (identified in 1980 by Schmid and 
colleagues) supersedes it with 76%.  There are five variable, highly sialylated 
heteropolysaccharide complex-type glycans Asn-linked at residues 15, 38, 54, 75, and 
85 - normally becoming bound in the first half of the polypeptide (Israeli and Dayton, 
2001; Eap and Baumann, 1993).  The presence of acidic amino acids and the -COOH 
group at C1 of SA (a common terminating sugar α2-3 or α2-6 linked to Gal; also called 
neuraminic acid-NeuAc) gives rise to the negative charge and the very low pI of 2.8-3.8 
(Hochepied et al., 2003; Elg et al., 1997).  There can be up to 16 SAs, which account 
for approximately 11-12% of the structure and each is reported to have a molecular 
weight of 314Da.  If the glycoprotein is desialylated, the molecule is rendered inactive.  
The structures are also constructed from 14% neutral hexoses [Gal, Man and GlcN (a 
hexosamine)] and 1% Fuc (Albani, 2003; Kremer et al., 1988; Dente et al., 1987).  As 
discussed in section 1.3, there is a region of commonality between N-linked glycans like 
those of AGP, namely the pentasaccharide core.   
 
Fuc is a terminating sugar which can link to GlcNAc (α1-3) on the external branch.  It 
can also be linked through an α1-6 bond to a core GlcNAc and α1-2 to Gal (Fournier et 
al., 2000).  It is therefore not surprising that the degree of fucosylation can vary between 
individuals, generally greater in structures with elevated tri- and tetra antennary chains.  
AGP is one of the few glycoproteins that contain tetra- as well as bi- and tri-antennary 
N-linked glycans.  Fournier et al. (2000) reported that 30% of human serum proteins 
actually have no Fuc.  Within the Byers et al., (1999) study, it was shown that AGP 
appeared to contain 11.3% NeuAc, 0.8% Fuc, 14.9% GlcNAc, 6.3% Gal and 5.2% Man. 
 
There is potential for the existence of 10
5
 different glycoforms of AGP due to the huge 
structural variability provided mainly by the presence of glycans (microheterogeneity).  
However in normal, non-pathological conditions there are only 12-20 expressed, each 
exhibiting various degrees of branching, fucosylation and sialylation (Albani, 1997).    
The number of feasible glycoforms is reduced because the Asn residues selective for the 
type of glycans they express in terms of the degree of branching (figure 1.9).  The first 
and second Asn sites (Asn 15 and 38) prefer to harbour bi-antennary glycans whilst Asn 
15 will not bind a tetra-antennary chain and Asn 38 never binds fucosylated glycans.  
Conversely, Asn 75 and Asn 85 prefer more branched glycans; in fact site Asn 75 never 
carries bi-antennary chains and Asn 85 usually expresses the greatest degree of α1,3-
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fucosylation (Higai et al., 2005).  This increased branching could explain why only 
these two sites potentially carry a tetra-antennary chain with more than one Fuc residue 
(Fournier et al., 2000).  It has been found that the majority of AGP glycans have a 
tri/tetra-antennary structure (85-90%) and the remaining 10-15% is bi-antennary 
glycans (Perkins et al., 1985).   
 
Anti-inflammatory properties have been shown to be dependent upon glycan 
composition.  For example, Pos and colleagues (1990) showed that biantennary glycans 
must be expressed by AGP if it is to inhibit CD3-induced proliferation of lymphocytes 
while another group (Williams et al., 1997) reported that the presence of SLe
x
 groups 
enable it to cause amelioration of neutrophil- and complement-mediated injuries.   
 
There are two types of microheterogeneity expressed by AGP; each can be further 
subclassified and are associated with the glycan chains not the peptide backbone; the 
peptide remains constant.  For the major form, type I causes the degree of tri- and tetra- 
antennary branching to be reduced in preference for bi-antennary chain expression; the 
opposite occurs in type II, as shown in ConA studies (van Dijk et al., 1994) where the 
most strongly retained fraction possess the greatest biantennary content while the 
unretained fraction represents those without any biantennary chains.  According to 
Bayard and Kerckaert (1980), in normal plasma the three fractions account for 46%, 
39.1% and 14.9% of the AGP conveyed (un-retained, weakly retained and strongly 
retained respectively), therefore supporting the theory that structure of AGP is highly 
branched.   
 
The minor form is not directly associated with branching but instead the extent of 
fucosylation and sialylation of the five oligosaccharide chains (Albani et al., 1997).   In 
2002, Smith and co-workers reported that the termini of tri- and tetra-antennary chains 
are more tightly bound to the polypeptide core than those of bi-antennary; this makes 
the glycoconjugate more metabolically stable.  It is the tissue-specific regulation of 
glycosyltransferase genes, the availability of sugar nucleotides, and competition 
between enzymes during glycan processing that determines the variation in glycan 
microheterogeneity.   
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Figure 1.9. A diagrammatic representation of possible N-linked glycosylation of 
AGP.  The common degrees of branching are indicated, as described in the text; the 
lengths of the chains can vary. Also, the specific Asn residues to which glycans become 
attached are labelled. Branching can be bi-, tri-, or tetra-antennary with some of the Asn 
sites specific in the type they will express.     
GlcNAc        Man                 Gal               NeuAc 
 
  
  PROTEIN 
GLYCO- 
183 amino acid backbone 
Asn 15 Asn 38 Asn 54 Asn 75 Asn 85 
Tri-antennary Bi-antennary Tetra-antennary 
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1.3.2 Analysis of glycan microheterogeneity 
 
The functions attributed to AGP, like all glycoproteins, are largely determined by the 
glycans with which they are associated. During various physiological and 
pathophysiological conditions, the heterogeneity of the glycoforms expressed can 
become altered, potentially affecting the functions subsequently performed.  It is 
therefore of interest to analyse these structures.  The microheterogeneity of AGP can be 
ascertained using CAIE (crossed affinity-immunoelectrophoresis), which uses a 
Concanavalin (con A) lectin isolated from the jackbean to interact with the glycans - 
fractionating AGP according to the bi-antennary content, without altering the structure 
(Van Dijk et al., 1994; Hansen et al., 1989).  Another highly desirable technique in the 
field of glycomics due to its sensitivity is high pH anion-exchange chromatography 
(HPAEC) which primarily separates structures based on the negative charge expressed. 
 
Coupling HPAEC with pulsed amperometric detection (PAD) transformed the analysis 
of glycans by offering highly sensitive (10–100 pmol) detection and effective separation 
without the need for prior derivatisation.  Both the monosaccharide components and 
whole oligosaccharides of N-linked glycans can be analysed using the technique 
(Townsend et al., 1989; Smith et al., 1997).  More than 20 years after its introduction, 
the use of HPAEC remains widespread and competitive with other techniques.  
Recently, Adamo and colleagues (2009) concluded that its sensitivity compared 
favourably with capillary electrophoresis–laser induced fluorescent detection and 
reverse-phase HPLC coupled to electrospray mass spectrometry for the analysis of the 
monosaccharides of IgG glycans.   
 
Tandem Mass Spectrometry (MS/MS) is seeing increasing use in glycoprotein analysis.  
It was first utilised in the analysis of N-linked glycans by Mock et al. (1991) but the 
methodology is not without problems, hindered by the potentially high proportion of 
peptides in a sample which can exceed that of glycopeptides.  Thus, because the signals 
generated by peptides are often much higher, those of the glycopeptides can be masked; 
especially if they are terminated in negatively charged SA residues (Annesley, 2003).  
Difficulties also arise in its ability to distinguish oligomers of similar masses and linear 
isomers unlike HPAEC-PAD.  
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1.3.3 AGP Structure and Disease 
 
It is unlikely that the exact cause of elevated AGP can be determined however, 
alterations in the microheterogeneity of the glycoprotein may offer more potential as 
they often correlate with specific conditions (Hansen et al., 1984).  Although the 
glycosylation of AGP is generally reproducible in healthy individuals, it is known to be 
altered – alongside the levels of its expression - in response to certain 
pathophysiological conditions like inflammation, cancer and RA (Van Dijk et al., 
1994).  
 
Hashimoto (2004) for example, reported that it may be possible to analyse the 
glycosylation pattern of AGP to determine the progression of cancer; there were 
significant differences between pre-operative patients and a healthy population, 
indicating their clinical status.  Merely analysing the levels of AGP, although 
significantly different between groups, did not allow the clinical status to be 
determined.  The poorest prognosis was found in patients with advanced malignancies 
and highly fucosylated triantennary and tetraantennary AGP glycans for long periods 
after surgery.  Significant changes to the level and glycosylation of AGP have also been 
reported by Haston (2003) during inflammation.  The degree of fucosylation and sialyl 
Lewis X (SLe
x
 : Neu5Ac α2-3Galβ1-4(Fucα1-3)GlcNAc-R) expression is increased 
during acute inflammation; thought to be part of a humoral feed-back response to the 
interaction of leukocytes with E-selectin which is required for extravasation into 
inflamed tissues (van der Linden, 1994).  A decrease in tri- and tetra-antennary 
structures but an increase in bi-antennary glycans attached to the five sites of 
glycosylation was reported in acute inflammation along with increased α1,3 
fucosylation at most sites (Higai et al., 2003; 2005).  In chronic inflammatory 
conditions like grade III and IV RA, Mackiewicz et al. (1987) reported that the 
expression of bi-antennary glycans and sialylation decrease in preference for tri- and 
tetra-antennary chains occurring alongside hyperfucosylation – as demonstrated a 
decade later by Elliott and colleagues (1997).  Asn 75 and Asn 85 (figure 1.9) show 
increased tri- and tetra-antennary α1,3 fucosylation.  When comparing acute and chronic 
sera to that of healthy individuals, they did not find any significant alterations in the N-
glycan composition.  In 2001, Rydén et al. (2002) indicated that AGP fucosylation was 
increased with disease severity in male patients.  An increase in α2-3 linked SA 
expression is also associated with RA (Elliott et al., 1998).  Smith et al. (2002) reported 
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on the possibility that AGP production is localised in rheumatoid synovial fluid (SF) 
because the AGP microheterogeneity differed to that in serum.  The latter expressed 
fewer branches and a lower degree of fucosylation.  
 
Increased α1,3 fucosylation in hepatitis B and some cancers can cause an increase in the 
expression of SLe
x
 on tri- and tetra-antennary glycans (Kobata., 1992; Dennis et al., 
1999).  Studies by Kremmer et al., (2004) indicated that the AGP of cancer patients 
expressed greater Fuc and SA content when compared to a healthy population.  The 
increase in SA expression in cancer was shown previously by Moule (1987) who 
studied the microheterogeneity of serum AGP in patients with RA, myocardial 
infarction (MI), cancer with elevated AGP, cancer without elevated AGP and compared 
them to that obtained a group of healthy volunteers.  Unlike the cancer groups, the level 
of AGP in RA patients decreased.  Cystic fibrosis (CF) sufferers have decreased 
sialylation and increased number of Fuc residues bound via an α1,3-linkage to 
antennary GlcNAc.  The length of the polymers affects the migration of cells; increased 
Fucα1,3GlcNAc and decreased SA on CF airway cells, may present a target for bacteria 
and leukocytes (Scanlin and Glick, 2000).  It has been shown that the severity of liver 
diseases like cirrhosis can be reflected in the structural changes in AGP (Mooney, 
2006).  Increased expression of Fuc residues occurred in cirrhosis as was indicated in 
1987 and 1989 by Biou and colleagues.  A decrease in sialylation occurred in fibrosis.  
Changes - including an increase in branching and sialylation - also occur under normal 
physiological processes like pregnancy (Orczyk-Pawiowicz et al., 2006).  Any changes 
which occur, whether during physiological or pathophysiological conditions, can cause 
alterations in the functions performed by the glycoprotein because they influence the 
overall structure and conformation of the biomolecule. 
 
 
1.3.4  Functions of AGP 
 
It has been established that the constitutive production of AGP contributes to the 
maintenance of homeostasis and that the glycan composition of AGP determines the 
functional roles of the glycoprotein like those in immunomodulation and drug binding 
(Ceciliani and Pocacqua, 2007).  However, its primary biological function remains 
elusive despite being investigated intensively since the 1950s.  AGP is a member of the 
lipocalin family (proteins with hugely diverse sequences but highly conserved 
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structures), enabling it to carry out the transport of small hydrophobic molecules 
(Treuheit et al., 1992; Flower et al., 2000).  As noted by Chiu et al. as early as 1977, 
many AGP functions depend on the structure of the attached glycans.   
 
1.3.4.1   Immunomodulation 
 
AGP has been reported to have potential physiological significance as a natural anti-
inflammatory and immunomodulatory agent, both in vitro and in vivo notably with 
respect to anti-neutrophil and anti-complement activity (Williams et al., 1997).  The 
microheterogeneity of AGP is responsible for its fairly non-specific immunosuppressive 
properties; it is involved in the inhibition of neutrophil activation, platelet activation, 
phagocytosis and – due to interactions formed with collagen - wound healing (Costello 
et al., 1979; Bennett and Schmid, 1980).  When asialylated and agalactosylated, 
immunosuppression of lymphocyte function was maximised (Hochepied et al., 2003; 
Bennett and Schmid, 1980).  The number of branches and degree of sialylation is 
thought to be responsible for its ability to inhibit lymphocyte proliferation. 
 
AGP can inhibit the complement cascade if the glycan composition is correct thereby 
reducing the harmful systemic effects induced during the initial stages of acute 
inflammation (Kalmovarin et al., 1991). Anti-inflammatory cytokines like IL-1β, IL-6 
and TNF-α, are produced in response to AGP production.  Daemen et al., (2000) 
indicated that exogenous AGP and another APP, α1-antitrypsin (AAT), might also 
inhibit inflammation and the apoptosis of hepatocytes.  It is possible that AGP evolved 
to become part of the body’s defence system, limiting the damage to healthy tissues 
caused by inflammation.  In vivo, normal serum AGP levels may protect against the 
activation of polymorphonuclear leukocytes (PMN) however, during inflammation 
chemotoxins and other activators could override this protection (Costello et al., 1984).   
 
The glycan moieties modulate the interaction of AGP with receptors and ligands, the 
extent of which depends on variations in glycosylation (Ceciliani and Pocacqua, 2007).  
One alteration, which occurs during acute inflammation, is the expression of the E-, L- 
and P- selectin ligand, SLe
x
.  Selectins are important for interactions between 
leukocytes and the endothelium thus any modification to the structure subsequently 
affects the interactions.  For example, E- selectin binds SLe
x
 on AGP and therefore 
competes with leukocytes expressing the E-selectin ligand ESL-1.  A consequence of 
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increased SLe
x
-substituted glycan expression is the inhibition of leukocyte rolling and 
diapedesis into inflamed tissues, acting similarly to a negative feedback mechanism (De 
Graaf, et al., 1993).  It was also shown that the glycans of AGP are critical in 
suppressing lymphocyte proliferation induced by mitogens (Pos et al., 1990).  
 
When investigating the anti-inflammatory effects of AGP, Tilg et al., (1993) were 
interested in determining if AGP and other APPs; α1-anti-trypsin and C-reactive protein 
could induce IL-1β and its specific antagonist, IL-1 receptor antagonist (IL-1Ra) in 
peripheral blood mononuclear cells (PBMC).  When incubated with AGP, the level of 
IL-1Ra induced was significantly less than that with CRP or AAT but the level was 
always preferentially induced over that of IL-1β.  From this information they concluded 
that IL-1Ra induction may contribute to the anti-inflammatory effects of APPs.  IL-1Ra 
prevents the binding of IL-1 (an important inflammatory mediator in fever, hypotension 
and the APR) to its receptors in a competitive manner both in vivo and in vitro (Arend, 
1991).  
 
In addition to the various immunological roles that AGP has, it is one of the most 
important non-specific binders of drugs. 
 
1.3.4.2  Drug binding 
 
Drug activity is dependent on a number of factors including its ability to bind to other 
molecules, affecting their tissue distribution.  For over 50 years there has been extensive 
research into the binding of molecules to human serum albumin (HSA), subsequently 
affecting their efficacy, distribution and disposition.  More recently there has been 
increasing interest in the study of the degree of binding to other plasma binding proteins 
including AGP (especially for basic drugs), to determine if binding affects their 
pharmacokinetics (PK) and pharmacodynamics (PD). Under non-pathological 
circumstances, AGP is present at lower concentrations than HSA (50-100mg/100mL 
compared to 4g/100mL); however its concentration may increase significantly to 
become the major drug binding macromolecule during certain pathophysiological 
conditions. Conversely, the level of HSA decreases. Such fluctuations in APP 
concentrations influences the ability of certain drugs to produce their effect (Ceciliani 
and Pocacqua, 2007; Israili and Dayton, 2001).  When the drug is administered, the 
binding equilibrium is immediately altered between drug and proteins (Kuroda, 2003). 
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Binding to AGP is not universal between drugs; it depends on certain properties and 
therefore they are not all affected similarly.  For example, AGP shows preference to 
basic and neutral drugs - propranolol, methadone and warfarin are among those that the 
glycoprotein has been shown to bind with a high-affinity and low capacity.  It can also 
bind steroid hormones like progesterone and some acidic molecules like the retinoic 
acids (Israili and Dayton, 2001).  This is in contrast to HSA which mainly binds acidic 
drugs as proven by Pike and colleagues (1983) who reported that HSA-deficient plasma 
showed a decrease in the binding of acidic and neutral drugs.  
 
The products of the genes encoding AGP (namely AGP-A, AGP-B and B') show 
preference for the binding of different drugs.  Basic drugs generally favour the ORM2 A 
variant, as reported using imipramine by Hervé et al. (1993), while acidic drugs like 
warfarin bind the ORM1 F1/S variant.  Hervé and colleagues concluded that the ORM2 
A variant binding site was specific for basic drugs while ORM1 F1 and/or S for acidic. 
 
There are a number of pharmacokinetic factors associated with the binding of drugs.  
When bound it cannot penetrate the blood vessel walls, a process required to reach its 
site of action thus it is consequently rendered inactive.  The ability to induce the 
pharmacological effect is determined by the remaining unbound drug - the free drug 
hypothesis (Tillement et al., 1988).  In order to produce the effects associated with the 
drug administered, a certain free level must be present at its site of action (minimal 
effective concentration, MEC), if not its efficacy is reduced.  Binding to AGP may 
prevent attainment of the MEC therefore rendering the drug ineffective if the dosage is 
not adjusted accordingly.  The level of bioactive drug therefore varies with altered AGP 
concentrations despite the total drug concentration being only marginally affected 
(Kremer et al., 1988).  
 
It is possible that binding to plasma proteins could be, at least in part, responsible for 
multi-drug resistance (MDR).  The concentration of free drug that reaches the target site 
may be too low to induce the therapeutic effect, providing time to evolve drug 
resistance (Fournier et al., 2000).  In some patients a commonly toxic drug dosage may 
not cause the associated adverse effects if the AGP concentration is elevated; although 
the total drug concentration is high, a large proportion will be inactivated through 
binding to the glycoprotein (Israili and Dayton, 2001; Silamut et al., 1991).  This 
concept was summarised in figure 1.10. 
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Figure 1.10. Representation of the therapeutic range of drugs.  The therapeutic 
range (represented in green) is the drug concentrations that, if present at the site of 
action, will produce the associated effects.  Concentrations greater than this can cause 
toxicity (red) and those below would be ineffective (blue) in the body, possibly causing 
withdrawal symptoms if the drug is used regularly. 
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The binding sites are thought to be buried in a hydrophobic pocket, thus drug binding is 
generally regarded as hydrophobic. It was initially suggested that AGP expressed one 
wide and flexible binding site for drugs (Maruyama et al., 1990).  However more recent 
studies have refuted this, reporting it to consist of at least three partially overlapping 
subsites; the basic ligand binding site, an acidic ligand binding site and a steroid 
hormone (SH) binding site (Matsumoto et al., 2002).  It has also been suggested that the 
number of binding sites expressed on AGP for a particular drug will depend on the 
genetic variants of the glycoprotein present (Hervé et al., 1993); imipramine for 
example was shown to bind one site on the A variant with high affinity and to two other 
sites with a low affinity while warfarin exhibited binding to fewer sites.  Therefore, 
differences in binding cannot be solely explained by variability in the affinity at a single 
binding site.  Methadone is thought to bind AGP at a single binding site with preference 
to that present on the ORM 2A variant.  
 
When AGP binds to ligands, the dynamics of the binding pocket are affected - the 
buried Trp residue becomes more exposed whilst the Trp at the surface becomes 
increasingly buried; (Fournier et al., 2000; Johnson and Smith, 2006).  It is the ability of 
Trp (and to a lesser extent, Tyr) residues to emit fluoresce between 300-400nm (max 
approximately 340nm) when excited at 280nm, that allows fluorimetry to be used in the 
analysis of drug binding – more binding causes a decreased fluorescence because it 
masks (quenches) the underlying fluorescing residues.  However, it must be noted that 
fluorescence resonance energy transfer (FRET) may occur in such studies. The 
phenomenon is particularly problematic when the drug under investigation has 
absorption spectra spanning wavelengths used to determine the fluorescence emitted by 
AGP and other proteins.  Chlorpromazine for example, is a yellow compound which is 
well known to absorb at wavelengths including those around 340nm.  Therefore a 
reduction in the fluorescence is likely to be at least partly due to absorption by the 
drugs’ (Shine & Mach, 1965).  
 
It is also possible that in some proteins, when there is a potential change in its 
conformation to accommodate the ligand, the position of residues - normally far apart in 
the absence of drug - may be altered.  Fluorescence of the residues may subsequently be 
reduced, not only because they become increasingly buried but due to potential transfer 
of fluorescence to other residues. A greater reduction would therefore be recorded than 
that solely due to the masking effect in the binding site brought on by the drug. 
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A number of factors affect the ability of AGP to successfully bind drugs in vivo, 
including physical-chemical properties and inter-individual differences.  Physical-
chemical properties include pH (binding increases with pH), the presence of alosteric 
co-operativity with proteins like albumin (Fournier et al., 2000; Israili and Dayton, 
2001), and altered glycoprotein concentration in various diseases like breast and liver 
cancers where AGP concentration increases (Jackson et al., 1982).  Major and minor 
heterogeneity, altered conformations induced by disease (for example altered 
sialylation, fucosylation and glycosylation pattern) and displacement by other ligands 
are further examples (Rydén et al., 1997; Israili and Dayton, 2001).   
 
Gender, age, ethnicity of donor and genetic polymorphisms are examples of inter-
individual differences.  It has been noted in a number of studies that healthy females 
appear to have more sialylated glycoforms than males but males generally have higher 
levels of AGP (Israili and Dayton, 2001).  Females can show further interindividual 
variation, which suggests their hormones have a role in altering AGP structure.  
Younger females, for example those in the later stages of pregnancy and those taking 
the contraceptive pill, express even lower levels of AGP (Routledge, 1989).  Reports 
regarding the levels of AGP in the elderly are in wide disagreement. Veering et al. 
(1990) for example, reported no correlation between the increased production of AGP 
and age, whilst Davis et al. (1985) found AGP increased slightly with age.  However it 
is possible, as suggested by Israili and Dayton (2001) that factors such as weight, 
inflammation and nutritional status could account for the variation.  Research has shown 
that there is a difference between Caucasians and African-Americans in the degree of 
binding salicylic acid and disopyramide.  Caucasians appeared to have more binding 
initially however no significant differences were noted when the correlation factor had 
been accounted for (Johnson and Livingston, 1997).  If any of the numerous factors 
cited cause alterations in the expression of AGP, the efficacy of drugs may be affected. 
 
Various studies have been undertaken indicating differences in the ability of the AGP 
variants to bind drugs.  Most drugs bind both AGP variants however there are some 
which show a preference.  Disopyramide and imipramine for example, bind only the 
ORM2 A variant while warfarin selectively binds to ORM1 F1*S (Matsumoto et al., 
2002).  It was Eap et al., (1988c and d) who first reported that the variants could express 
different binding properties - these differences could explain why some studies find 
only a small number of high-affinity binding sites for basic drugs like methadone 
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(Abramson 1982).  A study by Eap et al., (1990) indicated the presence of the AGP 
genetic variants could be responsible for interindividual differences in methadone 
binding, favouring ORM2 A. 
 
Increases in the concentration of AGP (and other proteins-IgA and C3) were found to 
occur in those with high stress perception compared to those with lower (Ebersole and 
Cappelli, 2000); other studies found this to occur in stress related to major depression.  
Also, Rostami-Hodjegan (1999) noted that heroin dependent individuals have elevated 
levels of AGP.  These findings could be relevant to this study, titration patients are 
newcomers to the therapy and thus still heroin-dependent with high stress levels 
common especially while they are titrated onto a steady maintenance dose; as discussed 
further in the opiate section of this introduction.  
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1.4     Opiates 
 
 
1.4.1  Opiate addiction: a global problem 
 
The opiates are a family of drugs commonly abused in society, but also used medically.  
Members include the illicit street drug heroin and naturally occurring morphine, from 
which heroin is synthetically derived.  A UNODC report suggested that in 2008 figures 
for opioid abuse ranged between 12.8 and 21.8 million individuals (World Drug Report, 
2010) – commonly in conjunction with another family of CNS depressants known as the 
benzodiazepines (BDZs), thus it is a huge problem. 
 
Between 0.4-0.8% of adults in Europe, USA and Australia reportedly develop opioid 
dependence, escalating their illegal drug habit (Hall and Mattick, 2007; Ward et al., 
1999).  A study in 2005 estimated that over 51,500 individuals misused these substances 
in Scotland and that were 2,400 registered heroin users in the Lothian region alone (Hay 
et al., 2005).  Epidemiological studies performed in 2003 in the U.S.A have indicated 
that, after marijuana, opioid analgesics are among the most frequently abused illicit 
drugs in secondary school students (Johnston et al., 2004).  Studies of a similar age 
group in the UK reported that, in 2005, 6% had been offered heroin in England and 
Wales, and 1% of respondents had used it within the preceding year (NHS Drug Misuse 
and young people report, 2005).  Long-term use of opioids is associated with abuse or 
addiction development; the term ‘addict’ often used to describe individuals whose 
repetitive drug taking behaviour stimulates the central nervous system (CNS) causing 
specific neurobiological changes which induce repetitive drug consumption (Scimeca et 
al., 2000).   
 
The death rate among heroin users is thought to be 13-fold higher than a healthy 
population of similar age and gender (Gossop et al., 2002).  Contributing factors include 
the spread of blood borne viruses associated with intravenous (i.v.) injection.  Similar to 
the UK, Italy has a high incidence of injecting drug abuse which allowed AIDS to 
surpass overdose as the main cause of death among heroin users in late 1980s and early 
1990s (peaking in 1991-1992).  Its incidence in Italy has reduced, like much of Western 
and central Europe, since the early 1990s (Davoli et al., 1997; Bargagli et al., 2001). 
Perhaps this is partially due to the widespread introduction of opioid substitute 
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programs which reduce the need for i.v administration (instead a substitute which can be 
orally administered is used).  However the incidence of HIV/AIDS and hepatitis C in 
injecting drug users has been on the rise in Eastern Europe.  The occurrence of suicides 
in these drug users also differs among countries; in the UK it is thought to be 
approximately 10-15 per 10
5
 of the population, similar to the USA and Australia. In 
Finland however it may be almost double - 30 per 10
5
 (Diekstra and Gulbinat, 1993; 
Lynskey et al., 2000).   
 
Methadone maintenance therapy (MMT) is the most common opioid substitute 
treatment.  The drug was first identified in the 1960s by Dole and Nyswander (1966) as 
a viable substitute in opioid dependence treatment despite decades of use as an 
alternative analgesic to morphine.  The rate of achieving successful annual abstinence 
from heroin in the absence of therapeutic support is reportedly as low as 1-2% (Hall and 
Mattick, 2007).  Those successful, commonly suffer relapses within 12 months if they 
do not receive any pharmacological or psychosocial assistance.  Of those receiving 
methadone, abstinence from both the abused and therapeutic substitute drug may only 
be achieved in approximately 3% of patients annually although figures vary between 
studies (McKeganey, 2006). In order to improve treatment and identify viable 
alternatives, research must continue to enhance our understanding of why success rates 
may be so low.  
 
 
1.4.2  The mechanism of opioid action  
 
The general pharmacological effect of the opiates is achieved through a depression of 
the CNS; promoting the onset of analgesia.  However, despite being a cornerstone in the 
treatment of moderate to severe pain, opioids can leave a patient more sensitive to pre-
existing pain: this is the concept of opioid-induced hyperalgesia (OIH), for which there 
is accumulating evidence (Angst and Clark, 2006).  Research has indicated that when 
compared to former heroin addicts who are not (or no longer) undergoing MMT or 
‘healthy’ subjects, those maintained on methadone are more sensitive to cold pressor 
pain with some hyperalgesia.  The increased pain sensitivity possibly predisposes them 
to recurring addiction as they attempt to prevent the onset of symptoms, thus a vicious 
cycle ensues (Doverty et al., 2001; Compton et al., 2000).  It is thought that opioid 
tolerance and OIH coexist because they share the same neurotransmitter and receptor 
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systems, which may explain why it can be very difficult to distinguish between an 
individual displaying tolerance and another suffering from OIH (Angst and Clark 2006).  
 
Under normal physiological conditions, the neurotransmitter γ-aminobutyric acid 
(GABA) is released from associated neurones and inhibits the release of dopamine (DA) 
from dopaminergic neurons when bound to its receptors on nerve terminals (figure 
1.11a).  Internally derived endogenous opioids (endorphins) may bind to µ, δ and κ 
opioid receptors (ORs) however, when heroin metabolites bind the μ-opioid receptors 
(µOR) of the nucleus accumbens (NA) and ventral tegmental area (VTA), the 
‘rewarding’ neurobiological circuit (dependent on DA release from opioid-sensitive 
neurones) is enhanced, as shown in figure 1.11b.  The active heroin metabolites bind to 
the ORs which in turn inhibit the synthesis and release of GABA, therefore DA is 
increasingly released into synapses and the post-synaptic membrane can be continually 
activated, inducing the euphoria and pleasurable feelings associated with heroin use.  
These ‘positive’ effects may explain the desire of users to repeatedly administer the 
drug despite the risks associated with them.  Conditioned responses develop whereby 
individuals associate the use of drug and its ‘positive’ effects with particular stimuli, 
therefore finding it difficult to resist re-use when faced with said stimuli.  In turn the 
users become dependent on the drug to perform activities related to daily life (Compton 
and Volkow, 2006).   
 
As the dose of drug administered by an individual increases, the body creates stronger 
compensatory responses to its effects therefore the user requires increased doses to 
produce the responses previously achieved at lower levels; they become increasingly 
tolerant.  If the concentration of bioactive drug present at receptors is insufficient to 
stimulate them effectively, withdrawal symptoms occur; an upregulation of the cAMP 
pathway and subsequent increased activity of its Noradrenaline (NAdr) secreting cells 
occurs in the locus ceruleus (LC) (Housová et al., 2005; Kreek, 1997).   
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a) 
    
 
 
b) 
 
 
Figure 1.11. Diagrammatic representation of synaptic activity in the absence (a) 
and presence (b) of heroin.  [Adapted from Schumacher et al., 2009].  Introduction of 
μ opioid agonists inhibits the normal release of GABA, therefore allowing greater levels 
of dopamine to be released.                      
Inhibition 
Inhibition 
44 
 
1.5 Heroin 
 
 
1.5.1 Heroin addiction 
 
Heroin is a lipophilic morphine derivative with two acetyl groups which allow it to pass 
through the BBB more easily than morphine (figure 1.12a and b respectively). The 
complete drug remains in this form for a matter of minutes before it is rapidly 
hydrolysed to its more stable metabolites morphine and 6-monoacetylmorphine; 
approximately 95% of a heroin dose is eliminated within 30minutes. The two main 
metabolites allow for the prolonged pharmacodynamic (PD) action of approximately 4-
6hours (Salmon et al., 1999; Rook et al., 2005).  
 
Essentially, increasing the rate of drug delivery to the brain is the primary ‘goal’ of the 
drug user.  Therefore, because heroin has a poor oral bioavailability (the hypothetical 
proportion of administered dose which reaches the circulation is low), users often 
progress from smoking to snorting.  A study undertaken by van den Brink (1999) noted 
many heroin users inhaled heroin vapours, produced when heating on tinfoil – 
commonly referred to as ‘chasing the dragon’.  Subsequent transfer to injecting the drug 
i.v. is widespread in heroin users as this provides the most direct rate of delivery to the 
brain ORs.  Hay et al. (2004) reported that in 2003, over 18,500 of the ~51,500 opiate 
and/or BDZ misusers were injecting the drugs in Scotland.  However, this route thereby 
increases the risk of transmitting blood-borne viruses like HIV (60% opioid-dependent 
persons are HIV positive according to Nadelmann and McNeely, 1996), and hepatitis C 
(50-70% injecting drug users infected; Krambeer et al., 2001) through the sharing of 
needles. Holmberg (1996) reported that up to 50% of newly diagnosed cases of HIV 
infection are linked to injecting drug use. 
 
It has been reported that heroin users tend to use a combination of drugs alongside 
heroin including BDZs (a common family of psychotropic drugs), cannabis, alcohol and 
amphetamines although they are not necessarily dependent on all of them (Klee, 1990).  
The use of alcohol and BDZs, alongside heroin is correlated with fatal and non-fatal 
heroin overdoses because they too are respiratory depressants, (Zador et al., 1996; 
Darke et al., 1996).   
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a) 
 
b) 
                         
 
c) 
 
 
Figure 1.12. The chemical structure of a) heroin (diacetylmorphine), b) morphine 
and c) methadone.  [Adapted from Rodriguez-Rosas et al. (2003) and Galloway and 
Bellet (1999)]. 
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1.5.2 Dependence and Tolerance 
 
All opiates have the potential to cause dependence; a complex condition involving 
social, psychological and biological components.  Within-system adaptations that can 
occur in the acute reinforcing activity of drugs may involve neurochemical changes 
associated with certain neurotransmitters.  The desire to re-experience positive ‘reward’ 
outcomes and prevent withdrawal symptoms which arise when dopaminergic and 
serotinergic transmission in the nucleus accumbens (NA) is reduced, affects the 
development of dependence.  To function normally, these individuals require opioid 
administration resulting in compulsive drug taking with which there are significant costs 
to society in terms of crime, social damage, loss of earnings and productivity (Weiss et 
al., 1992; Parsons et al., 1995).  Ward (1999) implied that dependence can be diagnosed 
if an individual persists in their use of a drug in spite of damages to health, law, social 
achievements and personal relationships.  Various schemes are available to aid in the 
identification of individuals displaying physical dependence, most commonly based on 
recommendation of the WHO in the UK or the DSM-IV (Diagnostic and Statistical 
Manual of Mental Disorders) as used in the USA. 
 
Upon initial heroin injection the drug rapidly occupies ORs to produce its effects, yet 
repeated administration causes a reduction in the drug’s potency or efficacy due to 
depleted expression of these receptors (physiological tolerance). Alternatively, as 
suggested by Borgland and colleagues (2003), the ORs may become internalised - 
consequently, receptor expression is reduced.  The effect is often not apparent during 
analysis because radiotracers used in these studies are not specific to surface ORs thus 
they can label internalised structures, causing the overall expression of ORs to appear 
relatively consistent. 
 
Increased doses are required to reproduce the effects previously acquired with lower 
concentrations; a threshold is associated with tolerance to drugs, which deviates 
between individuals.  When doses are below this level withdrawal symptoms may arise, 
including nausea, anxiety, tremors and dissipation of the euphoric ‘high’ (Drummer and 
Odell, 2001; Scimeca et al., 2000).  Conversely, if concentrations exceed the threshold 
too rapidly or by too much, the effects of an overdose are displayed.  When at the 
threshold, cognitive and motor functions are normal, making it difficult to determine if 
those persons are abusing opioids (Dole et al., 1966).  Therapy for opioid dependence is 
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therefore based on achieving a stable and continuous brain opioid receptor occupation to 
prevent heroin binding, consequently avoiding the unwanted effects like craving; 
allowing patients to gradually return to a normal lifestyle (Scimeca et al., 2000).   
 
 
1.6 Methadone 
 
 
1.6.1 Methadone: a brief history 
 
Methadone - (±)-6-dimethylamino-4,4-diphenylheptan-3-one – figure 1.12c) was first 
produced in Germany in the late 1930s as an alternative analgesic to morphine (figure 
1.12b); despite possessing a very different chemical structure, it binds the same 
receptors (Bernard et al., 2007).  Three decades later, in the 1960s, after the diligent 
research of Dole and Nyswander (1966), it was identified as the only viable synthetic 
opioid which could be substituted for abused heroin due to its low side effect expression 
and long half-life – criteria for treatment of opioid dependencies.  At the time the 
primary use of methadone was in treating chronic cancer pain, but this research 
pioneered it as a maintenance treatment.  Unlike heroin, its rapid absorption by the oral 
route and slow breakdown is favourable for use in therapy.  The drug is now employed 
worldwide.  In Scotland, its use as a controlled and allegedly safe heroin substitute was 
not realised until the 1980s (SACDM, 2007) and its use has become increasingly 
controversial.  Some countries, including Germany, have limited methadone use opting 
instead for shorter acting (half-life of 4h) dihydrocodeine (Krausz, 1998).   
 
It is a basic and lipophilic (fat soluble) drug that is mainly ionised at physiological pH 
(it has an ionisation constant, or pKa, of 9.0) and is primarily stored in the liver but 
quickly and widely distributed throughout tissues (Garrido, 1999).  Like heroin 
metabolites, methadone binds µ, δ and κ ORs which induce the release of intracellular 
messengers necessary to create the associated pharmacological effects; many of these 
are shared by the opioid agonists e.g. analgesia.  The binding of methadone to ORs 
prevents the attachment of heroin – the absence of its associated euphoric effects upon 
administration should therefore lead to a cessation of heroin use.  Due to its longer half-
life, the presence of methadone in the body outlives that of the abused drug.  However 
some studies have disputed this mechanism of action, arguing that there is no significant 
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alteration in the availability of receptors when methadone is administered (Melichar et 
al., 2005).  They suggested that as methadone is a high-efficacy agonist, the number of 
receptors required to exert its effect may be so low that it was undetectable using the 
techniques available.   
 
 
1.6.2  Methadone therapy: its usefulness and dosing schedule 
 
The primary goal of the administration of the synthetic opioid methadone is to prevent 
abstinence syndromes.  Blake and colleagues (1997) reported that it has a higher affinity 
constant (Ki 3.56nM±0.2) for µORs – the primary site of action - than that of other 
opioids like morphine (Ki 1.41nM±0.11).  Methadone normalises the hormonal 
disruptions often existing in heroin addicts, preventing the onset of euphoric effects and 
reducing narcotic cravings associated with heroin use (Vetulani, 2001).  It does not 
allow rapid abstinence from all drugs and therefore does not represent a cure (Housová, 
2005).  Nonetheless, the ability to orally administer the drug in a single daily dose 
(syrup and tablet forms) is advantageous as is its long duration of action (24-36 hours – 
compared to 2-3 hours for heroin) which prevents the onset of withdrawal symptoms for 
long periods of time (Fainsinger et al., 1993).  Methadone is useful because it has cross-
tolerance with other opioids, enabling it to be substituted for abused drugs such as 
heroin and morphine.  By binding the same receptors, the inhibition of DA release by 
GABA is prevented, similar to the effects of morphine described in section 1.5.2.  DA is 
increasingly released from the ventral tegmental area and binding of the drug at ORs in 
the nucleus accumbens and prefrontal cortex is associated with the acute reinforcing 
effects common to heroin use.  Their structural differences (refer to figure 1.12, section 
1.6.1) may explain the inability of methadone to induce euphoric effects like heroin, 
despite being an agonist for the same receptor – they may become bound differently.  
An additional advantageous property of the drug is that it acts as an antagonist at 
NMDA receptors therefore reducing characteristics associated with the major excitatory 
neurotransmitter glutamate, for example anxiety.  
 
Dole et al., (1966) reported that a 100mg dose of methadone can block the effects of 
80mg i.v. administered heroin.  It is not surprising more methadone is required than 
heroin as the latter is injected directly into the blood and the Vd of methadone is much 
higher than that of morphine with only 1% reported to be present in the blood (Morley 
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and Makin, 1998).  Therefore, in order to account for its loss, methadone must be 
administered in much greater doses to achieve the therapeutic plasma levels required.  
According to Eap et al. (2000), a 150-600ng/mL serum methadone level (SML) is 
necessitated to suppress opioid craving and a trough level ≥400ng/mL required for 
maintenance (to ensure sufficient blockade).  Reinforcing effects of shorter acting 
heroin like euphoria are avoided although there is an increased possibility of methadone 
accumulation upon repeated dosing due to its long half-life (Dole et al., 1966; Kreek, 
1992).  Four or five half-lives usually pass before the elimination and amount of drug in 
the body are balanced (attain a steady-state SML).  Considerable inter-individual 
variability in the PKs and PDs of methadone exist, as is the case for many drugs.  Hanna 
and colleagues (2005) indicated that interindividual variability in methadone PK 
parameters was up to 8-fold greater than that exhibited intraindividually.  Due to this 
variability in factors including metabolism, distribution, enantiomer selectivity, passage 
through BBB and binding to plasma proteins; the level of drug may differ and therefore 
adjustments must be made to the dose of orally administered methadone if the 
therapeutic concentration is to be attained.  Defining a threshold plasma trough level 
capable of achieving the desired response is therefore difficult (Loimer and Schmid, 
1992). 
 
The response to a drug is directly correlated with the length of time the active form is in 
the body.  Methadone is ‘foreign’ to the body (a xenobiotic) and is therefore 
metabolised in the liver by chemical reactions into more easily eliminated molecules. 
The primary metabolic pathway is sequential N-demethylation and cyclisation to 
inactive EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) chiefly involving 
liver cytochrome P450 (CYP450) enzymes, especially CYP3A4.  The activity of these 
inducible enzymes affects the rate of methadone clearance from the body and varies 
between individuals due to genetic, environmental and/or disease-related factors.  It 
follows that if the specific enzymes are absent or incorrectly expressed, methadone 
cannot be metabolised effectively.  Drugs, or other agents, that induce or inhibit the 
activity of CYP450 enzymes – especially that of CYP3A4 – can thereby alter the PKs of 
methadone.  Inducers including the anticonvulsant phenobarbital and the antibiotic 
rifampicin accelerate methadone metabolism, increase its rate of clearance, lower the 
SML, and potentially precipitate a withdrawal syndrome because insufficient drug 
reaches and blocks the ORs.  Conversely, inhibitors e.g. SSRIs (sertraline etc), SNRIs 
(venlafaxine etc) and HIV drugs (ritinovir, zidovudine) slow metabolism, raising the 
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SML, leading to accumulation which may cause methadone-related toxicity with 
oversedation and/or respiratory depression (Leavitt et al., 2000; Wolff et al., 2000).    
 
The interaction between alcohol consumption and methadone efficacy is one of great 
concern.  It has been reported that the drugs act in a reciprocal manner thereby 
enhancing their metabolism.  Patients in a study undertaken by Wolff et al. (1991) 
indicated that those with the lowest methadone concentrations also had long histories of 
alcohol abuse. 
 
The long half-life, although variable between individuals, requires patients to follow a 
dosing schedule where the methadone concentration is titrated over a period of 10-14 
days upon administration of the initial dose.  During this stage, patients must be 
monitored closely as it is associated with the greatest risk of overdose and subsequent 
death.  Doses ought to be kept low because methadone slowly accumulates in the tissues 
potentially causing toxicity during concurrent use of additional illicit opioids.  Many 
patients continue unsanctioned use of heroin and other CNS depressants to combat 
withdrawal symptoms like abdominal cramps and diarrhoea, arising due to the low 
methadone doses.  Wolff and colleagues (1991) reported that plasma methadone 
concentration is directly related to the dose of methadone administered.  Once the levels 
between tissue storage sites and the blood have equilibrated, a maintenance dose is 
administered over the remainder of therapy to prevent relapses; methadone is slowly 
released from tissues therefore the SML remains fairly constant (Krambeer et al., 2001; 
Borg and Kreek, 2003).  Small reductions are made when the individual decides to 
attempt a future of abstinence.  Again, monitoring patients is vital, any dramatic drop in 
methadone concentration may lead to a life-threatening relapse - their tolerance to the 
illicit drug is commonly reduced therefore toxicity could arise at lower doses than those 
administered prior to therapy.  Studies have indicated that the risk of death when using 
opioids is 3-4 fold lower when undergoing MMT however it is considerably higher than 
in the drug free population (Caplehorn et al., 1996). 
 
Guidelines issued in 1991 by the UK Department of Health indicated methadone 
prescribing was to be increasingly offered as a long-term treatment than previously 
reported when short-term treatment with subsequent detoxification was encouraged.  
Support was provided by the recently updated ‘Orange’ Guidelines issued in 2007 
(Department of Health, 1999 update 2007b).    
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It is unusual for the initial loading dose administered to patients to be greater than 60mg 
per day; between 35-100% (80% average) of a single, orally administered, methadone 
dose will pass into the bloodstream and can be detected there after 15-45 minutes.  
Therefore, if a patient vomits shortly after ingesting the dose there is uncertainty as to 
the extent of absorption; it takes 20-30 minutes for the drug to be fully absorbed.  
Similarly, if within the first few days there is strong evidence of withdrawal, doses may 
be increased if there is a low risk of abusing other substances.  Little is known about the 
relationship between dose, brain levels and receptor occupation despite its widespread 
use for three decades.   
 
McCarthy and colleagues (2000) demonstrated that when a group of mothers 
undergoing MMT consumed between 25 and 180mg of methadone per day, the level 
consumed by the infant was approximately 0.05mg/day if ingesting 475mL of breast 
milk a day.  When a patients’ dose of methadone is greater than 20mg/day, the 
American Academy of Paediatrics recommend that nursing should not be undertaken.  
Continuing on MMT is however associated with a number of positive qualities – it is 
thought to better prepare a mother for parenting and has been shown to improve 
obstetrical care compliance (Finnegan, 1991). 
 
Recently, a report compiled by McKeganey (2006), concluded that giving methadone to 
heroin addicts has a 3% success rate (97% failed to remain free of all drugs, including 
that used in treatment), which was barely better than those attempting abstinence 
without any treatment.  Subsequent to findings like these, there is a greater demand for 
alternatives, such as the opioid dihydrocodeine (DHC – refer to chapter 4), and 
increased availability of residential rehabilitation; only 2% of Scotland’s drug users 
have adequate access to residential rehabilitation systems (Hay et al., 2005).  Their 
research did however highlight the social benefits of remaining in therapy; individuals 
were 7 times less likely to commit crime and more likely (59%) to be in employment or 
education compared to addicts.  Despite the study relying on the honesty of the 695 
drug users interviewed, it supports previous findings that, regardless of high relapse 
rates, methadone is effective in improving the patients’ quality of life (Marsch, 1998).   
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1.6.3  Methadone has two forms administered during therapy. 
 
In the UK methadone is commonly prescribed as a 50:50 racemic mixture of two 
enantiomers (molecules which share a common chemical composition but differ in their 
special arrangements); (R)-(-)-methadone and (S)-(+)-methadone, or levo- (l) and 
dextro- (d) respectively, which differ in their activity. The (R)-enantiomer has 
reportedly ten times higher affinity for µORs than morphine (Kristensen et al., 1995) 
and is 50 times more potent as an analgesic than the (S)-enantiomer thus it accounts for 
most, if not all, the opioid pharmacological activity (Boulton and Devane, 2000; Eap et 
al., 2002).  There are a number of effects known to arise from the use of the racemic 
mixture including miosis (pinpoint pupils), antidiuresis, respiratory depression and 
analgesia.   
 
Hallinan et al. (2006) performed research with MMT patients classified as ‘responders’ 
and ‘non-responders’, based on initial urine toxicological analysis.  They reported that 
the optimal therapeutic daily dose in the patients was 100mg/day requiring (R)-
methadone concentrations of 200ng/mL and (R,S)-methadone of 400ng/mL, thus using 
the R-enantiomer alone is more effective at suppressing withdrawal than the racemate.  
The use of S-(+)-methadone alone was shown to be ineffective at preventing withdrawal 
symptoms.  Although certain patients require only a low dose of methadone in therapy, 
controlled studies have indicated that a dose-response relationship exists for methadone 
up to 80-100mg/day (Capelhorn et al., 1993; Strain et al., 1999).  Thus, the higher the 
dose, the better the response i.e. less likely the patient is to enter withdrawal and 
relapse. 
 
 
1.6.4 Minimal effective concentration and the role of AGP 
 
The ability of a drug to confer a desired therapeutic effect is primarily dependent upon 
attainment of a certain concentration at its site of action - the minimal effective 
concentration, MEC.  For the majority of drugs, this is accessed via the bloodstream and 
according to the free drug hypothesis, only free drug is capable of executing the 
associated effect.  There are a number of mechanisms postulated to cause methadone 
resistance, however often overlooked is the interaction formed with plasma proteins, 
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such as α-1-acid glycoprotein (AGP), potentially rendering it inactive and reducing the 
concentration of drug to below the MEC at the target site.   
 
Like many drugs, methadone binds to proteins in the plasma, lung, liver, kidney and 
spleen but as it is a basic drug, it is most strongly associated with AGP (Romach et al. 
1981).  Methadone binds the APP with an association constant of ~4x10
5
M
-1
.  
Therefore, alterations in the concentration of the APP, like the increase reported by 
Rostami-Hodjegan et al. (1999) in heroin-dependent individuals with signs of opiate 
withdrawal, are likely to affect the level of unbound active drug and subsequently its 
ability to enforce the desired pharmacological response.  In fact research by Olsen 
(1973) suggested that the affinity of methadone for AGP is stereoselective; greater 
affinity was recorded for the S-enantiomer (90% bound) than the R-form (86%), this 
was subsequently supported by Romach et al. (1981).  Thus, such high binding and 
enantiomeric preference may explain, to some extent, why large doses (mg level) are 
required to provide a low (ng) therapeutic plasma level.  Eap and colleagues (1988) 
suggested that in order to determine what concentrations of methadone are 
therapeutically useful; analysis of the enantiomers could be more valuable than total 
methadone.   
 
It is not only enantiomeric selectivity that must be considered; methadone possesses a 
degree of selectivity for specific genetic variants of AGP.  Therefore if the expression of 
the AGP-B/ B  gene products (ORM2 A) - the genetic variant for which methadone has 
the greatest affinity - is increased, the active concentration of methadone decreases.  
Additionally, the free level of other drugs which do not bind this glycoprotein variant 
will increase, generating an elevated risk of toxicity from their presence alongside the 
onset of withdrawal from the reduction of free methadone (Marsch, 1998).  Once the 
AGP level stabilises, the drug concentration will follow suit. 
 
If binding is enhanced and the plasma levels are insufficient to reach the MEC, an 
increase in GABA release and activation of NMDA receptors causes enhanced craving 
and withdrawal symptoms including anxiety.  An increase in the dose administered may 
compensate for binding but increases the risk of toxicity.   
 
A number of drugs have been shown to displace methadone from its binding sites on 
AGP including propranolol and chlorpromazine.  An elevation in the free plasma 
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concentration of methadone would arise if the drugs were taken simultaneously thus 
increasing the possibility of achieving toxic concentrations (Abramson, 1982).  
Although studies have acknowledged the ability of AGP to bind methadone, there is a 
paucity of research analysing the effect of glycosylation on this function. 
 
 
1.6.5 Methadone therapy is not without its problems 
 
As alluded to previously when discussing the extent of methadone use in the UK, it is 
not a cure for opioid dependence and a number of contraindications have been 
identified.  The main concern regarding the use of methadone in the treatment of pain is 
the risk of delayed toxicity due to its long and unpredictable half-life (Manfredi et al., 
2001).  Essentially, the adverse effects of methadone compare to those for other opioid 
analgesics for example nausea, vomiting, miosis, constipation, respiratory depression 
and possibly comas.  Upon long-term use – after accumulation and stabilisation - 
individuals usually develop tolerance to most of these effects (Scimeca et al., 2000).  
However they are likely to develop dependence on the opioid, becoming hesitant to 
reduce their dose and risk the onset of withdrawal symptoms which are reportedly 
worse than those for heroin.  This was clear in a study by Manfredi and colleagues 
(2001) describing patients who had been on the therapy for as long as 10 and 20 years. 
Greatest risk of overdose to users therefore occurs in the first 10 days during titration as 
the doses are kept low - additional unsanctioned use of opioids and other CNS 
depressants often continues, potentially leading to toxicity.  Deaths have been found to 
occur mainly during sleep after peak blood concentration is attained, usually three to 
four days after starting therapy where the risk of death is reportedly 6.7 fold greater than 
when not in the program (Caplehorn and Drummer, 1999).  During this stage, dosing 
must allow for the accumulation of methadone and the additional use of CNS 
depressants by patients in their attempt to prevent the onset of withdrawal.  In almost all 
deaths related to methadone, other CNS depressants are also present; the exacerbation 
of respiratory depression is extremely hazardous.  Risk decreases after stabilisation on 
the therapy; it is nearly 98 times lower than in newly recruited patients (Karch and 
Stephens, 2000).   
 
In the decade 1985 - 1995, it was reported that almost 50% of all UK opioid deaths were 
related to methadone use however whether the patients were stabilised on the therapy at 
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the time is unknown (Hall and Mattick, 2007).  Newcombe (1996) suggested that heroin 
actually contributes to fewer deaths than methadone and therefore the substitute may not 
be as protective as first assumed.   
 
Therefore, it can be seen that in the ongoing search for improved treatments for opioid-
dependencies a firm understanding of the mechanisms influencing the efficacy of drugs 
is being sought.  A particular aspect – specifically the structure of AGP and its potential 
affect on binding to, and therefore inactivation of, methadone - is the primary focus of 
the research detailed herein. 
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1.7 Research Strategy 
 
 
As a result of the APR, stimulated when certain pathological and physiological states 
are expressed, the plasma concentration of a positive acute phase protein called AGP 
can be elevated 2-5 fold.  Increased synthesis of AGP has been reported in highly 
stressed individuals and heroin users showing signs of withdrawal, ergo levels found in 
patients undergoing replacement therapy for heroin dependencies ought to differ from 
that of a ‘normal’ population.   
 
Alongside overall plasma concentration, the glycosylation pattern of AGP has been 
shown to differ in various conditions but has not been closely studied in patients 
undergoing methadone therapy.  Any alterations to the structure of a glycoprotein can 
greatly affect its function.  In the case of methadone, glycosylation changes expressed 
by AGP could increase the binding affinity thereby reducing the level reaching the 
target site and subsequently increasing the risk of withdrawal symptoms developing.  If 
binding significantly differed in treatment groups, the analyses of a patient’s AGP and 
its binding to methadone may have potential in a clinical setting.  Identifying 
individuals who are less likely to respond to methadone replacement therapy and 
therefore will require higher doses or perhaps an alternative substitute could, and 
should, improve treatment retention and success.  
 
Consequently, it was hypothesised that the level of AGP isolated from patients 
undergoing therapy would be greater than that from a healthy population.  Also, patients 
were expected to express modified glycosylation for which methadone displays 
increased affinity.  Although patients receiving higher doses of drug would be expected 
to express the greatest levels of AGP and glycans correlated with increased binding if 
any were found, these generalisations do not account for the likelihood that the 
methadone dose administered to patients newly recruited onto the program will be 
lower than that received by patients at the maintenance stage. Dosing during titration 
must reflect the ability of methadone to accumulate in vivo and the probability that the 
patients themselves will administer additional opiates. Therefore, in terms of relating 
methadone dose to AGP concentration it was expected that patients in long term therapy 
receiving the greatest doses, would have an increased level of AGP and/or increased 
affinity for the drug – more being inactivated by their AGP.  Those in the titration phase 
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were expected to express high levels of AGP however the doses were unlikely to be 
correlated. 
 
 
1.7.1  Aims and Objectives 
 
1.7.1.1 Aim:  
 
The primary aim of this research was to determine whether alterations in the level and 
glycosylation of AGP occurred in patients undergoing opioid replacement therapy when 
compared to a ‘normal’ healthy population. Whether such alterations could contribute to 
potential differences in the degree of binding was established. 
 
Preliminary studies such as that presented within could offer use in determining the 
likely success of the treatments for individuals; alternative treatment programmes could 
be initiated immediately in those unlikely to respond well to methadone. It would 
prevent starting a program which is unlikely to offer any benefit to the individuals. 
 
1.7.1.2 Objectives: 
 
Various stages were undertaken to test the hypotheses that the level and structure of 
AGP in patients influenced its binding to methadone. Initial experiments were 
performed with commercial AGP to ensure techniques were sound and offered controls.  
Ethical permission was sought from both the NHS and Edinburgh Napier University. 
 
Isolation and Purification of AGP from ‘normal’ (healthy individuals) blood - pooled by 
the blood transfusion service - adopted a method which prevented desialylation and 
denaturation i.e. structural integrity was not compromised and remained in the form 
found in vivo, which was important to the study.  The techniques were subsequently 
used in the isolation and purification of AGP from the blood of consenting patients, and 
from the serum of an additional ‘normal’ population.  
 
To determine if the glycosylation of AGP differed between subject groups, the 
monosaccharides and oligosaccharides were analysed.  Quantitative data was generated 
through monosaccharide compositional analysis by high pH-anion exchange 
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chromatography (HPAEC).  Subsequent oligosaccharide indicated if there were any 
changes in the branching of the glycan chains. The type of terminal sialic acid linkage 
was determined by ELISA. 
 
Methadone drug binding studies with commercial AGP, normal pooled blood and 
patient blood were performed to determine if AGP isolated from certain patients 
inactivated more drug.  This was then compared to data obtained during structural 
analysis to determine if there existed any correlations between AGP glycosylation and 
drug binding.  Another opioid – codeine - was used in similar studies with commercial 
AGP to investigate whether binding occurred.  Such studies provide an indication that 
other drugs may offer a superior choice in terms of reduced or no plasma protein 
binding, despite their use currently being more reserved than methadone.  The study 
only addressed binding to AGP and there were likely to be many other factors which 
could render these alternatives less effective than methadone.   
 
Overall, the project aspired to identify potential relationships between AGP 
glycosylation and methadone binding in patient groups so that further studies may be 
carried out with increased study populations.  
  
59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. Research Summary. 
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Chapter 2 
Materials and Methods 
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2.1 Materials  
 
 
2.1.1 Patient clinical samples 
 
The Lothian NHS and Edinburgh Napier University Ethics committees approved the 
initial study where ~5mL blood samples were obtained from patients (n=12) undergoing 
various stages of treatment for opioid addictions at the Community Drug Problem 
Service (CDPS) in Edinburgh.  Treatment groups included those initially recruited in 
the Titration phase (T), those attending the Harm Reduction scheme (HR), Long-term 
methadone (LT), buprenorphine (B), dihydrocodeine (D) and heroin (H) patients.  An 
application to increase the study size and specificity by recruiting additional patients 
from the T and LT phases was approved.   A total of twenty-six patients were recruited 
(table 2.1), mainly from LT maintenance therapy who were no longer required to attend 
the clinic daily (n=11).  Samples were collected in heparinised vacutainers (Becton 
Dickinson, France) by a trained phlebotomist and PEG precipitated as described in the 
Methods section 2.2.2.1, storing the supernatants at -20ºC until required.  The primary 
investigator discussed the study with the patients and only in the LT group was it 
feasible to involve their mentor in the recruitment process (Dr. Malcolm Bruce – 
collaborator).  In future studies of a similar nature it would be useful to pursue this 
additional interaction, potentially improving participant recruitment due to increased 
trust between the care user and mentor.  It would also standardise the recruitment 
process however careful consideration is required; it was not feasible to request the 
supervision of each individual’s mentor during this preliminary study due to constraints 
on their time and perception that the investigators were most qualified to discuss the 
study. 
 
Professor David George of the Glasgow Western Infirmary donated ‘normal’ serum 
samples; however upon analysis they were not deemed to offer a sound comparator as 
little information was known about the source population other than they were obtained 
from elderly cancer-free individuals.  Therefore it could not be known whether other 
factors could have initiated an acute phase response to alter AGP levels and 
glycosylation.  Instead, heparinised blood samples pooled from ‘normal’ healthy 
individuals supplied by the Scottish National Blood Transfusion Service were 
implemented throughout. 
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Patient number M/F Age Therapy group 
JB 0608 01 F 32 T  
JB 0608 02 F 23 T  
JB 0608 03 F 37 HR  
JB 0608 04 M 28 HR  
JB 0608 05 F 23 HR  
JB 0608 06 F 23 HR  
JB 0608 07 M 35 LT  
JB 0608 08 M 33 LT  
JB 0608 09 M 38 B 
JB 0608 10 F 36 LT  
JB 0608 11 M 29 B 
JB 0608 12 F 44 LT 
JB 0509 01 F 37 T   
JB 0509 02 M 30 B 
JB 0509 03 M 30 LT  
JB 0509 04 M 51 LT  
JB 0509 05 M 33 T   
JB 0509 06 M 20 T   
JB 0509 07 M 39 D 
JB 0509 08 M 30 B 
JB 0509 09 M 34 LT  
JB 0509 10 M 42 LT  
JB 0509 11 M 34 LT  
JB 0509 12 M 31 LT  
JB 0509 13 M * H 
JB 0509 14 M 30 LT  
 
 
Table 2.1 Patient Demographics. 
 
T - Titration phase with Methadone; HR - Harm reduction program Methadone 
LT – Long-term Methadone; B – Buprenorphine; D – Dihydrocodeine; H – Pure 
Heroin 
* Data regarding specific age was unavailable 
  
63 
 
2.1.2   AGP isolation 
 
Glacial acetic acid, polyethylene glycol (PEG) 3350, potassium chloride, potassium 
thiocyanate, Reactive Blue 2 Sepharose (Cibacron Blue 3GA), Red Sepharose CL-6B, 
sodium acetate, sodium azide, sodium chloride and Trizma base were supplied by 
Sigma-Aldrich

 (Poole, UK).  Ethanol was purchased from Bamford Laboratories Ltd., 
(Norden Rochdale, UK); diluted to give a 10% (v/v) solution.  HPLC-grade water was 
obtained from Rathburn Chemicals Ltd (Walkerburn, UK).  The poly prep disposable 
10mL columns were purchased from Bio-Rad, (Hemel Hempstead, UK).  To load 
buffers and sample supernatants, a Pharmacia LKB Pump P-1 was used and the 
absorbance of the mobile phase was measured by a single path optical UV-1 monitor 
and control unit (all from Pharmacia, UK).  The changing absorbance at 280nm was 
recorded by a Servogor 120 chart recorder, also from Pharmacia.  Blood samples were 
initially spun in an Eppendorf Centrifuge 5415C and all eluted samples concentrated 
using a Christ RVC 2-18 Concentrator (SciQuip Ltd, Shrewsbury, UK). 
 
 
2.1.3   De-salting  
 
HPLC grade water was purchased from Rathburn Chemicals Ltd (Walkerburn, 
Scotland, UK) and Centricon YM-10 Centrifugal filter devices with a dialysis 
membrane MW cut off 12,000-14,000Da were obtained from Millipore (UK) Ltd. 
(Hertfordshire, UK).  The company then replaced these with Amicon Ultra-4 centrifugal 
filter devices with a MW cut off of 10,000.  An MSE Centaur 2 (large scale) was used 
to spin the samples.  The Christ RVC 2-18 Concentrator was purchased from SciQuip 
Ltd (Shrewsbury, UK).   
 
 
2.1.4   Determination of AGP level in blood 
 
Calibration curves were produced using Commercial AGP obtained from Sigma-
Aldrich

 (Poole, UK) and HPLC grade water from Rathburn Chemicals Ltd. 
(Walkerburn, UK).  Absorbance was read on a BioMate 3 spectrophotometer purchased 
from Thermo Fisher Scientific

 (Loughborough, UK).  
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2.1.5 SDS-gel and Western Blot 
 
The production and staining of the gel required glacial acetic acid, glycine, methanol, 
TEMED, Tris-base, and SDS purchased from Sigma-Aldrich

 (Poole, UK), along with 
commercial AGP controls. A gel casting system VS10CBS was obtained from 
Geneflow (Staffordshire, UK).  Bromophenol blue, Dithiothreitol, sodium chloride and 
Na2 EDTA were purchased from New England Biolabs
®
 Inc (Hertfordshire., UK).  For 
the Western Blot the nitorocellulose membrane and filter paper were obtained from 
Whatman International Ltd., (UK).  Bio-Rad Laboratories (Hemel Hempstead, UK) 
supplied the non-fat dry milk and Promega (Hampshire, UK) the NBT and BCIP (with 
dimethylformamide). The primary antibody (anti-AGP antiserum, rabbit) and secondary 
antibody (goat anti-rabbit IgG, AP-linked) was purchased from New England Biolabs
®
 
Inc. (Hertfordshire., UK). Tween
®
20 was purchased from Sigma-Aldrich

 (Poole, UK). 
The omniPAGE gel casting system (VS10CBS) was purchased from Geneflow (UK). 
 
 
2.1.6    High pH anion Exchange Chromatography 
 
2.1.6.1 Monosaccharide Analysis 
 
Monosaccharide standards: 2-deoxy-D-galactose, fucose, galactose, glucosamine, 
mannose; along with the commercial AGP, 2mL hydrolysis reaction vials, aluminium 
lined screw caps, Dowex
®
-50WX8 cation exchange resin (hydrogen form, 12% cross 
linked, dry mesh 50-100) and constant boiling HCl were supplied by Sigma-Aldrich

 
(Poole, UK).  HPLC grade trifluoroacetic acid (TFA) was supplied by Thermo Fisher 
Scientific

 (Loughborough, UK).  Rathburn Chemicals Ltd. (Walkerburn, UK) supplied 
the HPLC-grade water and the 50% w/v sodium hydroxide was supplied by VWR 
International

 Ltd, (Lutterworth, UK).  The solutions were sparged and pressurised with 
helium using a Dionex Degas module. To perform HPAEC (High performance anion 
exchange chromatography) a CarboPac
TM
 PA-100 analytical (4x250mm) column and 
guard column (4x50mm), were used on a Dionex 600
TM 
system with pulsed 
electrochemical detection (PAD) (Dionex, Camberley, UK).  PeakNet
TM 
software run on 
a Dell OptiPlex GX110 computer controlled the GP50 gradient pump and ED40 
electrochemical detector (Dionex, Camberley, UK). 
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2.1.6.2    Oligosaccharide Analysis 
 
New England Biolabs

 Inc., (Hertfordshire, UK) provided the Peptide-N-Glycosidase F 
(PNGase F) purified from Flavobacterium meningosepticum, 10% NP-40 and NE 
Buffer G7.  HPLC-grade water was purchased from Rathburn Chemicals Ltd. 
(Walkerburn, UK).  Ethanol was obtained from Bamford Laboratories Ltd. (Rochdale, 
UK) and the AGP N-linked glycan library from Prozyme
® 
(Europa Bioproducts Ltd. 
Cambridgeshire, UK).  Sigma-Aldrich

 (Poole, UK) supplied the Sodium Acetate and 
the 50% w/v NaOH 50 by VWR International

 Ltd (Lutterworth, UK).  A CarboPac
TM 
 
PA-100 analytical column (4x250mm) and guard column (4x50mm) were used on a 
Dionex 500
TM
 system with GP50 gradient pump, ED40 electrochemical and pulsed 
electrochemical detection to carry out HPAEC (Dionex, Camberley, UK).  Samples 
were analysed using PeakNet
TM
 software on a Vtech 486X25 computer (Viglen, UK). 
 
 
2.1.7 Determination of SA content (ELISA) 
 
GALAB (Geesthacht, Germany) supplied the sialic acid linkage determination kit 
consisting of 96-well microplates, α2,3-sialic acid and α2,6-sialic acid lectin conjugates 
(<0.1% sodium azide), an enzyme conjugate, substrate, inhibition control, assay buffer 
(20x concentrated Tris buffered saline, pH8.0 – 20% Tris aminomethane, 8% Tris 
aminomethane, 0.1% sodium azide), detergent (Assay Buffer Additive), detection buffer 
(>10% diethanolamine) and equilibration buffer (2x concentrate tris buffered saline, pH 
8.0 - >2% Tris aminomethane (hydrochloride), 1% Tris aminomethane, 0.1% sodium 
azide).  Commercial AGP was purchased from Sigma-Aldrich 

 (Poole, UK).  Analysis 
was performed using a microtitre plate reader from Dynex Technologies (Sussex, UK). 
 
2.1.8 Drug binding 
 
(±)-methadone, theophylline, Dulbecco’s phosphate buffered saline and dimethyl 
sulphoxide were supplied by Sigma-Aldrich

 (Poole, UK).  Rathburn Chemicals Ltd 
supplied the HPLC-grade water (Walkerburn, UK).  96-well microtitre plates were 
purchased from Nunc (Germany).  A BMG Labtech Optima fluorimeter (Germany) was 
used to analyse the intrinsic fluorescence of samples. 
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2.2  Methods  
 
 
2.2.1   Clinical Samples   
 
A trained phlebotomist obtained 2-5mL blood samples from patients undergoing 
methadone therapy, after informed consent from volunteers over the age of 18 was 
acquired.  All samples were completely anonymised.  Initial methodology development 
was carried out using commercial AGP from Sigma-Aldrich

 and pooled heparinised 
‘normal’ blood (blood transfusion service).  
 
 
2.2.2   Isolation and determination of the level of AGP  
 
Protocols similar to that reported by Elliott et al. (1997) were implemented in the study.  
The method was first published in 1994 (Smith and colleagues) however certain aspects 
have been altered over time to allow for reduced sample volumes. 
 
2.2.2.1  Polyethylene Glycol Precipitation 
 
Prior to determining the level of AGP in each patient and normal sample, the blood was 
separated into 1mL aliquots and protein precipitation performed by mixing with 40% 
(w/v) PEG 3350 (0.4g/1mL sample).  They were incubated at 4°C overnight followed 
by a 30 minute centrifugation at 14,000 rpm.  Centrifugation was repeated if remnants 
of the red blood cells were detected.  The supernatant was collected in new eppendorfs 
and stored at -20°C until required for purification, the pellet was discarded. 
 
2.2.2.2  Low Pressure Chromatography 
 
The AGP present in the supernatant of each sample was isolated and purified through 
the use of two low-pressure chromatography columns, implementing dye ligand 
chromatography.  Two 10mL Bio-Rad poly-prep disposable columns were used; one 
filled with ~5mL of Cibacron Blue 3GA Sepharose resin (binds and removes human 
serum albumin, HSA) and the second with Red Sepharose CL-6B (to remove remaining 
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α1-anti-trypsin, AAT).  The resin slurries were kept wet at all times to ensure no air 
bubbles became trapped within the column, causing resin splitting which would affect 
the separation of plasma proteins.  Buffers required in the low pressure affinity 
chromatography protocol were prepared according to table 2.2 and utilised when 
necessary. 
 
Initially, the appropriate elution buffer was pumped through the Cibacron Blue 3GA 
Sepharose column at a rate of 0.5mLmin
-1
, using a Pharmacia LKB Pump P-1, until 
equilibration was attained.  This was illustrated on the Servogar 120 chart recorder, 
running at 12cm/hour, as a ‘flat’ base-line; recording the change in the eluent 
absorbance at 280nm, as measured by a UV
-1
 single path monitor optical unit.  The 
supernatant formed upon PEG 3350 precipitation of a blood sample was applied to the 
column.  Elution buffer was applied simultaneously and the eluted sample represented 
by the first peak generated by the chart recorder was collected in 15mL centrifuge tubes; 
this fraction contained AGP.  HSA was removed from the mobile phase – its bilirubin 
binding sites becoming bound to the Cibacron Blue.  The eluted fraction was then 
concentrated to approximately 2mL in a rotary evaporator. 
 
Once entirely collected, the column was regenerated by adding the desorption buffer to 
dislodge the HSA bound to the column.  It was re-equilibrated using elution buffer to 
prepare it for the addition of subsequent samples.  All samples were dried under a 
vacuum to approximately 2mL ready for loading onto the Red Sepharose CL-6B 
column.   
 
After equilibration of the Red Sepharose column with its elution buffer (table 2.2), a 
concentrated sample from the Cibacron Blue column was applied and further elution 
buffer used to collect the AGP fraction.  The eluted AGP peak, the first distinguished by 
the chart recorder, was collected in 15mL centrifuge tubes.  Any bound AAT was 
finally removed upon addition of the cleaning buffer (table 2.2).  The pure AGP-
containing fractions were again dried to 2mL in the rotary evaporator prior to desalting. 
 
In order to prevent bacterial growth and the columns drying out after use, 10% Ethanol 
was added to each column and stored at 4°C. 
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Column Buffer Reagents 
Cibacron Blue 3GA 
Sepharose 
Elution 0.1mM Potassium Chloride  
0.02% Sodium Azide  
50mM Trizma 
pH 7 
(albumin binds to column) 
Desorption 0.1mM Potassium chloride  
500mM Potassium thiocyanate 
0.02% Sodium Azide 
50mM Trizma 
pH7 
(removes bound albumin) 
Red Sepharose CL-6B 
Column 
Elution 1.15% Glacial Acetic Acid 
 30mM Sodium Acetate, 
pH 5.7 
(α1-antitrypsin binds column) 
Cleaning Buffer 30mM Sodium Acetate  
1M Sodium Chloride  
 
Table 2.2. Isolation buffers for low pressure chromatography. 
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2.2.3   De-salting 
 
Salt introduced during isolation was removed from samples T1, T2, HR1 and LT1 using 
individual centricon
®
 centrifugal cartridges to prevent contamination.  Three drops of 
HPLC grade water were used to moisten the membrane.  Concentrated sample (~2mL) 
collected after isolation was added and, by centrifugation at 4,000 rpm, any salts 
introduced during low-pressure chromatography, were removed by filtering through the 
membrane (MW cut-off 10,000).  Once the salt solution passed through the membrane, 
the sample was washed with HPLC grade water until the filtered solution was clear.  To 
collect the dry desalted AGP sample on the membrane, the cartridges were inverted and 
three drops of HPLC-grade water added.  The samples were collected in fresh 
eppendorfs, dried to completion under a vacuum, and reconstituted in 1mL HPLC grade 
water to allow the level of AGP to be determined. 
 
The remaining samples were desalted using Amicon filter devices due to a design 
modification made by the company (Millipore, UK). The 2mL sample from the 
isolating stage was added to the cartridge and made up to approximately 3.5mL using 
HPLC-grade water.  The dissolved salt passed through the membrane (MW 10,000 cut-
off) and the sample was washed several times with HPLC-grade water.  Desalted 
samples collected in the tube were reconstituted in approximately 500µL HPLC-grade 
water and added to new eppendorfs; they did not require inversion like the previous 
design.  These were then dried and reconstituted as above.    
 
 
2.2.4   AGP level determination 
 
Using the samples re-constituted in 1mL HPLC-grade water, the level of isolated AGP 
was determined using a spectrophotometer. Reference was made to a Standard curve 
produced using the absorbance values at 280nm of a series of dilutions of commercial 
AGP standards in HPLC-grade water (0mg/mL to 3mg/mL) – refer to section 5.2.3.  
This wavelength is often chosen in the determination of protein levels because proteins 
absorb strongly while other substances commonly in protein solutions do not.  A 1mL 
quartz cuvette with pathlength of 1cm and an extinction coefficient of 29.7 mM
-1
 cm
-1
 
was used in spectrophotometric determination. 
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2.2.5 SDS-gel and Western Blot 
 
2.2.5.1 Discontinuous SDS-PAGE 
 
To determine whether the isolation and purification procedures were effective, sodium 
dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) was performed.  
Separation of proteins present in the supernatant of a PEG precipitated blood sample 
and those present after the isolation process was performed alongside commercial 
controls and a ladder; based on their size and molecular weight.  This was not used to 
isolate AGP because SDS is an anionic detergent which can damage sugar structures 
and would therefore be detrimental in the analysis of glycoproteins.  When SDS is 
added to a sample of protein and heated to 100
o
C the protein becomes denatured into 
separate polypeptides and a negative charge is generated when they become bound to 
SDS, the size of this is dependent on the length of peptide. 
 
The large pore polyacrylamide ‘stacking’ gel - approximately 2pH units lower than the 
electrophoresis buffer – was cast over a small pour acrylamide ‘resolving’ gel to 
produce a discontinuous buffer system; their preparation is described below.  SDS-
bound proteins become concentrated in the stacking gel ready to migrate into the 
resolving gel to allow separation based upon size. 
 
2.2.5.2 Resolving gel preparation 
 
Spacers of 2mm and a 2mm, 12-well comb were used to set up the omniPAGE gel 
casting system (VS10CBS) and allowed 10cm vertical separations to be performed.  
Acrylamide resolving gels (10% w/v) were used because the molecular weight of AGP 
is ~43kDa and this gel has a resolution of ~20-75kDa, therefore it is capable of 
resolving proteins including albumin and AAT (MW 67kDa and 52kDa respectively). 
  
The gel consisted of the components as stated in table 2.3; all components were added 
in the order stated.  A final addition of 7.5µl of N,N,N’,N’-tetramethylethyenediamine 
(TEMED, >99% pure) allowed polymerisation of the gel components, this was 
catalysed by the addition of the oxidising agent APS.  To ensure no bubbles formed, the 
mixture was carefully mixed before loading between the two glass plates.  A 3cm space 
was left above the gel and 1mL isopropranol layered on to reduce the gels contact with 
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air and ensure an even surface was formed.  This layer was then decanted after a 30min 
polymerisation and the top of the gel was rinsed with distilled water and filter paper 
used to blot it dry. 
 
2.2.5.3 Stacking gel preparation 
 
On the addition of 6.7µl of TEMED (>99% pure) to the stacking gel components in 
table 2.4, the mixture was poured on top of the resolving gel.  A comb was inserted and 
the gel was left at room temperature for 30min while the gel polymerised.  Upon setting, 
the comb was removed and the gel rinsed with Tris-glycine electrophoresis buffer (table 
2.5) to remove un-polymerised material. 
 
The gel was transferred from the casting chamber into an electrophoresis tank and 
submerged in Tris-glycine electrophoresis buffer.  The samples and ladder were heat 
denatured for 5 min at 100
o
C and up to 25µl loaded into appropriate wells.  The 
molecules were concentrated in the stacking gel over 15 min at 50V then separated in 
the resolving gel at 100V for a further 50 min.  
 
2.2.5.4 Protein gel staining 
 
When the dye had run the length of the gel, it was carefully separated from the plates 
and any electrophoresis buffer was removed through two 10 min washes with distilled 
water on a slow rotating platform (50rpm).  The gel was immersed in 5x volume of 
Coomassie blue protein stain (table 2.6) and put back on the rotating platform (50rpm) 
for 1h.  The stain was decanted and the gel was de-stained over 6-8h with the solution 
recorded in table 2.7, changing the de-staining solution 3-4 times.  The gel was then 
visualised. 
  
72 
 
10% Resolving gel 1 x 10cm gel 
Distilled water 
30% (w/v) Stock acrylamide 
4x Resolving tris solution pH 8.8* 
10% (w/v) Ammonium persulphate 
3.15mL 
2.5mL 
1.875mL 
75μL 
 
Table 2.3. Composition of the 10% (w/v) resolving gel for SDS-PAGE. 
The APS was always added last.  * (1.5M Tris-HCl; 0.4% (w/v) SDS). 
 
Stacking gel 1 x 10cm gel 
Distilled water 
30% (w/v) Stock acrylamide 
4x Stacking tris solution pH 6.8* 
10% (w/v) Ammonium persulphate 
2.1mL 
0.325mL 
0.8mL 
3.35μL 
 
Table 2.4. Composition of the stacking gel.   
The APS was always added last. * (0.5M Tris-HCl; 0.4% (w/v) SDS). 
 
Reagents 1 x 10cm gel 
Tris-base 
Glycine pH 8.3 
SDS 
5mM 
50mM 
0.02% (w/v) 
 
Table 2.5. Composition of Tris-glycine electrophoresis buffer. 
 
 
 
 
 
 
 
 
Table 2.6. Composition of the coomassie blue protein stain.  
 
Reagents Percentage present 
Methanol 
Distilled water 
Glacial acetic acid 
45% (v/v) 
45% (v/v) 
10% (v/v) 
 
Table 2.7. Composition of de-staining solution. 
 
Reagents Percentage present in stain 
Coomassie brilliant blue R250 
Methanol 
Distilled water 
Glacial acetic acid 
0.25% (w/v) 
45% (v/v) 
45% (v/v) 
10% (v/v) 
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2.2.6 Western Blotting 
 
2.2.6.1 Blot sandwich assembly 
 
Filter paper – 2mm thick – and nitrocellulose membrane (0.2 µm, Optiran BA-S 83) 
were cut to fit the gel and pre-soaked in 1x continuous transfer buffer (CTB, table 2.8) 
for 15 min, alongside two fibre pads. 
 
The blot sandwich was assembled using forceps with the gel facing the negative pole. 
Some pre-chilled CTB was poured into the tank and a magnetic stirrer added.  The 
module containing the blot sandwich was inserted and the tank placed in a polystyrene 
container of ice.  The remainder of the cooled CTB was placed in the electrophoresis 
tank and the blot run at 75V for 100 min with a magnetic stirrer keeping the cool CTB 
circulating. 
 
2.2.6.2 Blocking of the membrane (reduction of non-specific binding) 
 
To saturate the unbound sites in the nitrocellulose membrane the blot was incubated in 
50ml 3% (w/v) non-fat dry milk in 1x Tris-buffered saline (table 2.9) for 1.5 h at room 
temperature.  The blot and solution were placed on a rotating platform (50 rpm). 
 
2.2.6.3 Immunoprobing with primary antibody 
 
Primary anti-AGP antibody (5μl) from the rabbit was added directly into the blocking 
solution (1:2,500 dilution).  It was then incubated for 30 min at room temperature on a 
rotating platform (50 rpm) to allow the antibody to mix, and then incubated overnight at 
4
o
C to bind.  Any unbound primary antibody was removed by washing the membrane in 
1x TBS/0.1% (v/v) Tween
®
20 for 6x 10 min washes. 
 
2.2.6.4 Immunoprobing with secondary antibody 
 
A 3μl volume of the secondary antibody (goat anti-rabbit IgG, AP-linked) was added 
into 50ml 3% (w/v) non-fat dry milk in 1x TBS (a 1:16,667 dilution) and incubated at 
room temperature for 1h on a rotary platform (50 rpm). Any unbound secondary 
antibody was washed off as described in section 2.2.6.3.  
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Table 2.8. Composition of 1x continuous transfer buffer (pH 8.3). 
 
Reagents Percentage present 
Tris-HCl pH 7.4 
NaCl 
50mM 
0.9% (w/v) 
 
Table 2.9. Composition of 1x Tris buffered saline. 
 
Reagents Percentage present 
Tris HCl (pH 9) 
MgCl2 
NaCl 
100mM 
1mM 
150mM 
 
Table 2.10. Composition of substrate buffer. 
 
 
 
  
Reagents Percentage present in stain 
Tris 
Glycine 
Methanol 
25mM 
192mM 
20% (v/v) 
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2.2.6.5. Immunodetection of proteins 
 
A BCIP (5-bromo-4-cholo-3-indoyl-phosphate)/NBT (nitro blue tetrazolium) 
chromogenic assay was used to identify proteins on the membrane.  It consists of three 
components; a combination of BCIP, NBT and an alkaline buffer resulting in a substrate 
solution for alkaline phosphatase.  An insoluble NBT diformazan product is formed 
upon incubation with the enzyme and was identified as a purple precipitate therefore 
allowing colorimetric detection of alkaline phosphate-labelled molecules. 
 
The membrane was rinsed in 50ml alkaline phosphatase buffer (table 2.10) to 
equilibrate the pH of the blot.  NBT (50mg/ml; 70% (v/v) dimethylformamide) and 
BCIP (50mg/ml; 100% (v/v) dimethylformamide) were added to a further 50ml of the 
alkaline phosphatase buffer; 330 µl and 165µl respectively.  The solution was mixed 
and added to the membrane, this was incubated at room temperature in the dark. Colour 
development occurred in approximately 30 minutes.  The membrane was rinsed with 
distilled water to stop the colour reaction and was blotted dry with filter paper.  The 
membrane was then visualised. 
 
 
2.2.7   High pH Anion Exchange Chromatography 
 
2.2.7.1   Acid hydrolysis 
 
Volumes of commercial and patient AGP samples corresponding to 50μg were added to 
individual reacti-vials and 100μL of 2M TFA added.  After replacing the aluminium 
lined caps, the samples were incubated at 100°C for 4 hours.  The basic sugars fucose 
(Fuc), galactose (Gal), and mannose (Man) were hydrolysed using this treatment.  
Simultaneously 50μg of AGP taken from the same samples were hydrolysed with 50μL 
of 4M HCl, at 100°C for 6 hours to hydrolyse the amine sugar GlcNAc.  Subsequently, 
1cm glass wool was packed in Pasteur pipettes to act as a plug for 1mL (pH4) Dowex
®
-
50 WX8 H
+
 cation-exchange resin, using separate columns for each sample to prevent 
contamination.  To wash the column, 6mL HPLC-grade water was added and eluted, 
followed by the sample hydrosylate from TFA hydrolysis treatments only.  HPLC-grade 
water (2mL) was added to collect the sample.  The eluted solutions were dried to 
completion in the rotary evaporator.  The HPLC-grade water and acid from HCl 
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hydrolysed samples were evaporated in a rotary evaporator (similar to the method 
adopted by Fan et al., 1994).  
 
All samples were then reconstituted in 20µL HPLC-grade water and 5µL internal 
standard (2-deoxy-D-galactose) to prepare the samples for monosaccharide analysis 
with high pH anion exchange chromatography (HPAEC). 
 
2.2.7.2   Monosaccharide analysis 
 
After drying to completion and reconstituting samples from the different hydrolysis 
conditions, the components of the glycans were analysed. The separation of the 
monosaccharides was performed using a Dionex 600
TM
 High pH Anion Exchange 
Chromatography (HPAEC) system with pulsed ampertomic detection (PAD). The 
pulsed potentials during PAD were 0 seconds (sec), 0.05V; 0.29sec, 0.05V; 0.49sec, 
0.05V; 0.5sec, 0.05V; 0.51sec, 0.6V; 0.6sec, 0.6V; 0.61sec, -0.6V; 0.65sec, -0.6V; 
0.66sec, 0.05V (refer to figure 2.1). The Dx-600 was fitted with CarboPac PA-100 
(containing quaternary-ammonium-bonded pellicular resins) analytical and guard 
columns, a GP50 gradient pump and ED40 electrochemical detector.  It was operated at 
ambient temperature.   
 
Before injecting any samples, the CarboPac PA-100 column was regenerated using 50% 
1M NaOH/50% HPLC-grade water for 15 minutes - this was repeated.  Mixtures of five 
monosaccharides – 5µg of Fuc, GlcNAc, Gal, Man and internal standard (2-deoxy-D-
galactose) - were injected and 3% 1M NaOH / 97% HPLC-grade water was passed 
through the column at a flow rate of 0.5ml/min in an isocratic gradient to ensure 
effective separation over 35minutes.  This was followed by 50% 1M NaOH/50% 
HPLC-grade water for 15minutes to allow regeneration of the column. The 
monosaccharide represented by each peak was identified by calculating the ratio of their 
retention times with the internal standard and comparing the values to those generated 
when the individual monosaccharides were run with internal standard.  Before any 
samples were analysed, standard curves for each of the five monosaccharides were 
produced, plotting the peak area values against the mass of monosaccharide present 
(µg).  The respective equations were used to quantify the monosaccharides present in 
the samples of AGP.  
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Figure 2.1. Pulsed potentials of the PAD system during HPAEC.  
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Subsequent to sample hydrolysis and reconstitution in 20μL HPLC water and 5μL of 
internal standard (1mg/ml), each was independently injected and separated by the 
column (using 3% 1M NaOH / 97% HPLC water – pH13) over 50 minutes at a flow 
rate of 0.5mL/min - this included a 15-minute regeneration period using 50% NaOH/ 
50% HPLC.  The system was then ready for the injection of the next sample.  Again, the 
peaks generated for each sample were identified based upon the ratios of retention time 
with the internal standard and the monosaccharide. 
 
2.2.7.3 Oligosaccharide analysis 
 
2.2.7.3a  Enzyme Digestion 
 
AGP sample volumes corresponding to 100µg of the glycoprotein were dried to 
completion under a vacuum and reconstituted in 100µl of HPLC-grade water. The 
samples were transferred into separate glass vials and aluminium lined caps fitted. They 
were then denatured at 100
o
C for 3 hours and dried to completion under a vacuum.  
 
A reaction mixture was prepared by adding the reactants stated in table 2.11 to the dry 
AGP samples to make a total reaction volume of 100µl.  The mixtures were incubated 
for 24 hours at 37
o
C followed by a second addition of 5U of PNGase F.  It was then 
incubated for a final 24 hours at 37
o
C.   
 
To separate the protein from the glycan chains ethanol precipitation was performed.  
After the 48 hour incubation period, 300µl of ice-cold 80% ethanol was added to the 
reaction mixture to provide a ratio of 3 parts ethanol to 1 part reaction mixture.  Once 
mixed, the samples were incubated overnight at -20
o
C.  They were then centrifuged at 
14,000 rpm for 30 minutes and the supernatant (containing the glycans) was collected in 
clean eppendorfs, the pellet discarded.  The supernatant was dried to completion using a 
rotary evaporator ready to be reconstituted in 25µL HPLC-grade water for 
oligosaccharide analysis. 
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reagents Volume present 
HPLC-grade water 
NE Buffer G7 
NP-40 
PNGaseF 
79µl 
10µl 
10µl 
5U 
 
Table 2.11. Composition of reaction mixture for enzyme digestion. 
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2.2.7.3b  Oligosaccharide HPAEC Analysis 
 
A Dionex 500
TM 
system was used with the same pulsed potentials for the PAD as 
described in figure 2.1.  A CarboPac PA-100 pellicular anion exchange column was 
used to separate the differently branched glycans.  It was first regenerated over two 
20minute cycles using 50% 1M NaOH and 50% HPLC grade water.  The dry sample 
supernatants from the enzyme digestion stage were reconstituted in 25µL of HPLC-
grade water.  Each was independently applied to the PA-100 column and the glycans 
separated based on their degree of branching using a series of different eluent 
conditions, all added at a flow rate of 1mL min
-1
.  The column was equilibrated for 10 
minutes using 10% NaOH/ 5% 1M NaOAc/ 85% HPLC grade water, the sample was 
then separated during a linear gradient over 45 minutes when the eluent proportions 
were 10% NaOH/ 20% NaOAc/ 70% HPLC grade water.  The column was regenerated 
over 10minutes with an eluent composition of 50% NaOH/ 50% HPLC grade water.  
The final equilibration step, lasting 5 minutes, required 10% NaOH/ 5% NaOAc/ 85% 
HPLC grade water.  
 
To allow comparison of sample and commercial AGP oligosaccharide composition, a 
human N-linked oligosaccharide library was separated, providing a reference profile.  
Approximately 5µg was injected. 
 
 
2.2.8 Sialic acid determination ELISA 
 
A 1:20 dilution of assay buffer (Tris buffered saline with detergent; concentration 
unavailable) was added to the first row of two 96-well microtitre plates (50% v/v), 
representing the 100% signal control i.e. where the binding of lectin enzyme conjugates 
would not be inhibited.  In the second row the inhibition control (positive control) 
supplied was plated (50% v/v) to represent 0% signal – no additional preparation was 
required of the reagent. 
 
Serial dilutions of AGP (5mg/mL) from a ‘normal’ healthy heparinised blood sample 
and isolated from patients undergoing titration, harm reduction and long-term 
methadone therapies were prepared with assay buffer and plated in triplicate (50% v/v) 
in the order of decreasing concentration. 
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To one plate, Sambucus nigra agglutinin (SNA) – the lectin conjugate for α2,6-linked 
SA - was added (50% v/v) to each well.  Macckia amurensis Leukoagglutinin (MAL) 
was added in the same volumes to the wells of the second plate to detect α2,3-linked SA 
residues.  The lectin conjugates were supplied in 100x concentrated form therefore they 
were diluted prior to their use. 
 
The microtitre plates were incubated at room temperature in the dark for 2 hours.  Upon 
removal, they were cooled at 4°C for 5minutes then washed with cold Assay buffer 
(~200μL in each well).  The plates were then emptied and washed a further four times 
with cold assay buffer dropped onto paper towels between each wash to remove 
unbound lectin conjugate and AGP. 
 
The enzyme conjugate, which was supplied in a 10,000-fold concentrated form, was 
diluted to a working concentration and added to all wells of the two plates in 100μL 
aliquots and both were incubated at room temperature in darkness.  After 2h incubation 
the plates were cooled for 5minutes at 4°C and subsequently washed with cold assay 
buffer (200μL pre well) a total of three times. 
 
All wells were then washed twice in diluted equilibration buffer (1:2 dilution of the 2x 
concentrated buffer supplied with deionised water).   
 
Immediately prior to measurement of the absorbance of the well reagents at 405nm, 
100μL of enzyme substrate was added to each well (2.8mg/mL solution in detection 
buffer supplied in the kit; 0.36% w/v) to catalyse the reaction which was followed 
colourimetrically.  
 
Absorbance was analysed after 5, 20, 35 and 50 minutes to determine the most 
appropriate time interval for the reaction to take place and highlight the greatest 
variation between controls and samples. 
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2.2.9  Drug Binding Assay 
 
2.2.9.1 Commercial AGP and Methadone standards 
 
To conserve as much sample as possible and allow drug binding analysis to be 
replicated, the study was performed at the microtitre level, using Nunc 96-well 
microtitre plates. This technique was tested using theohylline; a drug known to bind 
AGP as described in the method validation chapter (section 3.4). 
 
Initially commercial AGP (5mg/mL) was added to a microtitre plates in 10µL volumes 
alongside a range of methadone concentrations (25-2500µM), diluted from a 5mM 
stock; each at 10µL.  The drug was dissolved in DMSO.  D-PBS was used to make 
wells up to a final volume of 100µL, 80µL applied to those wells containing both AGP 
and drug and 90µL in those only containing AGP (0mg/mL drug).  Therefore, the AGP 
and drug standards were diluted 10 fold on the plate.  All conditions were plated in 
triplicate.  The plates were then excited at 280nm and the fluorescence emitted at 
340nm (emission maximum of AGP) was recorded using an Optima fluorimeter.  The 
method was modified using commercial AGP at a concentration of 0.5mg/mL in order 
to provide data relative to that of samples; limited sample availability meant 
concentrations of 5mg/mL were unachievable.  The concentration of drug standards 
remained the same because when made 10 fold lower, the fluorescence was undetected 
by the fluorimeter, thus the technique was ineffective.  
 
2.2.9.2   Determination of methadone binding to sample AGP 
 
AGP isolated from the blood of healthy volunteers and patients undergoing methadone 
therapy was used at a concentration of 0.5mg/mL (reconstituted in d-PBS).  Methadone 
standards were produced using DMSO to include values representing the therapeutic 
level of methadone (~400ng/mL).  The lowest concentration was 370ng/mL (1.07µM); 
10 fold lower than the 3700ng/mL (10.7µM) plated.  Concentrations much lower than 
this did not alter the fluorescence emitted.  Higher concentrations were added; 
30µg/mL, 75µg/mL and 865µg/mL (86.7, 216 and 250µM respectively) to indicate the 
change in binding; all were diluted ten-fold upon plating.  Thus, because AGP levels 
were not 10 fold greater when plated, results are not indicative of the situation in vivo 
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but still represent useful data when determining differences in binding between 
individuals. 
 
 
2.2.10  Statistical Analysis 
 
The Pearson correlation coefficient (R
2
) was calculated for the monosaccharide 
calibration curves, using Microsoft
®
 Excel 2007; a linear fit represented by a value of 1.  
To calculate mean and standard deviations of data Microsoft
®
 Excel 2007 was also 
used. Two sample t-tests and one-way ANOVAs (with Tukey’s post hoc) were 
performed using Minitab, version 15, to determine the statistical significance of all 
quantitative data generated during the various analyses. 
 
 
 
SUMMARY STATEMENT 
Methods required for the structural analysis of glycans were only utilised and analysed 
in subsequent chapters for AGP isolated from heparinised blood samples provided by 
the Blood Transfusion Service and patients recruited from various stages of opioid 
replacement therapy.  That isolated from serum samples taken from elderly individuals 
(cancer-free) and commercially sourced AGP were not deemed adequate representations 
of a ‘normal’ healthy population – little information regarding the potential presence of 
an APR in the former population was available while isolation of commercial AGP 
differed to that utilised in this study.  The use of acidic conditions in isolation could not 
be avoided in the large-scale commercial methodology. 
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Chapter 3 
Validation of Methods 
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3.1 Introduction 
 
 
The following chapter describes the studies that were performed prior to the main 
investigation in order to determine the optimal conditions for monosaccharide 
compositional analysis and drug binding studies. 
 
Analysis of the monosaccharide composition of AGP glycans required the use of acid 
hydrolysis to cleave the glycosidic bonds between the monomeric units prior to 
separation by HPAEC.  It had been common practice in the laboratory to incubate 50μg 
AGP for 4 hours at 100ºC with trifluoroacetic acid (TFA) and hydrochloric acid (HCl) 
simultaneously.  However, similar studies indicated that separate use of HCl and TFA 
provided optimum hydrolysis (Fan et al., 1994).  Therefore it was deemed necessary to 
investigate the most efficient methodology because the research documented in this 
thesis was based on structural analysis thus insufficient cleavage or monosaccharide 
instability under acidic conditions risks the generation of erroneous data and subsequent 
conclusions drawn would be inaccurate. 
 
Additionally, adaptations to the methodology utilised previously by the group (Johnson 
and Smith, 2006) to analyse drug binding to AGP were required.  The concept of 
exploiting the intrinsic fluorescence of specific amino acids (namely Trp and Tyr) in the 
hydrophobic binding pocket for such studies was introduced by Parikh and co-workers 
(2000).  The fluorescence emitted is highest at 340nm for AGP due primarily to the 
emission by Trp residues, and is reduced (quenched) on the binding of drugs or ligands 
hence fluorescence studies offer potential in the detection of drug binding.   
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3.2 Methodology  
 
 
3.2.1 Optimisation of monosaccharide release  
 
3.2.1.1 Monosaccharide stability 
 
Before hydrolysis was undertaken, it was deemed important to ensure the 
monosaccharides under investigation were not degraded when incubated at 100°C under 
acidic conditions for up to six hours. 
 
Monosaccharide standards (Sigma-Aldrich), each approximately 7μg, were incubated 
with TFA or HCl alone, or a combination of the two. HPAEC-PAD (described in 
section 2.2.7.2) was performed on the samples of monosaccharide every hour (n=3) 
with final analysis occurring at 6h, to determine if they remained stable under the 
different conditions.   
 
3.2.1.2   Development of optimal hydrolysis conditions 
 
In order to determine which of the techniques employed by the various groups provided 
the optimum hydrolysis of AGP glycans, experiments were performed with 50μg 
commercial AGP hydrolysed for 4h with both 100 μL 2M TFA and 50μL HCl, the same 
conditions but incubated for 6h, 50μg hydrolysed for 4h with 100 μL 2M TFA alone 
and 50μg hydrolysed for 6h with 50μL 4M HCl alone.  The levels of each 
monosaccharide were determined after these incubation periods.  Additionally, 
commercial AGP samples were incubated under the same conditions but analysed each 
hour to determine whether the hydrolytic conditions deemed most effective in the 
previous experiment were not bettered if incubated for alternative time periods. 
 
3.2.1.3 Dowex
®
 Cation-Exchange Column study 
 
A study was carried out to test whether Dowex
®
-50 H
+
 cation-exchange resins interfere 
with the elution of monosaccharide components when used to remove proteins after 
hydrolysis.   Three 25μg aliquots of the standard control HPAEC mixture (5μg of Fuc, 
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GlcNAc, Gal, Man and an internal standard of 2-deoxy-D-galactose) were passed 
through the Dowex
®
 column.  The mass of each monosaccharide obtained was 
compared to values for an identical mixture that was directly injected into the HPAEC 
system in order to determine any losses due solely to the resin.   
 
Additionally, 50µg commercial AGP samples - hydrolysed using the four acidic 
conditions above (4M HCl alone for 4 hours, TFA alone for 6 hours, and both acids for 
4 and 6 hours), but not passed through Dowex
®
-50 H
+
 cation exchange columns - were 
analysed to establish whether there were any significant effects on the component 
monosaccharide levels when compared to those passed through the columns.  In place 
of the Dowex
®
 column, the hydrolysed samples were dried in a rotary evaporator after 
hydrolysis and subsequently washed twice with 200µL HPLC-grade water (as reported 
by Fan et al., 1994).  Post-hydrolysis all samples, regardless of the treatment, were 
immediately dried and reconstituted in 20µL water and 5µL IS to allow separation by 
HPAEC upon injection, subsequently assisting the identification of the method least 
likely to compromise monosaccharide yield.  
 
The hydrolysis conditions chosen after comparing all the results from the studies above 
was described in section 2.2.7.1.  
 
 
3.2.2  Microtitre plate drug binding assay  
 
Initial fluorescence studies were undertaken at the University of Strathclyde where 
fluorescence emission spectra were generated in the absence and presence of drugs 
known to bind AGP (refer to section 3.3.2).  The studies affirmed that maximum 
emission occurred at approximately 340nm as has been well documented for Trp 
residues (Chen and Barkley, 1998).  Therefore in subsequent studies at Edinburgh 
Napier University, where the scanning function was unavailable, a specific filter was 
utilised. 
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3.2.2.1 Testing method with Theophylline 
 
Initially the micro-titre plate method was tested by performing studies using a range of 
theophylline concentrations (25-2500µM), diluted from a 5mM stock, and 5mg/mL 
commercial (Sigma) AGP.  Both were dissolved in d-PBS. Commercial AGP (5mg/mL) 
was added to individual wells on a Nunc 96-well microtitre plate at a volume of 10µL 
(10% v/v).  Each drug standard was then added to the AGP wells, also at a volume of 
10µL (10% v/v) and d-PBS was used to make up a final volume of 100µL.  All 
conditions were plated in triplicate.  The plates were then excited at 280nm and the 
fluorescence emitted at 340nm (emission maximum of AGP) was recorded using an 
Optima fluorimeter.  Results were graphed in figure 3.4. 
 
The method was modified to allow for small volumes of sample AGP; 5mg/mL was 
unobtainable due to restrictions enforced on the project.  Therefore 0.5mg/mL was used 
(figure 3.4).  The concentration of drug standards remained consistent with the previous 
experiment because when made 10-fold lower, fluorescence was undetected.  
 
3.2.2.2  Microtitre plate and Methadone 
 
The same range of concentrations (25-2500µM) were produced with methadone, in d-
PBS, and added to wells containing 10µL of either 5mg/mL or 0.5mg/mL commercial 
AGP.  As described above (section 3.2.2.1), finite sample volumes meant 0.5mg/mL 
AGP was used in all sample analyses. The effects on the fluorescence of AGP in the 
presence of methadone in this case were graphed in figure 3.5.  
 
3.2.2.3  Methadone dissolved in d-PBS versus DMSO 
 
The two concentrations of commercial AGP - 0.5mg/mL and 5mg/mL were made using 
d-PBS, as above (section 3.2.2.1).  A concentration range similar to that of theophylline 
was produced for methadone (25-2500µM) but using DMSO.  Each drug standard was 
added to wells containing 10% (v/v) of either 5mg/mL or 0.5mg/mL commercial AGP 
and made up to 100µL with d-PBS (methadone was therefore present in the 
concentration range 2.5-250μM).  The results (figure 3.6) were compared to those 
generated when d-PBS was used a solvent (figure 3.5), the reduction in fluorescence 
was far more evident with DMSO. 
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3.3 Results 
 
 
3.3.1 Optimisation of monosaccharide release methodology 
 
3.3.1.1 Monosaccharide stability 
 
Overall, the neutral monosaccharides displayed decreased stability in the presence of 
HCl (figure 3.1a-c).  When combined with TFA, the stability was generally improved 
on that in the presence of HCl alone.  Fuc levels were most stable over longer periods in 
the presence of TFA alone; the other acidic conditions caused a decrease, over time.  
Gal and Man also appeared to become less stable as incubation periods lengthened 
when HCl was present, either alone or alongside TFA.  The basic monosaccharide GlcN 
(GlcNAc is deacetylated during hydrolysis) remained largely unaffected by the acidic 
conditions however it was more stable in the presence of HCl than any other 
monosaccharide (figure 3.1d). 
 
3.3.1.2 Acid Hydrolysis optimisation 
 
Table 3.1 summarises the mean values of each monosaccharide obtained – according to 
HPAEC separation and detection – upon hydrolysis of commercially sourced AGP 
under four acidic conditions (n=4 for each condition).  The amount of monosaccharides 
obtained during the combined hydrolysis technique was compared to the other 
conditions tested (reported in table 3.2).  Tables 3.1 and 3.2 indicate that the most 
effective yield of neutral monosaccharides was obtained by using TFA alone (p<0.05).  
Greatest significance was found for Gal which is a monosaccharide only present in the 
branches of N-linked complex chains, its presence is therefore correlated with chain 
branching.  Ensuring its optimal release was important for the subsequent structural 
studies.  
 
Although the most effective method of cleaving GlcNAc residues initially appeared to 
be the combined use of acids (table 3.1 and 3.2), a further study was deemed necessary 
upon reading the literature and analysing the values generated during hydrolysis of 
commercial AGP, which seemed low.  This involved the removal of the dowex column 
as described in section 3.1.3.   
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a)
 
b) 
 
 
Figure 3.1. Stability of monosaccharides.  
a) Fuc and b) Gal when incubated under three acidic conditions; 
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c) 
 
d) 
 Figure 3.1 continued. Stability of monosaccharides.  
c) Man and d) GlcN when incubated under three acidic conditions; 
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Firstly, when a mixture of the five monosaccharides of known masses (each 5µg) was 
passed through a dowex
®
 column, the level of GlcN (deacetylated GlcNAc) recorded by 
HPAEC was significantly lower than 5µg (approximately 3.1μg, p<0.05).  The other 
monosaccharides were unaffected.  Subsequently 50µg (n=6) commercial AGP samples 
were hydrolysed using a combination of 2M TFA and 4M HCl incubated for 4h and 
50µg hydrolysed using the acids alone (n=6). Three samples treated under each 
condition were passed through dowex
®
 columns and the remaining six samples were 
washed with HPLC-grade water (2 x 200µL) and directly injected.  As shown in table 
3.3, it was found that when the AGP samples were hydrolysed with HCl and washed, 
not passed through dowex cation-exchange resins, the levels of GlcN detected were 
significantly greater than those in table 3.1 where the column was used (+1.434 µg, 
p<0.05).  Nevertheless, the neutral monosaccharides benefited from passage through a 
dowex column.  Therefore, the separate use of acids was found to improve the 
hydrolysis of the glycan chain monosaccharide components.  
 
The above investigation only analysed samples after four or six hour incubation periods 
as described by the protocols tested (described by Fan et al. (1994) and past researchers 
in the Smith group).  To ensure these time periods were optimal for monosaccharide 
cleavage, samples were incubated under the same conditions but, each hour, aliquots 
amounting to 100µg of AGP were analysed (in triplicate) to identify the level of the 
monosaccharides present at each time point; shown in figure 3.2, where peak area 
values are correlated with the mass of monosaccharide.  
 
Again, it can be seen that incubating the samples separately was most effective, 
particularly for Gal and GlcNAc hydrolysis.  Importantly, it was shown that, for Man, 
the use of TFA for 4h provided maximal release of the monosaccharide.  Incubation 
with TFA for 4h also provided elevated cleavage of Fuc and Gal; although the values 
were not significantly different to that at 3 or 5h (p>0.05).  When HCl was combined 
with TFA, the peak area values at each time point were generally lower than those when 
TFA was used alone. In the presence of HCl alone, hydrolysis of the neutral 
monosaccharides was not effective.  For GlcN, the study showed that isolated use of 
HCl provided most effective hydrolysis at 6h, supporting the results in table 3.3.  
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 Mean mass of monosaccharide ± stDev (µg) 
Hydrolysis condition Fucose GlcNAc Galactose Mannose 
2M TFA/ 4M HCl 4h 0.13 ± 0.02 3.04 ± 0.35 3.24 ± 0.41 1.62 ± 0.04 
2M TFA/ 4M HCl 6h 0.09 ± 0.08 2.37 ± 0.13 3.13 ± 0.33 1.48 ± 0.17 
2M TFA 4h 0.26 ± 0.05* 1.54 ± 0.08 4.52 ± 0.80* 2.27 ± 0.25* 
4M HCl 6h 0.15 ± 0.15 2.74 ± 0.05 3.62 ± 1.27 1.57 ± 0.46 
 
Table 3.1. A comparison of the mean mass of monosaccharides.  Generated 
during hydrolysis of commercial AGP under the four different acid hydrolysis 
conditions ± standard deviation 
 
 Mean difference in mass of monosaccharide compared to 
that generated using 2M TFA/ 4M HCl 4h (µg) 
Hydrolysis condition Fucose GlcNAc Galactose Mannose 
2M TFA/ 4M HCl 4h  0.13  3.04  3.24  1.62 
2M TFA/ 4M HCl 6h - 0.06 - 0.67 - 0.10 - 0.13 
2M TFA 4h + 0.14 - 1.50 + 1.29 + 0.65 
4M HCl 6h + 0.02 - 0.30 + 0.38 - 0.05 
 
Table 3.2. Summary of the difference in mass of monosaccharides obtained 
during hydrolysis.  Commercial AGP glycan composition under the four different acid 
hydrolysis conditions compared to the combined use of TFA and HCl for 4h. 
 
 Mean mass of monosaccharide ± stDev (µg) 
Hydrolysis condition Fucose GlcNAc Galactose Mannose 
2M TFA/ 4M HCl 4h 0 4.217 1.344 0.563 
2M TFA 4h 0.050 4.000 2.047 0.881 
4M HCl 6h 0 4.477* 1.133 0.341 
 
Table 3.3. Mean mass of monosaccharides obtained upon removal of the dowex 
cation exchange resin.  * Statistically significant improvement compared to 2M 
TFA/4M HCl 4h (p<0.05). 
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a) 
 
b)
 
 
 
Figure 3.2. Release of monosaccharides from commercial AGP.   
a) Fuc and b) Gal over 6h when incubated with: 
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c) 
 
 
 
 
d) 
 
 
 
Figure 3.2 continued. Release of monosaccharides from commercial AGP.   
d) Man and d) GlcN over 6h when incubated with;  
 
0
5000000
10000000
15000000
20000000
25000000
30000000
35000000
40000000
0 1 2 3 4 5 6 7
P
ea
k 
A
re
a
time (hours)
Man
0
5000000
10000000
15000000
20000000
25000000
0 1 2 3 4 5 6 7
P
ea
k 
ar
ea
time (hours)
GlcNAc
  * 
96 
 
3.3.2 Microtitre plate drug binding assay  
 
The excitation of AGP at 280nm generates a fluorescence emission spectra between 
300-400nm, as illustrated in figure 3.3a, with the maximum fluorescence occurring at 
approximately 340nm. When STI571 - a drug known to bind AGP (Jørgensen et al., 
2002) was introduced to commercial AGP at increasing concentrations, the bell-shaped 
curve was found to reduce in height (figure 3.3b); the fluorescence was quenched.  
Conversely, when a drug was introduced which did not bind AGP, the spectrum was not 
affected (figure 3.3c) hence fluorescence studies are useful in the detection of drug 
binding. As formerly stated, emission spectra could not be generated using the 
equipment available and therefore a specific 340nm filter was used to detect the 
maximal values; important in fluorescence-based drug binding analysis.  
 
As shown in figure 3.4, microtitre plate assays are useful in detecting fluorescence 
emitted by Trp and Tyr residues of AGP, a decrease occurring when a drug becomes 
bound. Theophylline is a drug known to bind AGP and therefore the various 
concentrations allow the effect of increased drug binding on intrinsic fluorescence to be 
determined (refer to figure 3.4).  The degree of fluorescence was markedly decreased as 
the drug concentration was increased thus the drug was used as a positive control 
throughout.  All drug standards were made 10-fold more concentrated but graphed as 
the concentration present on the plate i.e. 2.5-250μM.  The values were plotted against 
theophylline concentration (figure 3.4) to show the reduction in fluorescence which 
occurred with drug binding.  When the microtitre plate method was repeated using 
methadone in place of theophylline, no significant effect on the fluorescence emitted by 
AGP was detected (figure 3.5).  However upon adaptation of the method, specifically 
by replacing d-PBS with DMSO as the solvent used for dissolving the drug, the level of 
binding - as indicated by a reduction in fluorescence - was more apparent, especially at 
high concentrations (figure 3.6).  The level of binding was not as high as that seen with 
theophylline, but the technique remained feasible for the analysis of methadone binding. 
 
The organic solvent DMSO was subsequently deemed the solvent of choice in which to 
dissolve methadone; as described in the previous chapter (section 2.2.6.1).  It is capable 
of dissolving both polar and nonpolar compounds and although concentrated solutions 
can cause oxidation of -OH groups to produce ketones, it should not affect the structure 
of methadone which does not have free –OH groups. 
97 
 
a) 
           
Figure 3.3. Fluorescence spectra of commercial AGP over 300-400nm when 
excited at 280nm in a) the absence and b) the presence of STI571. 
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c) 
 
 
 
 
 
Figure 3.3 continued. Fluorescence spectra of commercial AGP over 300-
400nm when excited at 280nm in c) the presence of hydroxyurea.  [Reprinted with 
permission of Dr. P Mooney]. 
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Figure 3.4. Intrinsic fluorescence at 340 nm of 5mg/mL and 0.5mg/mL 
commercial AGP in the presence of theophylline. 
 
 
 
 
Figure 3.5. Intrinsic fluorescence at 340nm of 5mg/mL and 0.5mg/mL 
commercial AGP with methadone. 
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Figure 3.6. Intrinsic fluorescence of 5mg/mL and 0.5mg/mL commercial AGP 
with methadone dissolved in DMSO. 
 
 
  
15000
20000
25000
30000
35000
40000
45000
50000
0 50 100 150 200 250
fl
u
o
re
sc
e
n
ce
 R
FU
concentration methadone (µM)
Sigma 0.5mg/mL AGP Sigma 5mg/mL AGP
101 
 
3.4 Discussion 
 
 
3.4.1 Monosaccharide release optimisation 
 
It is important to determine the composition of glycan chains when studying the 
function of AGP; their specific monosaccharide arrangements influence the overall 
glycoprotein structure, dynamics, and subsequently their functions.  Analysis requires 
the identification and validation of an appropriate analytical technique i.e. acid 
hydrolysis.  As specific monosaccharides, for example Gal, are unique to the branches 
of complex N-linked glycans, alterations in the monosaccharide composition can 
suggest changes to the branching. Confirmation requires additional analysis of complete 
glycans (chapter 7). 
 
HCl cleaves the basic sugar GlcNAc (causing it to be de-acetylated to GlcN; Kim, 
2000) whilst TFA is used to hydrolyse the neutral sugars Fuc, Gal and Man.  In the past, 
TFA was used alone (e.g. Davies et al., 1993; Elliott et al., 1997) however it is unable 
to effectively cleave the basic monosaccharide GlcNAc because the monosaccharide has 
a higher degree of resistance to acids, the innermost GlcNAc attached to Asn residues of 
a polypeptide backbone particularly. 
 
The use of HCl was introduced to provide more effective hydrolysis of this 
monosaccharide (French et al., 2002). An earlier study performed by Fan and 
colleagues (1994) suggested that in combination with TFA the yield of the 
monosaccharides can be compromised.  Therefore an experiment was undertaken within 
this study with commercial AGP to determine the most efficient method, it was found to 
compare to that described by Fan et al. (1994).  Hardy and Townsend (1994) reported 
that Man in particular was destroyed with 4M HCl – as supported by this study -
however in the presence of only TFA, it was effectively hydrolysed and stable, thus 
supporting the decision to implement separate acid hydrolysis for release of the neutral 
and basic monosaccharides.  
 
Dowex
®
 cation-exchange resins are generally used after acid hydrolysis to remove the 
polypeptide component of the glycoprotein; the negatively charged amino acids interact 
with the column and are thus removed from the monosaccharide components which 
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theoretically elute unhindered.  Polypeptide removal is often necessary because it can 
interfere with the separation of monosaccharides by HPAEC-PAD; the large structures 
may shift the elution of monosaccharides or even prevent their resolution by eluting at 
the same time – particularly possible with Fuc which elutes early - rendering it difficult 
to determine the monosaccharide composition.  During the present study, the level of 
GlcN collected after this stage – using commercial AGP samples - was lower than 
expected.  To determine whether the 2mL of HPLC water used to wash the sample 
through the column was insufficient to elute all GlcN, a further 2mL was added and 
collected.  However, this was not found to generate any further GlcN detected by 
HPAEC-PAD.  It was postulated that unlike the neutral monosaccharides, GlcN may 
interact with the column due to its negative charge.  As described above, upon removal 
of the column, the level of GlcN was significantly improved which was in agreement 
with Fan et al (1994).   
 
Although it had often been reported that the level of GlcN detected by HPAEC-PAD 
after hydrolysis with TFA and HCl alone, or in combination, was significantly lower 
than that expected and a correction factor was sometimes applied, the possibility that the 
Dowex
®
 column could reduce the levels of GlcN made available to the HPAEC-PAD 
detector was not considered and therefore its use continued (Smith et al., 2002; Mooney 
et al., 2006).   
 
Interestingly, the removal of the Dowex
®
 column did not significantly affect the 
resolution of the neutral monosaccharides; further supporting the idea that only GlcN 
interacted with the column.  Furthermore, the pH of the Dowex
®
 was taken upon each 
use to ensure a pH of 4 was maintained therefore it was never overly acidic so could not 
cause an unusual increase in sugar degradation.  Finally, the detectors of the HPAEC 
equipment were cleaned to ensure the detection system was not at fault i.e. causing the 
low GlcN data.  Fluctuations were minimal with no clear differences to that obtained 
before cleaning. 
 
Therefore Dowex
®
 cation-exchange columns were only implemented for TFA 
hydrolysed samples to ensure optimal generation of neutral monosaccharides, removing 
the protein which potentially complicates and confuses chromatograms.  It was not used 
for the HCl hydrolysed samples to improve GlcN resolution – its retention is late on in 
chromatographic separation therefore any peptide present should not elute alongside.  
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Even if the retention time was prolonged, that of the internal standard would be 
similarly affected therefore the peak would still be identifiable.  Despite requiring twice 
the mass of AGP to perform analysis of the monosaccharide composition, the enhanced 
effectiveness could not be ignored.  This was especially true when considering the 
significantly improved levels of Gal and GlcN obtained (Man or Fuc were increased but 
statistically not significant).  These two monosaccharides are present in glycan branches 
and thus provide useful evidence of structural changes. Gal is only present in branches 
and therefore it was important to ensure the separation and hydrolysis of this 
monosaccharide was as effective as possible.  Although GlcN can provide similar 
information, it is also present in the pentasaccharide core and therefore it must be 
analysed with caution alongside Gal levels and oligosaccharide analysis.  The innermost 
GlcNAc attached to the peptide backbone is difficult to hydrolyse as the bond is very 
strong (Fan et al., 1994) thus higher levels in some patients are not necessarily 
correlated with branching but instead perhaps more efficient cleavage of the core 
GlcNAc residues.  If an elevation coincides with that of Gal levels then it is probable 
that branching has increased.  
 
In summary, it has been found that the use of a cation-exchange column, although 
important when analysing neutral monosaccharides, affects the level of GlcN 
subsequently detected by the HPAEC equipment.  Therefore, for the monosaccharide 
analysis of AGP samples, separate hydrolytic conditions were implemented.  Using 
these methods in the study may give an indication of, but does not definitively allow, 
the degree of branching of glycans attached to the AGP protein backbone to be 
determined however in chapter 7, the analysis of complete oligosaccharide chains is 
described and allows qualitative estimation of glycan branching. 
 
 
3.4.2   Drug binding analysis 
 
Although a more in-depth discussion will follow in chapter 8, when reporting the 
binding of methadone to patient AGP samples, a short discussion is necessary in order 
to explain why the particular assay was chosen. 
 
All drugs must attain a specific level at their site of action in order to exert their 
pharmacological effect (minimal effective concentration, MEC).  It is well documented 
104 
 
that, at physiological pH, AGP is capable of binding basic and neutral drugs with a high 
affinity and low capacity (Fournier, 2000; Israili and Dayton, 2001).  When a drug 
becomes bound and therefore rendered inactive, the level present may fall below the 
MEC.  If the effect is widespread the drug subsequently loses its ability to provide the 
desired pharmacological effect. 
 
As methadone is a basic drug, it binds AGP (Kremer et al., 1988; Rodriguez-Rosas et 
al., 2003).  However, whether the glycosylation of this glycoprotein affects the degree 
of binding and subsequent level of free active drug available, has remained largely 
unstudied in patients undergoing opioid replacement therapy.  Analyses such as those 
detailed in this study are limited by the availability of sample thus performing large-
scale techniques to analyse drug binding was unfeasible (even the cuvette-scale requires 
10 fold more reactants), especially as samples were required for structural analysis.  
Therefore, the use of a microtitre plate method was useful.  It was first described by 
Parikh and colleagues (2000) as a valuable mechanism for drug binding analysis; 
detecting alterations in intrinsic fluorescence.  Essentially, as a drug becomes bound, the 
underlying Trp and Tyr residues which fluoresce when excited at 280nm are masked 
and therefore the fluorescence is decreased (quenched). 
 
The studies with commercial AGP indicated that 5mg/mL AGP allowed the effects of 
drug binding on fluorescence to be distinguished more clearly than in the presence of 
0.5mg/mL.  Initially, the methodology was tested using theophylline (results graphed in 
figure 3.4) as its binding to AGP has been well documented (Parikh et al., 2000) and so 
allowed the validity of the experiment to be tested.  Despite this, restrictions meant the 
lower concentration was used in all subsequent analyses; higher concentrations were 
impractical.  Nevertheless, 0.5mg/mL commercial AGP responded to the presence of 
increased concentrations of drug (theophylline and methadone) with a decreased 
fluorescence (figures 3.4 and 3.6 respectively).  It was unsurprising as an increase in 
concentration renders more drug available to the binding sites therefore their occupation 
was enhanced thus masking increased Trp and Tyr residues.  As methadone became 
increasingly concentrated the degree of quenching slowed – the availability of binding 
sites must have become limited.   
 
Overall it can be seen that the microtitre plate method was useful in intrinsic 
fluorescence analysis, as reported in previous studies (e.g. Johnson and Smith, 2006) 
105 
 
providing an indirect indication of drug binding when samples are low in supply.  
Chapter 8 discusses in detail why methadone may not be able to quench the intrinsic 
fluorescence of AGP to the same extent as theophylline.   
 
 
 
SUMMARY STATEMENT 
It was shown that separate hydrolysis of isolated AGP with 2M TFA and 4M HCl was 
necessary to ensure effective glycan structural analysis, which is important in studies 
such as this investigating whether altered glycosylation may affect the function of a 
glycoprotein.  Therefore these conditions were adopted throughout. Additionally, drug 
binding studies implementing fluorescence at the microtitre plate level were shown to 
be useful.   
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Chapter 4 
Patient demographics 
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4.1 Patient Demographics 
 
 
A trained phlebotomist obtained blood samples from consenting individuals who were 
enrolled in different stages or types of opioid replacement therapy at the Community 
Drug Problem Service (CDPS) in Edinburgh, Scotland.  The subjects were grouped by 
type and stage of therapy (table 4.1) including those having recently become enrolled in 
the initial two week Titration phase of the program receiving methadone (n=5), those 
attending the Harm Reduction program having received maintenance doses for less than 
1 year (n=4) and finally those who have been stable on methadone therapy for 
prolonged periods of time thus attending the clinic only occasionally (n=11).  Patients 
receiving alternative treatments were also included; buprenorphine (n=4), 
dihydrocodeine (n=1) and heroin (n=1).  Methadone was prescribed at the clinic as a 
solution with a 1mg/mL or 2mg/mL concentration.  
 
The dose of opioid substitute administered to each patient, additionally prescribed 
medications and recent recreational drug use (within last week) was noted and 
summarised in table 4.1. New identities were assigned to the blood samples to 
correspond with the drug therapy they were receiving, reducing confusion in the 
subsequent chapters.  Eighteen male and eight female volunteers were recruited into the 
study, ranging from 20 to 51 years of age with a mean ± standard deviation of 33.0 ± 
7.0 (33.5 ± 6.7 and 31.9 ± 7.0 for males and females respectively) – refer to section 
2.1.1.  
 
Blood samples were also obtained from the Blood Transfusion Service; these consisted 
of a mixture of blood from a healthy ‘normal’ population, hence no individual patient 
data was available.  ‘Normal’ serum samples were provided by Professor David George 
of the Glasgow Western Infirmary.  These samples were taken from a cancer-free 
elderly female population resident in the West of Scotland.  No other medical 
information specific to each individual was provided.  
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Patient 
Number 
Stage/type of 
therapy 
Dose 
(mg) 
Additional 
prescribed 
drugs 
Recent 
Recreational 
drug use 
New 
Identity 
JB 0608 01  
 
Titration 
(T) 
95 * Heroin – smoke T1 
JB 0608 02 65 - Heroin T2 
JB 0509 01 55 -  T3 
JB 0509 05 40 Diazepam  T4 
JB 0509 06 60 -  T5 
JB 0608 03  
Harm Reduction 
(HR) 
90 * Heroin HR1 
JB 0608 04 85 * Heroin HR2 
JB 0608 05 150 * Heroin HR3 
JB 0608 06 150 - - HR4 
JB 0608 07  
 
 
 
Long Term 
(LT) 
95 Diazepam Cocaine 
MDMA, Speed 
LT1 
JB 0608 08 150 - - LT2 
JB 0608 10 40 Mirtazapine, 
Statin 
Chlorpromazine LT3 
JB 0608 12 90 Diazepam Amitryptline LT4 
JB 0509 03 105 Diazepam Heroin, Crack 
cocaine 
LT5 
JB 0509 04 85 - - LT6 
JB 0509 09 150 Diazepam Prozac LT7 
JB 0509 10 50 Diazepam Cannabis LT8 
JB 0509 11 150 Diazepam Cannabis LT9 
JB 0509 12 200 Diazepam - LT10 
JB 0509 14 90 Diazepam - LT11 
JB 0608 09  
Buprenorphine 
(B) 
1.6 Diazepam, 
Chlorpromazine 
- B1 
JB 0608 11 10 Mirtazapine, 
Amitryptiline 
- B2 
JB 0509 02 6 Diazepam, 
Mirtazapine 
Cannabis B3 
JB 0509 08 6 Diazepam, 
Mirtazapine 
- B4 
JB 0509 07 Dihydrocodeine 
(D) 
60 Amitryptiline, 
Olanzepine, 
Depixole 
- D1 
JB 0509 13 Heroin (H) * * * H1 
 
 
Table 4.1. Patient data 
T: Titration phase; HR: Harm Reduction; LT: Long-term methadone;  
B: Buprenorphine; D: Dihydrocodeine; H: Heroin. 
M/F: Male/Female;  *   Data was unavailable;  -   Nothing to declare 
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It could be seen from table 4.1 that a large number of patients undergoing opioid-
replacement therapy were co-prescribed the benzodiazepine diazepam (n=12).  The 
actual number may have been greater but data was not available for all patients.  In 
terms of the study group for which prescribed drug data was available, this equated to 
57.1% of patients.  Interestingly, almost three quarters of LT patients were receiving 
diazepam alongside methadone (~72.7%).  Mirtazapine – a tricyclic antidepressant 
(TCA) - was prescribed in four patients, three of which were receiving buprenorphine as 
the substitute opioid.  Another TCA, amitryptiline, was prescribed to two individuals. 
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4.2 Discussion 
 
 
As discussed with some depth in section 1.5.1, the identification of effective treatment 
strategies is central to addressing the huge problem opioid dependence poses not only to 
the UK but worldwide.  A recent Scottish Government study (SACDM, 2007) used 
information provided by the country’s NHS boards to illustrate that there has been an 
increase in GP-based patient treatment; approximately 22,224 (including 1,093 in 
prison) were receiving substitute therapy – an increase of 1,904 on the figures in 2004 
(19,227 - not including prisoners).   
 
As reported in table 4.1, not all patients recruited into this study were receiving 
methadone as the substitute treatment, instead four received buprenorphine, one 
dihydrocodeine and another individual was prescribed pure heroin. Generally, 
alternatives are only considered when methadone has proved unsuccessful in aiding an 
individual to abstain from illicit heroin use.  Initially it was hoped to focus sample 
collection to the long-term and titration methadone groups however this was virtually 
impossible, certainly for the latter group where recruitment was hindered by their 
apprehension.  Therefore it was decided an interesting alternative for this preliminary 
study was to recruit patients undergoing therapy at the clinic with the alternative drugs.  
Limitations put in place by the NHS ethics board regarding the number and volume of 
blood samples rendered it difficult to recruit a larger number of individuals in each 
category. 
 
A report by Strang et al. (2005) indicated that DHC is the most commonly prescribed 
drug after methadone in the UK although the number of studies and trials undertaken 
with the drug are few.  As for patient D1, it is generally implemented if methadone is 
unsuccessful.  Within the four year period of 1995-1999, prescriptions for DHC 
increased by 11% in the West of Scotland alone.  It has been shown that the sedative 
effects and dangers of toxicity associated with methadone mean patients would often 
prefer the shorter acting DHC (Robertson et al., 2006).  Within the same period of the 
late 1990s, an increase in the number of DHC-related deaths was also reported; 55% of 
deaths in a study population of 89 individuals were a direct result of DHC use (Seymour 
et al., 2001; Power et al., 2002).   
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Buprenorphine is a partial opioid agonist which is demonstrating increased usage and 
competes with full agonists like heroin for the opioid receptor.  It carries a decreased 
risk of overdose due to its longer t1/2 and helps achieve stabilisation of neurobiological 
pathways (Auriacombe et al., 2001).  Efficacy can therefore be maintained with less 
frequent dosing than methadone, as reported by patients B1-B4 in this study.  The 
bioavailability of buprenorphine is lower than methadone with much of it lost during 
first pass metabolism therefore it is administered sublingually rather than orally, 
allowing diffusion into the tissues under the tongue. Therefore, lower doses of 
buprenorphine are required in comparison to methadone, as demonstrated in table 4.1.   
 
It can potentially increase the number of patients seen by a single clinic as the number 
of visits required is decreased (making it more convenient for the patient) and the need 
for take-home doses is lessened. Accumulation of the drug should also be less likely.  
At high doses the euphoric effects are low thus it has potential in the long-term 
treatment of opioid dependence as a substitute but also in the short-term management of 
withdrawal (Walsh and Eissenberg, 2003).  In France it has been used as a substitute 
therapy since 1996 with less monitoring required than that associated with methadone 
therapy because it is only available from specialised centres.  It does however carry a 
greater risk of adverse effects and diversion than methadone.  In 2001, Auriacombe and 
co-workers estimated that there were 1.4 times more buprenorphine-related deaths in 
France during 1994-1998 than those due to methadone however, to put this in 
perspective, 14 times more patients received buprenorphine than methadone.  It was 
found in the current study that 75% of the patients receiving buprenorphine were also 
prescribed diazepam which was similar to those having received methadone long-term 
however only four patients were recruited from this treatment group.  
 
Despite the widespread recreational use of impure heroin, research has shown the 
potential of pure heroin as a means of treating illicit heroin use.  Studies performed in 
Switzerland (Rehm et al., 2001) suggested 70% of individuals treated with pure 
injectable heroin can be retained on the treatment over a year which may make it a 
useful alternative treatment in those where MMT is unsuccessful, as was the case for 
patient H1.  It was found that this heroin-assisted treatment was more effective than 
methadone and a feasible treatment for reducing physical, mental and social problems. 
However, the research did not account for any psychological treatment received by 
patients.  A more recent German study (Haasen et al., 2007) subsequently examined the 
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effectiveness of medically prescribed heroin and supervised heroin injection in an open-
label randomised controlled trial while addressing the problems identified in the Swiss 
study.  Some of the participants had not responded sufficiently to MMT and others were 
not in a drug misuse program.  It was found that heroin-assisted treatment of people 
with severe opioid dependence and treatment resistance, had significantly improved 
health and decreased illicit drug use than MMT individuals, supporting the results seen 
by previous studies like Rehm et al. (2001) and Perneger et al. (1998).  Pilot studies 
undertaken in England and the Netherlands indicated the combined prescription of pure 
heroin and methadone could provide a 25% improvement in physical and mental health 
compared to methadone alone (SACDM, 2007).  Recently news headlines indicated the 
Scottish government have been contemplating the introduction of pure heroin treatment 
and clinics where users can inject heroin safely. 
 
As can be seen from the tables in section 4.1, despite receiving substitute treatment, 
patients are often discovered to continue a degree of illicit heroin drug use, certainly in 
the earlier stages (T and HR).  Such behaviour is partly expected due to the low doses of 
methadone administered during the initial titration phase while treatment teams 
determine the degree of tolerance possessed by a patient - the doses are rarely sufficient 
to prevent the onset of withdrawal symptoms.  However it is important that treatment is 
administered in this manner and patients are closely monitored because - although the 
effects of methadone take a number of days to be expressed - the drug slowly 
accumulates in tissues therefore additional opioids can exacerbate its effect potentially 
causing overdose.   
 
Heroin addicts are also commonly reported to co-abuse BDZs, particularly 
flunitrazepam (Woods and Winger, 1997; Peles et al., 2007) probably due to their anti-
anxiolytic properties; individuals often become extremely anxious as part of 
withdrawal.  In one study 35-41% of patients undergoing MMT reported use of BDZs 
three or more times a week (DuPont, 1988).  Therefore, when undergoing substitute 
therapy patients are often prescribed a BDZ e.g. diazepam in an attempt to treat both 
addictions; unless the patient is pregnant in which case diazepam should not be 
administered as it is known to cause birth defects (Laegreid et al., 1992).  Similar 
treatment regimens with both a substitute opioid and a BDZ were recorded for the 
patients recruited in this study.  More than half the patients, for which data was 
available, were prescribed diazepam, the majority receiving approximately 5mg along 
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with their daily methadone dose.  As a BDZ, it enhances the activity of γ-aminobutyric 
acid (GABA), causing sedative effects which help stabilise the patient’s sleep patterns 
and – alongside other drugs including the anti-psychotics chlorpromazine and 
olanzapine - it has anxiolytic properties.  Darke and Ross (1997) administered the BDZ 
diazepam (10 or 20mg per 70kg) to patients on MMT and found that their subsequent 
methadone consumption was reduced, supporting earlier research by Preston et al. 
(1984) where a combination of diazepam and methadone enhanced the opioid effects.  
Thus less opioid was required to achieve similar effects as that previously attained with 
higher doses of methadone alone.  When comparing the patients in the current study 
there was no clear reduced dosing in those co-prescribed diazepam. 
 
The TCAs, co-prescribed in some patients, are normally given to treat mood-disorders 
such as depression. Euphoria is not the only effect produced by heroin, like other 
opioids and the BDZs, its administration is correlated with the occurrence of depression 
in frequent users (Havard et al., 2006) perhaps explaining why certain individuals 
require a TCA alongside their opioid substitute. 
 
While the current study was interested in the possibility the efficacy of methadone was 
affected by the presence and structure of a specific protein in the blood, it was only 
possible to compare patients receiving opioid-replacement therapy to a ‘normal’ healthy 
population.  A useful comparative group would be heroin dependent individuals whom 
are not receiving therapy to determine whether any effects detected in the patients were 
a direct result of therapy or perhaps due to underlying stresses associated with the prior 
illicit drug use.  This was impossible in the current study.  Instead the structure and 
level of AGP isolated from patient blood was analysed, its ability to bind methadone 
determined and compared to all other patients and a ‘normal’ healthy population.  
Results pertaining to these studies are described in the following chapters. 
 
 
SUMMARY STATEMENT 
Numerous opioids can be utilised as substitutes in the treatment of opioid dependencies.  
Methadone is the most commonly prescribed in the UK with huge variability in doses 
required to prevent withdrawal symptoms.  Increasing our understanding as to why 
methadone may be less effective in certain individuals is important and investigated 
further in the following chapters.  
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Chapter 5 
AGP isolation and level determination 
Results and Discussion 
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5.1 Introduction 
 
 
5.1.1  Isolation of AGP 
 
Prior to the 1980s it was commonplace to disregard sugar components during 
investigations into the functions performed by glycoproteins - instead interest was 
focussed on the underlying polypeptides which were more easily analysed.  It is now 
well established that glycans are vital in the determination of overall structure and 
subsequent function of these biomolecules, often uniquely altered during some 
physiological and pathophysiological states.  Thus it is not only the hepatic synthesis of 
AGP which is augmented during the APR.  Consequently, a prerequisite of studies 
investigating the structure and subsequent roles of glycoproteins like AGP is that their 
in vivo glycan structures must remain uncompromised during isolation from other 
plasma proteins. 
 
Despite the availability of a number of well documented isolation techniques developed 
for proteins and glycoproteins, the majority require harsh acidic conditions thereby 
causing a loss of glycan structural integrity - desialylation and other forms of 
degradation common under acidic conditions.  In the first reported methods for AGP 
isolation, described by Schmid (1950) and Weimer et al. (1950), ammonium sulphate 
was used to precipitate AGP at low pH.  The first large-scale fractionation of AGP-
containing Cohn Fraction V supernatant, described by Hao and Wickerhauser (1973) 
also implemented acidic conditions to promote the removal of HSA. AGP became 
bound to diethylaminoethyl (DEAE)-Sephadex and the DEAE elate was then introduced 
to a carboxymethyl (CM)-cellulose column to allow separation of the Cohn Fraction V 
by ion-exchange chromatography.  Before these techniques, AGP had often been 
contaminated with HSA, its removal is therefore important especially as HSA generally 
represents the main proportion of plasma proteins - over 50% (by weight) - thus 
complicating isolation of other proteins, especially if they share similar MW or charge.   
 
In 1978 Plancke et al. implemented ion-displacement chromatography, gel filtration 
chromatography and ion-exchange chromatography to purify AGP, a method later 
repeated by Albani et al. (2000).  In the preparation of the glycopeptides from AGP, the 
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samples were in brief contact with HCl.  Therefore to ensure the structure remained 
unchanged, the use of methods similar to those cited was discouraged. 
 
Methods like those utilised in this study where AGP isolation and purification was 
undertaken without the use of acids, were previously employed in the mid 1980s by 
Laurent and colleagues (1984), using a three-stage purification procedure; Cibacron 
Blue F3GA and Procion Red HE3B pseudo-ligand chromatography columns followed 
by isoelectric focusing (IEF).  HSA was removed through strong interactions formed by 
its bilirubin binding sites to the Cibacron Blue resin.  It had previously been suggested 
by Wilson and colleagues (1976) that weak interactions were formed with hydrophobic 
fatty acid-anion-binding sites or dinucleotide-binding domains.  IgA, IgG, 
ceruloplasmin, most transferrin and prealbumin were then removed during passage 
through the Procion Red column with NaOAc buffer.  Any remaining contaminants 
were eliminated by isoelectric focussing (IEF) to ensure the final 88% AGP yield 
obtained was of enhanced purity as indicated by gel electrophoresis and 
immunoelectrophoresis. ConA crossed affinity immunoelectrophoresis (CAIE) 
demonstrated that the glycans remained intact with no loss of structural integrity - 
probably because acids were not required.   
 
Both Cibacron blue and Procion Red sepharose columns were fundamental to the 
methodology reported by Smith and colleagues (1994).  However, eluent from the Blue 
column was passed through a Q-sepharose column before its introduction to Red 
sepharose in an attempt to improve the purity of isolated AGP.  The intermediary Q-
sepharose column removed α1-antitrypsin (AAT) by anion-exchange chromatography 
thus reducing potential contamination.  They considered this a useful alternative to the 
Laurent method, the results of which they were unable to reproduce. Purity was 
demonstrated through the use of SDS-PAGE and immunodiffusion; indicating the 
presence of AGP at each stage and the efficiency of the purification process.  
 
Therefore, in terms of glycan analysis, isolation through low pressure chromatography 
has proven efficiency; the absence of acidic conditions prevents any structural 
degradation.  The levels of isolated AGP can then be determined; values thus 
representing only the glycoprotein, not other contaminants. Although other 
methodologies may provide a greater yield, they also risk altering the glycosylation of 
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AGP, rendering them useless when glycan structure is the primary focus of studies such 
as that detailed herein.  
 
 
5.1.2 Level determination 
 
It is well understood that the hepatic production of AGP, a positive acute phase protein 
(APP), increases during the APR.  The levels present under ‘normal’ disease-free states 
can rise 2-5 fold during conditions such as rheumatoid arthritis and cancer (Fournier et 
al., 2000). 
 
In order to perform comparative studies of the structure of AGP between different 
groups of individuals, it was important to determine the level present in an isolated 
sample.  The volume required to ensure mass consistency in each analysis could then be 
determined.  If not, it would be impossible to ascertain whether variations were 
structural or due to disparity in the level of AGP between samples. 
 
There are numerous techniques utilised in the determination of AGP concentration.  
Commonly an immunoturbimetric assay technique was used by the group (French et al., 
2002) which relies on the spectrophotometric measurement of the formation of an 
immunoprecipitate with AGP antiserum at 340nm. However, these studies were 
indulged by the availability of large volumes of sample which could be distributed to 
other groups for the relevant analyses.  Alternative means were sought in the current 
study to accommodate the sample availability. It was shown that absorbance of AGP is 
dependent on the Beer Lambert Law (Albani, 2004) thus absorbance values of AGP 
standards at 280nm (primarily due to Trp residues) can be used to produce standard 
curves and determine the relative level of AGP isolated from blood samples. 
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5.2 Results 
 
 
5.2.1 Isolation and purification of AGP from samples 
 
For the purpose of this study, an adapted form of the large-scale low pressure 
chromatography procedure established by Smith et al. (1994) to isolate and purify AGP 
from patient blood samples was used, thereby conserving structural integrity through 
the absence of acidic buffers.  Cibacron Blue 3GA and Procion Red CL6B sepharose 
columns were used but the Q-sepharose intermediary step was removed to minimise 
loss of AGP.  SDS-PAGE and Western Blots were performed to indicate that the two 
column technique preserved AGP purity, as reported in the following section (5.2.2). 
 
Upon precipitation with PEG3350, AGP isolation and purification was initiated by 
introducing the remaining soluble proteins to a Cibacron Blue 3GA Sepharose low-
pressure chromatography column. The first fraction, containing AGP, eluted after 
approximately 5 minutes and was illustrated by the chart recorder as a peak extending 
from the baseline (figure 5.1a). The fraction was collected until the baseline was 
retained, usually within 45- 55 minutes.  Removal of HSA bound to the Cibacron Blue 
Sepharose beads by desorption buffer was represented by the second peak (figure 5.1a). 
Complete column regeneration occurred within approximately 30 minutes.  The 
concentrated fraction collected during the previous stage was applied to the Red 
Sepharose CL-6B column.  The first AGP-containing fraction eluted within 
approximately 10 minutes of application and, again, was represented by a peak (figure 
5.1b) which required roughly 20 minutes to elute.  Impurities such as α1-antitrypsin 
(AAT) were removed from the sample, binding to the column.  They were eluted upon 
application of a cleaning buffer and represented by the smaller peak (figure 5.1b) 
allowing regeneration of the column after approximately 40 minutes.   
 
All samples were desalted and concentrated using Amicon or Centricon filter devices to 
prevent sample contamination and any subsequent interference with the absorbance of 
AGP at 280nm during spectrophotometry which was used to calculate the relative AGP 
level isolated from samples.  
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a) 
 
 
b) 
 
 
 
Figure 5.1. Traces generated during the isolation of AGP by low pressure 
chromatography using a Cibacron Blue Sepharose (a) and Red Sepharose (b) column.         
        collection started         collection stopped 
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5.2.2 Evaluation of isolated AGP purity  
 
Isolated and purified AGP was analysed using SDS-PAGE and Western Blots to 
determine the effectiveness of the two-column low-pressure chromatography technique.  
It was necessary to ensure that the adaptations made to the large-scale methodologies of 
Smith and colleagues (1994) did not compromise the final purity of the glycoprotein.  
 
The Coomassie brilliant blue-stained SDS-PAGE gel and Western Blot (figure 5.2a and 
b respectively) indicated that PEG3350-precipitated blood samples contained numerous 
highly soluble proteins, demonstrated by a number of bands in lane 2.  HSA, ATT and 
AGP are the three most common (MW 67, 52 and 41-43kDa, respectively).  The 
inclusion of commercial AGP (lane 1) in the analysis further supported the presence of 
the glycoprotein in the PEG3350-precipitated and isolated samples; each lane contained 
a band which migrated the same distance, corresponding to the ladder marker at 
~43kDa.  The two isolated samples tested (which had also been desalted), appeared to 
be relatively pure; only one band was present in lanes 3 and 4 with no others evident.  
On performance of the Western Blot using anti-AGP antibody, the bands present in 
lanes representative of isolated and desalted samples were confirmed to be AGP.   
 
Importantly, the SDS-PAGE performed in this study was used only to determine 
whether AGP was successfully isolated using the techniques of section 2.2.2.2; 
indicated through a reduction in the number of bands visualised when compared to the 
PEG-precipitated sample (lane 3).  The band densities could not be used as a means of 
determining whether the mass was compromised during isolation.  Although the same 
level of AGP was used for the commercial and isolated samples, it was not possible to 
determine the specific level of AGP present in the supernatant of PEG-precipitated 
protein. 
 
Overall, the use of an SDS-PAGE and Western Blot indicated that the isolation process 
generated pure AGP and therefore the two-stage low pressure chromatography was a 
valid technique at the micro-scale.  Analysis of the eluted components after each stage 
of isolation was deemed unnecessary as the final isolated samples showed no indication 
of contamination by other proteins. Also, the group recently implemented 
immunodiffusion to indicate that albumin was removed by the Blue sepharose column 
and most of the remaining contaminants like AAT, by the Procion Red column 
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(Gallacher, 2010). Subsequent spectophotometric analysis at 280nm, the results of 
which are provided in the following section, therefore allowed the level of AGP present 
in samples to be determined.  The absence of contaminating trace proteins assured that 
values were not skewed. 
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a) 
                Ladder            1           2           3   4 
 
 
 
 
 
b) 
 
                ladder                   1        2         3 
                
 
Figure 5.2. The effectiveness of low pressure chromatography in isolating and 
purifying AGP as shown by a) an SDS-PAGE gel and b) a Western Blot with anti-
AGP.  Ladder – ladder of MW markers, lane 1 – Commercial (Sigma) AGP positive 
control, Lane 2 - PEG-precipitated normal blood sample; Lane 3 - isolated AGP sample 
no.1; Lane 4 (SDS-PAGE only) - isolated AGP sample no.2. 
43kDa 
42.7kDa 
66.4kDa 
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5.2.3 AGP level determination  
 
Absorbance values of the commercial AGP standards (0-3mg/mL, n=5) at 280nm, 
produced a line of best fit (figure 5.3) with equation y = 0.8316x (R²= 0.99).  Table 5.1 
summarises the level of AGP isolated from normal blood samples pooled by the blood 
transfusion service (n=4), those from ‘normal’ serum samples obtained from an 
unknown group of elderly patients (n=4), and from each patient undergoing various 
stages of opioid replacement therapy (n=26).  The values were reported as the sum of 
four 1mL blood aliquots, the mean in each aliquot and finally the difference in the level 
of AGP per mL of blood compared to that isolated from ‘normal’ blood.  Samples were 
separated into more manageable 1mL volumes to ensure that if errors in the isolation 
procedure occurred, the whole sample would not be compromised.  Statistical analysis 
of the difference in level between each patient group and a ‘normal’ population was 
undertaken with two sample t-tests.   
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Figure 5.3. Standard curve produced using commercial AGP (Sigma-Aldrich) 
standards (n=3).  R
2
>0.9.  Relative amount of AGP in a sample (x):      
x = Abs at 280nm/0.8316. 
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Sample Mean level of isolated 
AGP  (mg/mL) 
Level compared to 
1mL normal blood 
Normal pooled blood 1 ۩ 0.076 - 
Normal pooled blood 2 ۩ 0.080 - 
Normal pooled blood 3 ۩ 0.066 - 
Normal pooled blood 4 ۩ 0.081 - 
Normal pooled blood 5 ¥ 0.072 - 
Normal pooled blood 6 ¥ 0.084 - 
Normal pooled blood 7 ¥ 0.086 - 
MEAN normal blood 0.078 - 
T1 0.337 +0.261 
T2 0.141 +0.065 
T3 0.248 +0.172 
T4 0.131 +0.055 
T5 0.175 +0.099 
MEAN T group 0.210*  
HR1 0.227 +0.151 
HR2 0.169 +0.093 
HR3 0.258 +0.182 
HR4 0.143 +0.067 
MEAN HR group 0.190*  
LT1 0.152 +0.076 
LT2 0.125 +0.049 
LT3 0.333 +0.257 
LT4 0.196 +0.120 
LT5 0.208 +0.132 
LT6 0.173 +0.097 
LT7 0.083 +0.007 
LT8 0.078 +0.002 
LT9 0.172 +0.096 
LT10 0.113 +0.037 
LT11 0.132 +0.056 
MEAN LT group 0.163*  
B1 0.111 +0.035 
B2 0.168 +0.092 
B3 0.272 +0.196 
B4 0.231 +0.155 
MEAN B group 0.138*  
D1 0.178 +0.102 
MEAN D group 0.178  
H1 0.078 +0.002 
MEAN H group 0.078  
 
Table 5.1. Summary of the levels of AGP in blood samples. 
*p<0.05,  ۩ isolated from same source and using same techniques as patient 
samples. ¥ Data obtained from previous studies (unpublished). 
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The mean level of AGP in each group was also highlighted in table 5.1 and graphed in 
figure 5.4 to summarise the differences in expression between groups of individuals.  
Approximately 0.08mg/mL AGP was isolated from the healthy ‘normal’ blood group; 
this was significantly lower than that isolated from ‘normal’ serum.  However, values 
derived from the blood samples were deemed the most appropriate representation of a 
‘normal’ population when compared to that from serum and commercially sourced 
AGP.   
 
The T, HR, LT and B treatment groups expressed significantly higher levels of isolated 
AGP than that in a ‘normal’ population (p<0.05).  Recruitment of a single patient from 
the D and H treatment populations rendered statistical analysis somewhat uncertain as it 
was unknown if the values were representative of the groups as a whole.  The 
parametric two-sample t-test could not be applied using single values.  When a one-way 
ANOVA with Tukey’s post hoc test was performed to allow all groups to be compared 
to one another, not just to the ‘normal’, the H1 and D1 individuals were included.  No 
significant difference in the levels isolated were identified between the treatment groups 
(p>0.1), excepting H1.  The level of AGP isolated from the single patient receiving 
heroin (0.078mg/mL) was indistinguishable from the ‘normal’ group (0.076mg/mL). 
Finally, the levels of AGP within each group were similar; no statistically significant 
difference was found between the patients within a single group.  
 
In summary, the levels of AGP isolated from patients undergoing T, HR, LT and B 
opioid-replacement therapies were significantly higher than that from a ‘normal’ 
population but showed no significant variation from each other.  Despite the indication 
that H1 expressed significantly lower levels of AGP than other treatment groups, a 
single sample was not deemed reliable enough on which to base conclusions. 
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a) 
 
b) 
  
Figure 5.4. Summary of the mean level of AGP isolated.  
from a) all treatment groups and b) patients at different stages of methadone therapy. 
* statistically different to ‘normal’ blood (p<0.05). 
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5.3  Discussion  
 
 
As described by Gelpi (2003), both purity and integrity of biologically active analytes 
are the most important prerequisites in structural and functional studies.  It was 
therefore essential that the glycoprotein of interest to this study (AGP) was isolated 
from patient samples using methods which retained its structural integrity.  Although 
methods available for the isolation of AGP from blood or plasma are plentiful, many of 
these utilise harsh acidic conditions which can compromise the structure of the glycans. 
These are therefore unacceptable as any results pertaining to subsequent structural 
analysis would be erroneous - in order to determine the degree of branching of AGP 
glycans for example, SA residues must remain intact which is unlikely at low pH.  
 
Therefore, low pressure chromatography (based upon the Smith et al., 1994 method) 
using two consecutive columns was implemented without the need for harsh acidic 
conditions; it was also sufficiently sensitive to isolate AGP from other plasma proteins.  
Despite the common use of SDS-PAGE in isolating specific proteins from samples with 
variable content (Zdebska and Koscielak, 1999), the acidic conditions rendered it of use 
only when testing the purity of fractions eluted from the low-pressure chromatography 
columns in this study.  The small masses required were sacrificed from the ‘normal’ 
blood sample to ensure the techniques were effective in generating pure AGP before 
patient samples were subjected to the treatment.  The Western Blot (figure 5.2b) 
confirmed that the single band in lane 3 (figure 5.2a) was AGP as the same sample was 
run in both SDS-PAGE and Western Blot.  AAT, which had previously been shown to 
be present in trace levels by Gallacher (2010), was not found during this study; a band 
in lanes 3 and 4 of the SDS-PAGE gel (figure 5.1) corresponding to its molecular 
weight (approximately 67kDa) would have been expected had it been a contaminant.  Its 
absence was important in this study as it too is a glycoprotein therefore it could have 
affected structural analysis. Other contaminants could include albumin with a molecular 
weight of approximately 67kDa; the presence of either of the proteins would have 
suggested incomplete removal by the blue and red sepharose columns respectively.  
However the absence of bands corresponding to the MW of the protein in lanes 3 and 4 
of the SDS-PAGE gel (figure 5.1) suggested there was no such contamination.  
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The Western Blot appeared to indicate other proteins or contaminants were present on 
the membrane in addition to AGP that were not picked up by the coomassie stain (the 
amount of protein was probably below detectable levels).  Due to the nature of the 
antibody used, non-specific binding was possible; polyclonal antibodies are not directed 
towards AGP solely.  Also, it is possible that not all proteins were transferred onto the 
membrane, affecting the clarity of the blot and as experiments were preliminary, the 
protocol requires optimisation.  Restaining the gel to confirm the transfer of AGP would 
potentially allow this to be taken into consideration.   
 
As anticipated, the PEG-precipitated sample generated numerous bands because the 
polymer does not exhibit specificity to a single plasma protein.  PEG 3350 was used at 
40% w/v to separate soluble proteins like AGP from less soluble proteins and blood 
cells.  Proteins precipitate in its presence because the water soluble polymer boosts the 
number of protein-protein interactions by drawing water molecules away from the 
protein; when these interactions become sufficiently extensive, the protein can no longer 
dissolve and therefore they concentrate – or ‘precipitate’ (Ingham, 1990).  An additional 
quality of PEG was that it does not denature the proteins it comes into contact with, 
which is extremely important if the in vivo structure is to be maintained.  A sample 
which had been precipitated with PEG3350 was included in the blot to demonstrate the 
success of two-stage low pressure chromatography in removing other soluble proteins, 
leaving a single anti-AGP reactive band in the lane 3 representing samples from which 
AGP had been isolated.  Commercial AGP was included as a control, migrating the 
same distance as corresponding bands in the other lanes.  It was not deemed necessary 
to analyse the eluted samples after each stage of low-pressure chromatography because 
the final isolated sample was shown to be AGP thus the technique was effective. 
 
Isolated samples were run in the desalted form to reduce any possibility that the 
presence of salt (primarily introduced by sodium acetate buffer) could interfere with the 
migration of the proteins.  It was removed by Amicon or Centricon filter devices 
(molecular weight cut off 10,000Da); molecules greater than 10kDa (AGP) are collected 
on the filter while those with a lower MW (including the salt) dissolve in HPLC-grade 
water and pass through the filter, thus removing them from the sample.   
 
The potential of Cibacron Blue sepharose in HSA removal from serum has been 
acknowledged for decades; Travis and colleagues (1976) reported that 98% of HSA 
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could be removed from a sample through its use – sodium thiocyanate (NaSCN) is 
required to cause desorption and collection of the protein.  Leatherbarrow and Dean 
(1980) showed this was possible because the dye binds to the bilirubin binding sites of 
HSA – like bilirubin, cibacron blue contains planar aromatic ring systems with negative 
charges in analogous positions.  A similar interaction was not found for other serum 
albumins sourced from bovine, horse or rabbit; instead a low level of binding occurred 
at long-chain fatty acid binding sites in these species.  It should be noted that Cibacron 
blue is capable of binding other proteins, not just HSA; in 1978, Angal and Dean 
reported the elution of 11 proteins from the column using a pH gradient.  For the 
purpose of this study, the value of the Cibacron blue column was in the ability to 
separate AGP from its common contaminant HSA, the latter formed interactions while 
the former eluted unhindered. 
 
Smith et al. (1994) indicated the removal of the protein by subjecting the first eluted 
fraction to immunodiffusion, highlighting the presence of AGP and AAT but no HSA. 
Subsequently, the second fraction representing the proteins which were bound to the 
column surface was eluted and reacted with anti-albumin in immunodiffusion 
experiments.  Further research by the group using SDS-PAGE and immunodiffusion 
indicated that PEG precipitation, low-pressure and dye-ligand chromatography with 
Cibacron Blue Sepharose, Q-sepharose and Red Sepharose columns yielded pure AGP 
(Smith et al., 1994; Elliott et al., 1997; Haston et al., 2003).   However this was for 
isolation on a relatively large scale and recently, it had been proposed that the slight 
improvement in purity bestowed upon isolated AGP by the Q-sepharose column did not 
justify the reduction in the level of protein isolated.  Gallacher (2010) indicated that 
when the Q-sepharose column was removed the AGP isolated was relatively pure with 
virtually undetectable levels of contaminants in immunodiffusion; the blue and red 
sepharose columns were still useful at the micro-scale.  Although it was found that HSA 
was incompletely removed after passage through the blue column, comparable to the 
study by Travis and colleagues (1976), the subsequent use of Red Sepharose columns 
removed additional HSA along with most other contaminants.  The purity of AGP after 
two-stage low-pressure chromatography was supported by the current study using SDS-
PAGE and Western Blots. 
 
There have been other combinations of techniques described since the early 1990s 
offering variable success in yielding pure AGP. Non-miscible solvent extraction 
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demonstrated potential in the isolation of AGP from serum (Kremmer et al., 1995) with 
a recovery over 95%; however the actual yield was approximately 89% due to loss 
during phase separation. Hervé and colleagues (1996) also utilised IEF techniques, 
alongside Cibacron blue F3GA cross-linked to agarose and chromatography on 
hydroxyapatite (buffers pH 5.8-5), achieving an 80% yield.  Acidic conditions were not 
required but the techniques used are more appropriate on a larger scale which was not 
feasible in the current study.   
 
More recently, low-pressure chromatography has demonstrated consistent effectiveness 
in the isolation and purification of AGP e.g. Elliott et al. (1997), Jørgensen et al. (2002) 
and Haston et al. (2003); although the exact methodology often deviates depending 
upon sample availability.  A similar yield to that of Hervé et al. (1996) was obtained by 
Azzimonti et al. (2003) using a single-step precipitation with Cibacron Blue F3GA, but 
use of acidic buffers (pH 4.0 and 4.95 respectively) render such a technique invalid for 
investigations of this nature.  It was however useful in the separation of the genetic 
variants of AGP. To isolate AGP from patients with cancer and acute inflammation, 
Szollosi and colleagues (2004) also implemented Cibacron blue F3GA dye-ligand 
chromatography using Toyopearly AF-Blue HC-650M columns that had been 
equilibrated with 10mM Phosphate buffer at a pH of 5.8, collecting UV detectable 
fractions which were then desalted and lyophilised. They also compared methods for 
isolating AGP; deducing that 100% recovery was feasible using solvent extraction and 
precipitation while affinity chromatography, using a new generation of dye-ligand 
phase, yielded over 85%.  Ethanol was used by the group to eliminate the bulk of serum 
proteins (mainly albumin), and/or solvents and low molecular contaminants. 
 
Contamination of isolated AGP by salts primarily introduced during low pressure 
chromatography would interfere with and skew the calculation of AGP levels because 
they too absorb at 280nm, therefore affecting all subsequent analyses which were reliant 
on the use of consistent masses of AGP to ensure valid interindividual comparisons.  
The presence of salt could explain why the level of AGP in patient T1 (0.337mg/mL) 
was considered higher than in other patients in this group; perhaps it was not completely 
removed thus absorption figures were inaccurately high.  However, later analysis of 
glycan composition proved this not to be the case; the levels of components were not 
significantly low in comparison to other glycans of AGP samples which would be 
expected if AGP was contaminated with salt (chapter 7).  The high values may instead 
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be due to contamination by other proteins which also contain the Trp and Tyr residues 
responsible for absorbance at 280nm.  As most plasma proteins are glycosylated any 
contamination would be problematic in structural analysis if wrongly assumed to be 
AGP.  The tests used to determine purity of AGP samples (section 5.1.2) indicated the 
technique, which was common to all samples, provided pure AGP, thus contamination 
by other glycoproteins was unlikely to be noteworthy.  The patient must therefore 
express a higher level of AGP.  
 
Although the construction of a calibration curve with commercial standards was not the 
most accurate way to determine the level of AGP in a sample, it was the most 
appropriate considering the restrictions in place, such as sample availability.  
Importantly, the terms ‘concentration’ and ‘level of AGP isolated’ were not used 
interchangeably within this study because some of the glycoprotein may have been lost 
during isolation and purification, therefore it was inaccurate to suggest that the levels 
obtained were identical to the in vivo concentrations.  As the same procedures were 
implemented in the isolation and purification of AGP from all samples, the results 
themselves were comparable.  The partial desialylation which can occur during large-
scale isolation, like that used by Sigma-Aldrich (based on that originally described by 
Hao and Wickerhauser, 1973), would not affect the reliability of the standard curve in 
the determination of patient sample AGP levels because it is the Tyr and Trp residues of 
the protein backbone responsible for absorbance at 280nm – which are unaffected 
(Stoscheck, 1990).  The correlation between absorbance and AGP level was 
demonstrated by an R
2 
value >0.9.   
 
Alternative methods used in the determination of AGP concentration include a 
sandwich-type ELISA using antihuman AGP and horseradish peroxidise-conjugated 
antihuman AGP (Hashimoto, 2004).  Despite the requirement of minimal levels of 
sample in techniques such as this and immunoturbimetric assays, it still reduces that 
available for use in structural and drug-binding analysis.  Spectrophotometry was useful 
because it did not require the removal of any AGP or cause its degradation. 
 
The levels of AGP determined in table 5.2 were found to be at least two-fold higher 
which is comparable with the APR (Ceciliani and Pocacqua, 2007).  In a clinical setting, 
levels of C-reactive protein (CRP) are commonly used to gauge the expression of 
inflammatory conditions.  As described in section 1.2, the concentration of the class III 
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positive acute phase protein is increased during inflammatory conditions when the APR 
is initiated.  It is normally present at concentrations lower than 10mg/L but levels may 
be amplified up to 1000-fold during the APR to bacterial infections, as described by 
Clyne and Olshaker (1999). Although levels were not so grossly elevated in patients, 
levels over 10mg/L supported the probability that an APR was expressed in the patients. 
In some cases, the level of AGP appeared to be correlated to dose (summarised in 
chapter 4).  However it was not possible to include the titration phase patients within 
this generalisation; the individuals commonly received low doses of methadone or 
substitute opioid to allow for the accumulation and the continued administration of 
illicit opioid sources.  The risk of overdose is high during this stage so precautions must 
be enforced.  Patients with high levels of AGP in this group would perhaps be expected 
to require higher doses of methadone to become stable due to its potential removal by 
AGP; however such follow-up information was unavailable due to the nature of the 
study. 
 
The five samples taken from the titration phase participants indicated a significant 
increase in the level of AGP isolated, perhaps a result of the APR.  Commonly, in the 
clinical setting, levels of C-reactive protein (CRP) are used to gauge the presence of an 
APR – as described in section 1.2, the concentration of class III positive acute phase 
protein is increased during the APR  
 
Rostami-Hodjegan and colleagues  (1999) reported that the levels of AGP in heroin 
dependent individuals with signs of opiate withdrawal (a common problem in the initial 
stages of therapy when methadone doses are kept low) were greater than in a drug free 
population and also showed a higher proportion binding to the glycoprotein when 
analysed ex vivo.  Therefore over time, as treatment-related stresses are expected to 
decrease, the stimulation of the APR may lessen in order to regain baseline homeostasis.  
For example, anti-inflammatory cytokines may be released in order to stop the APR 
(negative feedback) and therefore the levels of AGP stabilise or even decline during this 
period; possibly explaining why patients LT7 and LT8 for example, had lower levels of 
AGP – they have been maintained on the therapy for over 4 years and with generally 
less chaotic lifestyles than those faced with the sudden change from short acting heroin 
to long acting methadone.  However, this was not true for the majority of other patients 
in the LT group, with levels similar to those in the titration phases, thus there must be 
other explanations.  Perhaps a sustained response by the body to the xenobiotic 
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occurred, at least partly explaining why all patients had elevated levels.  This would 
also correlate with the fact that patients in LT therapy were often receiving high doses 
of the drug to remain withdrawal-free even if a decrease was expected - AGP levels 
may remain high as a mechanism to remove the drug from the system.  A cycle could 
ensue - like tolerance an increase in AGP in response to the drug could lead to the 
requirement of higher doses if the drug binds with a high affinity, removing it from the 
active concentration. Thus the levels required to induce the desired effect were not 
attained.  It may be possible that the stimulation of dopamine (DA) release during 
heroin use causes an increase in the synthesis of AGP.  DA is a neurotransmitter 
commonly released during stress; perhaps the increase in production deceives the body, 
causing further stimulation of an APR (Pruessner et al., 2004).  The concept of drug 
binding is described more thoroughly in chapter 8.  
 
Alternatively, the elevated levels of AGP in patients may be completely unrelated to 
stress or the presence of opioid substitute; smoking for example has been shown to 
increase level of AGP (Benedek et al., 1984b). The possibility that factors such as 
smoking may be responsible cannot be ignored and should be investigated in more 
detail.  Recruitment of non-smoking patients, in an already hesitant study population, 
was near impossible.   
 
It must therefore be acknowledged in studies such as this that various factors may be 
responsible for the disparity seen in levels of AGP.  Thus it would not be valid to 
presume all data collected from analyses is due to the therapy alone. 
 
 
 
SUMMARY STATEMENT 
The level of AGP isolated from heparinised blood samples taken from a ‘normal’ 
population (the Blood Transfusion Service) differed significantly to that isolated from 
patients undergoing various stages of opioid replacement therapy.  The level between 
treatment groups did not differ.  If methadone exhibits considerable binding to AGP, the 
increase in its expression detected may affect the drug’s efficacy.  However, important 
to the current study is that alterations in the glycosylation can affect the function of a 
glycoprotein – this concept was investigated further in the following chapters. 
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Chapter 6 
AGP Monosaccharide Analysis 
Results and Discussion 
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6.1 Introduction 
 
 
Certain physiological or pathological conditions can alter the structure of glycans 
attached co- or post-translation to a polypeptide backbone thereby causing the 
conformation of the glycoprotein to be incorrect, rendering it unable to perform the 
functions normally attributed to the particular glycan expression.  Structural analysis of 
the glycan chains and their components (microheterogeneity) is therefore important.  
Some of the monomeric units used in the construction of complex N-linked glycans, 
like those in AGP, are exclusive to branches - for example galactose (Gal).  These offer 
potential indicators of altered branching if distinctly different between two populations. 
 
A common technique for the analysis of glycan monosaccharide composition is 
HPAEC-PAD, the use of which has been well documented since its conception (for a 
recent review refer to Behan and Smith, 2010).  Although a number of alternative 
analytical methods are available to investigate glycan structural composition, including 
lectin ELISAs (Rydén et al., 1999), nuclear magnetic resonance (van Halbeek et al., 
1981) and Mass Spectrometry (Imre et al., 2008), HPAEC remains one of the most 
effective (Sim et al., 2009).  The implementation of HPAEC in oligosaccharide analysis 
of AGP is discussed in the following chapter, supporting the versatility of the technique.  
Its use in this study was valuable as a means of providing sensitive analysis (it is 
capable of detecting 10-100 picomolar quantities) without the requirement for large 
samples or prior derivatisation as is the case in gas chromatography and other liquid 
chromatography-based methods (Hardy et al., 1988; Townsend et al., 1989; Smith et al., 
1997).  Techniques like MS are commonly undertaken offline due to the high salt 
concentration of the mobile phase. However the coupling of the technique to HPAEC 
has been reported (Okinaga et al., 1992). 
 
Prior to separation by HPAEC-PAD, component monosaccharides must be released.  
Commonly implemented are TFA and HCl for the cleavage of the different 
monosaccharides respectively.  Zdebska and Koscielak (1999) hydrolysed samples from 
SDS-PAGE with 0.2M TFA for 1h at 80°C to release sialic acids, then 2M TFA for a 
further 4h at 100°C – releasing the neutral sugars.  Finally 6M HCl was utilised to 
remove the amino acids maintaining the temperature at 100°C.  TFA and HCl were also 
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used in the current study, in order to prepare the neutral and basic monosaccharides for 
HPAEC-PAD analysis respectively - optimal conditions were discussed in chapter 3. 
 
Analysis of the released monosaccharides by HPAEC required the use of a stationary 
phase with high mechanical and chemical stability - usually a column with polymer 
based pellicular resin, the active component of which is a quaternary ammonium ion 
(for a recent review of columns available that allow selective analysis see Behan and 
Smith, 2010).  An alkaline mobile phase (0.03M NaOH) and detection by pulsed 
amperometry were also important (McGuire et al., 1999).  NaOH was used in an 
isocratic gradient, to cause electrocatalytic oxidation of weakly acidic sugars, ionising 
the hydroxyl groups (-OH) and forming oxyanions when the pH is 12 or higher (figure 
6.1).  There are therefore several potentially ionisable –OH groups and due to variation 
in the position of these groups in monosaccharides, each exhibit different dissociation 
constants (pKa 12-14).  Anomeric –OH groups are the most acidic, the others follow a 
hierarchy of acidity: 1-OH>2-OH>>6-OH>3-OH>4-OH.  The strength with which 
oxyanions bind to pellicular anion-exchange resins of CarboPac
TM
 PA-100 columns 
commonly used in HPAEC analysis to separate monosaccharides, subsequently depends 
on their pKa values; those with higher pKa form weaker interactions with the resin and 
are therefore eluted more easily (Lee, 1990; McGuire et al., 1999).  Fuc oxyanions for 
example have a high pKa and are therefore less well retained compared to Man thus 
they elute early in a chromatogram.  Sugars expressing anomeric -OH groups are less 
well retained than essentially the same sugar with normal -OH groups at this position; 
this effect is exemplified by the long retention times of inositols which do not contain 
anomeric -OH groups.  Generally, the greater the collative negative charge of a 
monosaccharide, the stronger the interaction formed with the column.   
 
Fouling of the gold electrode occurs as the oxides build up and form a coating.  
However the addition of PAD in the 1980s, as first documented by Rocklin and Pohl 
(1983) and highlighted during research by the Johnson group (Neuburger and Johnson, 
1987; Johnson et al., 1992), was shown to vastly improve the technique.  Pulsed 
potentials (figure 2.1, chapter 2) allow oxides to form as the potential is increased but 
follow this by lowering the potential to remove the layer of oxide from the electrode 
surface.  Therefore, reproducibility is ensured as the electrode is constantly ‘cleaned’.  
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Figure 6.1. Oxyanion formation at C1 (mannose).  The presence of NaOH causes basic 
separating conditions (pH 13) where the monosaccharide oxyanion interacts with positively 
charged Na
+
 ions until it is introduced to the positively charged resin. The strength of interaction 
– based on the negative charge of the monosaccharide – determines when it will elute.  
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6.2 Results 
 
 
In any study of the structure of glycans it is important to ensure efficient cleavage and 
subsequent separation of components - degraded or un-cleaved monosaccharides are not 
detected, thus compromising the accuracy of the analysis. 
 
HPAEC separation of two mixtures of standard monosaccharides is shown in figure 
6.2a and 6.2b; the former a mixture of monosaccharides common to glycans in general 
and the latter those representing the components of complex N-linked glycans.  The 
traces demonstrated the ability of the technique to separate stereoisomers; isomers that 
differ in the orientation of their atoms in space e.g. Glc and Man (figure 6.2a), the 
structures of which were illustrated in figure 1.1 (refer to section 1.1.2, chapter 1).  
HPAEC resolves monosaccharides, which can be identified by the ratio of their 
retention times in relation to that of an internal standard (2-deoxy-D-galactose). 
Standards for GlcNAc and GalNAc were glucosamine (GlcN) and galactosamine 
(GalN) respectively, representing the deacetylation of the N-acetylated hexosamines 
which occurs during acid hydrolysis with HCl and subsequent HPAEC under alkaline 
conditions (NaOH).   
 
However, as mentioned, Glc and GalNAc are not routinely present in N-linked complex 
glycans - AGP was no exception.  The retention ratios of the unknown peaks generated 
on separation of commercial AGP glycan monosaccharide components (figure 6.3) with 
the IS were compared to those generated during the separation of six standard 
monosaccharides (figure 6.2a) and no values were ascertained to represent Glc or GalN.  
Therefore, a mixture of five monosaccharides Fuc, IS, GlcN, Gal and Man were used as 
a standard solution injected prior to samples; not only ensuring the effective operation 
of equipment, but also to assist in the identification of peaks generated upon HPAEC 
analysis of samples (figure 6.2b). 
 
Figures 6.3 and 6.4 demonstrate the need for separate use of TFA and HCl, the former 
effectively hydrolysed neutral monosaccharides (figure 6.3a and 6.4a) but that of 
GlcNAc (represented as a small GlcN peak) was incomplete.  HCl (figures 6.3b and 
6.4b) was required as investigated in greater detail in chapter 3.   
140 
 
a) 
 
 
b) 
 
Figure 6.2. Traces generated during HPAEC separation of a) a mixture of 
monosaccharides common to glycoproteins, separating isomeric monosaccharides and 
b) the 4 monosaccharides commonly found in AGP alongside an I.S. 
Fucose (Fuc), 2-deoxy-D-galactose (I.S), Galactosamine (GalN), Glucosamine (GlcN), 
Galactose (Gal), Glucose (Glc), Mannose (Man). Nano Culon (nC) 
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a) 
 
b) 
 
 
Figure 6.3. Traces generated during HPAEC separation of a) neutral and b) 
basic monosaccharides from commercial AGP alongside an I.S.      
No Fuc detected at the expected retention time. 
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a)
 
 
b) 
 
 
Figure 6.4. Traces generated during HPAEC separation of a) neutral and b) 
basic monosaccharides from patient sample AGP alongside an I.S. 
No Fuc detected at the expected retention time. 
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The denaturation of the peptide backbone and desialylation which occurs at low pH 
does not hinder the analysis of glycan structure at this stage because the individual 
monosaccharides of interest are uncompromised and removed from the protein. 
Exclusion of terminal SA residues at this stage was unimportant; their presence was not 
essential until the analysis of complete glycan chains (chapter 7).   
 
Unknown peaks generated by HPAEC-PAD separation for each ‘normal’ heparinised 
blood, commercial and patient sample were identified through comparison to those 
obtained during separation of the mixture of standard monosaccharides (figure 6.2b).   
Generally, every sample was analysed in triplicate. 
 
To quantify the newly identified monosaccharides in patient (titration, HR, long-term 
methadone, buprenorphine, DHC or heroin) and ‘normal’ heparinised blood samples; 
standard curves were produced for Fuc, GlcN, Gal and Man (figure 6.5). Analysis of 
each mass (0-5 µg) was repeated five times to determine the mean values and standard 
deviations (error bars). The peak area data generated by HPAEC analysis indicated that 
the area increased with mass of each monosaccharide.  Each R
2
 value was >0.9 
therefore there was a strong linear association between the two variables.   
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Figure 6.5. The five monosaccharide standard curves; mass of monosaccharide 
versus the mean peak area values (n=5) - error bars signify the standard deviation.  All 
correlation coefficients (R
2
)
 
>0.9. 
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Following the identification of unknown peaks in the HPAEC chromatograms generated 
for all patient AGP samples, the relative mass of each monosaccharide present was 
finally converted to moles of each sugar / mol AGP.  Values were recorded as the mean 
± standard deviation in table 6.1, 6.2 and 6.3 (‘normal’ heparinised blood; titration, 
harm reduction and long-term phase patients; non-methadone therapies respectively). 
This allowed comparisons to be made between the glycosylation of AGP expressed in 
patient blood samples with that from a ‘normal’ healthy population.  It must be 
remembered that data for the glycan composition of commercial AGP and that isolated 
from ‘normal’ serum was not included – as summarised previously in chapter 2, these 
were not deemed adequate representatives of ‘normal’ AGP.  
 
Four ‘normal’ heparinised blood samples were hydrolysed using the two acids 
individually.  All patient samples were similarly treated with the exception of LT3, LT9 
(with HCl), B4 (TFA) and HR4 (HCl and TFA) where only single analysis for each acid 
was possible.   
 
Fuc was detected in some ‘normal’ heparinised blood samples.  Other monosaccharides 
common to complex N-linked glycans were detected in the patient, ‘normal’ and 
commercial samples.  Statistical analysis of the data was performed using one-way 
ANOVA with a Tukey’s post hoc to allow comparison not only with a ‘normal’ 
population but also between treatment groups.  Whether variation in the data generated 
achieved statistical significance was indicated in table 6.2 and 6.3.  The levels of the 
monosaccharides in commercial AGP were greater (p<0.05) than those in AGP isolated 
from ‘normal’ blood.  Direct comparisons were not deemed adequately valid, despite 
the analysis of consistent masses of AGP because the large-scale techniques used in the 
isolation of commercial AGP differed to those used in this study.  Therefore, in making 
comparisons between patient samples and ‘normal’ populations it was considered more 
appropriate to use the blood values as comparisons as they were isolated using a 
common technique.  Also, serum samples were donated by individuals who, although 
known to be cancer free, were an elderly group and therefore may have an APR 
expressed; the samples may not be an accurate representation of a truly healthy 
population.  
 
One-way ANOVA analysis indicated that the level of Gal and GlcN (GlcNAc in the in 
vivo structure) were significantly greater in patients from the various stages of 
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methadone therapy (T, HR and LT treatments) compared to ‘normal’ blood (p<0.05) 
which may suggest an increase in chain branching.  The p-value was slightly improved 
upon removal of the outlying value in GlcN analysis (representative of patient LT6) 
however, significance was gained without its removal.  Although some of the AGP 
isolated from individuals receiving buprenorphine therapy displayed apparently higher 
levels of the two monosaccharides than that in the ‘normal’ group, the values were not 
found to reach significance upon statistical analysis. 
 
The level of the two monosaccharides remained relatively constant within and between 
treatment groups.  Patient T1 and LT6 expressed higher levels of GlcN (also Gal in 
patient T1) compared to other members of their respective groups, making the deviation 
from the mean relatively high in comparison to other groups. Levels of Gal varied 
between 3.87-5.97 mols/mol AGP, 2.55-4.47 mols/mol AGP, 3.27-4.63 mols/mol AGP, 
2.24-4.06 mols/mol AGP for T, LT, HR and B treatment groups respectively.  GlcN, 
which is not exclusive to branches like Gal, was higher at 6.52-10.2 mols/mol AGP, 
5.47-9.03 mols/mol AGP (both groups indicating a large variation about the mean due 
to patients T1 and LT6), 6.70-8.84 mols/mol AGP and 4.99-8.99 mols/mol AGP in the 
groups above. 
 
Although patient D1 and H1 had a significantly lower level of Gal (p<0.05) than the 
titration phase group but no significant differences in the level of either monosaccharide 
to that of ‘normal’, it could not be known if these levels were representative of others on 
the therapy thus it would have been inaccurate to assume so. 
 
The level of Man was relatively consistent – no statistically significant differences were 
found in the AGP of patient and ‘normal’ samples - suggesting the presence of 
pentasaccharide core structures remained consistent and therefore, as required, the 
approximate level of the glycoprotein analysed was equivalent; Man is only present in 
core structures of complex N-linked glycans.   
 
Therefore, as the only significant alterations occurred in the Gal and GlcN levels, there 
was a suggestion of increased branching of glycans in the AGP of patients, although it 
did not appear to be dependent upon stage or types of opioid replacement therapy as the 
groups do not significantly differ to each other.  
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 Mols monosaccharide/mol AGP 
Sample Fuc GlcN Gal Man 
Normal 1 0.0 2.55 2.36 0.905 
Normal 2 0.57 3.7 1.02 0.98 
Normal 3 0.7 4.27 2.41 1.22 
Normal 4 0.0 3.86 1.47 0.75 
Normal 5 ¥ 0.7 6.27 2.41 1.22 
Normal 6 ¥ 0.55 4.62 2.23 1.08 
Normal 7 ¥ 0.57 5.70 3.00 0.75 
Normal 8 ¥ 1.29 5.60  1.29  0.60  
Mean ‘normal’ heparinised 
blood 
0.32±0.37 3.60±0.74 1.82±0.68 0.96±0.20 
 
Table 6.1. Monosaccharide composition of ‘normal’ AGP samples. 
 
 Mols monosaccharide/mol AGP 
Sample GlcN Gal Man 
Mean ‘normal’ heparinised 
blood 
3.60±0.74 1.82±0.68 0.96±0.20 
T1 9.99±0.51▪ 8.24±0.46▪ 2.77±0.24 
T2 6.79±0.87▪ 3.51±0.61▪ 1.53±0.33 
T3 10.69±0.24▪ 3.65±0.26▪ 1.03±0.43 
T4 7.45±0.08▪ 4.21±0.49▪ 1.65±0.05 
T5 6.88±0.54▪ 4.99±0.10▪ 2.11±0.48 
Mean T 8.36±1.84 ♦ 4.92±1.05 ♦ 1.82±0.66 
HR1 9.24±0.31▪ 3.60±0.27▪ 1.14±0.02 
HR2 7.63±2.04▪ 3.81±0.06▪ 1.44±0.09 
HR3 7.22±1.02▪ 4.87 ª 2.07 ª 
HR4 6.98* 3.51* 1.52* 
Mean HR 7.77±1.07 ♦ 3.95±0.68 ♦ 1.54±0.47 
LT1 6.21±3.82▪ 4.64±0.42▪ 2.17 ±0.13 
LT2 4.03±1.02 ‡ 1.67 ª ‡ 1.00 ª 
LT3 7.38 * 3.45±0.70▪ 2.60±0.19 
LT4 7.08±1.95▪ 4.46±0.37▪ 2.21±0.07 
LT5 5.56±0.43▪ 3.30±1.00‡ 1.12±0.20 
LT6 10.57±0.36 ▪ 4.65±1.89▪ 1.93±0.22 
LT7 7.95±0.76 ▪ 2.27±0.04‡ 0.49±0.02 
LT8 7.38±0.51▪ 3.03± 0.41▪ 1.32± 0.09 
LT9 9.62 * 3.52 ª 1.73 ª 
LT10 7.08±1.95▪ 4.21±0.37▪ 2.01±0.16 
LT11 6.92±0.49▪ 3.40±0.26▪ 1.98±0.05 
Mean LT 7.25±1.78 ♦ 3.51±0.96 ♦ 1.45±0.96 
 
Table 6.2a. Monosaccharide composition of AGP from ‘normal’ blood and 
patients undergoing titration (T), harm reduction (HR) and long-term (LT) 
methadone therapies. 
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 Mols monosaccharide/mol AGP 
Sample GlcN 
 
Gal 
 
Man 
 
Mean normal heparinised blood 3.60±0.74 1.82±0.68 0.96±0.20 
B1 9.62±0.51▪ 4.18±0.21▪ 1.11±0.09 
B2 6.92±0.49▪ 1.97±0.35 0.56±0.18 
B3 7.38±1.90▪ 3.31±0.07▪ 0.81±0.17 
B4 4.03±1.02 3.13* 1.20* 
Mean B 6.99±2.00 3.15±0.91 0.83±0.29 
D1 3.81±0.9 3.26±1.00 1.38±0.58 
H1 5.56±0.75 1.01±0.32 0.95±0.42 
 
Table 6.2b. Monosaccharide composition of AGP from ‘normal’ and patients 
undergoing Buprenorphine (B), DHC (D) and heroin (H) opioid replacement 
treatments. 
 
Data in tables 6.2a and 6.2b is reported as the mean number of moles of 
monosaccharide / mole AGP ± the standard deviation (n=3).  Exceptions are those 
where the monosaccharide was only detected in a single run due to equipment 
malfunctions (ª) or where there was insufficient sample to duplicate analysis (*).  Mean 
values for each group are highlighted in green; ♦ Mean value significantly different 
(p<0.05) to ‘normal’ heparinised blood. ‡ Individual level expressed in patient glycan 
not significantly different to normal. ▪ Level significantly different to ‘normal’ mean 
value (p<0.05).  ¥ Data obtained from analysis of monosaccharides during a previous 
study using the same techniques. 
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The mean monosaccharide levels were then graphed in figure 6.6a however because 
there was only a single patient representing the treatment groups for DHC and heroin, 
these values were removed (figure 6.6b); it could not be known if they represented the 
majority of patients on the respective therapies.  To allow closer inspection of the 
difference in the level of sugar in each group, a series of boxplots were created (figure 
6.7), indicating the distribution of the sugar in each group and highlighting the outlier in 
the LT group mentioned previously.  Again, patients D1 and H1 were not included as 
there was only one sample and therefore only variation in the levels detected in it, not 
within a group.  Both the graphs and boxplots illustrated the findings of statistical 
analysis, with an apparent increase in the Gal and GlcN (therefore GlcNAc in the in vivo 
structure) components in the methadone patients, suggesting an increase in the 
branching of glycans in patients undergoing treatment for opioid dependencies.   
 
 
  
150 
 
a)
 
b) 
 
 
Figure 6.6. Bar chart summarising the mean level of monosaccharide / mol AGP 
in a) the separate treatment groups and b) in the different stages of methadone therapy,   
where ‘normal blood’ represents heparinised blood from the Blood Transfusion Service 
 
* Statistically significant difference compared to normal heparinised blood sample 
(p<0.05) HR – harm reduction; LT – long term treatment. ‡standard deviation 
calculated from triplicate analysis of a single sample while others were calculated from 
data from more than one patient (n = 4/+).    
0
2
4
6
8
10
12
Fuc GlcN Gal Man
0
2
4
6
8
10
12
normal blood Titration HR LT methadone
Fuc GlcN Gal Man
Treatment group 
M
o
l 
m
o
n
o
sa
cc
h
a
ri
d
e 
/ 
m
o
l 
A
G
P
 
Treatment group 
M
o
l 
m
o
n
o
sa
cc
h
a
ri
d
e 
/ 
m
o
l 
A
G
P
 
* 
* 
* 
* 
* 
* 
‡ 
* 
* 
* 
* 
* 
* 
* 
* 
151 
 
a) 
long-termharm reductiontitrationnormal blood
11
10
9
8
7
6
5
4
3
2
D
a
ta
Boxplot of normal blood, titration, harm reduction, long-term
 
b) 
long-termharm reductiontitrationnormal blood
9
8
7
6
5
4
3
2
1
0
D
a
ta
Boxplot of normal blood, titration, harm reduction, long-term
 
Figure 6.7. Box plot of monosaccharide distribution - a) GlcN (and by extension 
GlcNAc) and b) Gal in AGP isolated from ‘normal’ heparinised blood, patients 
undergoing titration, long-term methadone, HR and buprenorphine treatment for opioid 
dependence.  
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Figure 6.7 continued.   Box plot of monosaccharide distribution c) Man in AGP 
isolated from ‘normal’ heparinised blood, patients undergoing titration, long-term 
methadone, HR and buprenorphine treatment for opioid dependence.  
 
 
 
 
 
 
  
m
o
l 
M
an
 /
m
o
l 
A
G
P
 
153 
 
6.3 Discussion 
 
 
It is not only the in vivo concentration of AGP which can be altered as a result of the 
APR, structural alterations may also arise in the glycosylation, potentially affecting the 
ability of the glycoprotein to perform functions for which it was intended.  Müller 
(1989) reported that AGP glycans are not critical in the interaction with drugs at the 
binding site and instead it is solely dependent on the formation of the correct tertiary 
structure; describing the folding of the protein into its three dimensional structure which 
is essentially determined by the sequence of amino acids (primary structure).  However, 
it has become increasingly understood that glycans play an important role in 
determining the ability of glycoproteins to bind drugs and other ligands by ensuring the 
correct folding of the polypeptide backbone and therefore without it, the binding site 
would not form correctly.  Therefore it is important to analyse glycan structures during 
studies interested in the functions of glycoproteins, such as that undertaken and 
documented. 
 
Although cleavage of glycan chains into component monosaccharides does not allow 
the exact sequence to be determined, they can provide an indication of structural 
changes; especially when coupled to data gathered during analysis of the complete 
glycans (chapter 7).  Gal is a key example because its presence is limited to the 
branches of complex N-linked glycans (Hashimoto et al., 2004).  GlcNAc is another 
however its levels have the potential to be misleading – it is not unique to the branches 
of these structures as two residues also form part of each pentasaccharide core alongside 
three Man (GlcNAc2Man3).  As it is difficult to ensure the strong covalent interaction 
between the innermost GlcNAc and the Asn residues of the polypeptide chain is 
cleaved, an increase in its detection does not automatically denote changes in branching 
but perhaps improved cleavage of this bond.  Nevertheless, when levels are increased in 
conjunction with Gal it is likely they signify structural changes in glycans. 
 
Commercially sourced AGP was rendered an inappropriate representation of ‘normal’ 
AGP in this study because it was isolated using alternative methodologies to those 
implemented in this study – adapted from the large-scale methodology developed by 
Hao and Wickerhauser in 1973.   All factors considered, it was deemed most suitable to 
use AGP isolated from ‘normal’ blood as the source material and isolation techniques 
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were common to those for patient samples, reducing the number of factors which may 
induce structural changes. 
 
Results generated after acid hydrolysis and subsequent separation by HPAEC-PAD 
indicated a significant change in the glycosylation of AGP in individuals receiving 
methadone as an opioid replacement therapy compared to that from a ‘normal’ healthy 
population.  All had significantly greater levels of Gal and GlcNAc.  In the 
buprenorphine group, the levels appeared to be similar to the HR and LT groups but it 
did not reach significance.  Patients D1 and H1 expressed significantly lower levels of 
Gal when compared to the titration group but there was no difference when compared to 
those of the ‘normal’ population.  Although the increased expression of Gal and 
GlcNAc could infer increased branching, additional analysis of intact glycans was 
required (chapter 7).  It could not be established without said analysis whether 
expression was a result of branching or perhaps elongation of the branches already 
present.  Unlike AGP isolated from ‘normal’ blood, the monosaccharide Fuc was not 
detected in any patient sample.  A negligible level or apparent absence of Fuc is typical 
of the glycans expressed by the AGP in healthy individuals; its expression is generally 
increased in pathophysiological conditions such as inflammation and cancer (Turner et 
al., 1985; Listinsky et al., 1998).   
 
Also, as was mentioned in section 6.2, no patient AGP glycans contained GalNAc or 
Glc; this was expected as these monosaccharides are not associated with complex N-
linked glycans.  Instead, GalNAc is a common constituent of O-linked glycans while 
Glc expression generally targets the structure to the calnexin/calreticulin cycle because 
it should be cleaved prior to transfer from the ER lumen to the cis Golgi (refer to figure 
1.3, section 1.1.3.1). 
 
The separate use of TFA and HCl in achieving optimal hydrolysis of neutral and basic 
monosaccharides respectively had been discussed in chapter 3 with cleavage of Gal and 
GlcNAc being especially improved.  If the monosaccharides were not effectively 
cleaved or became denatured, they would not have been detected during HPAEC 
separation because formation of correct oxyanion structures would be hindered thus an 
accurate picture of the glycan composition would not be obtained.   
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Zdebska and Koscielak (1999) reported that a low ratio of Gal or SA to Man in 
glycoproteins may reflect either underglycosylation of the outer portions of glycan or an 
excess of core Man.  The current study suggested the opposite occurred in the AGP of 
patients studied as there was always a high level of Gal compared to Man. 
 
It must be remembered that although suggestions of altered branching after analysis of 
this type were apparent, even if levels of Gal and GlcN were extremely high, it could 
not be unequivocally ascertained whether this was due to an increase in the number of 
branches or perhaps an increase in the length of the branches already present.  Sialic 
acid (SA) residues may provide more detailed information as the residues terminate 
branches and therefore an increase in their presence suggests an increase in the number 
of branches.  However, it is well known that acid hydrolysis causes the SA of glycans to 
become unstable and destroyed therefore undetected by HPAEC-PAD (Smith et al., 
1997).  During monosaccharide analysis, it was sufficient to analyse the other 
components because not only is it accepted that the majority of branches are terminated 
by SA (if not, the exposure of Gal targets the structures for degradation or repair), but in 
the following chapter, when complete glycans were analysed, the SA residues remained 
intact to allow determination of the relative level of branching using HPAEC and an 
ELISA. 
 
The moles mono/mol AGP data was compared to determine whether any disparity 
existed in the glycosylation of patient samples and ‘normal’ blood samples.  Patients 
T1, T3 and LT6 had the greatest mol GlcN/mol AGP however only T1 also had a higher 
level of Gal compared to other individuals in the treatment group.  Although the level of 
AGP isolated from patients T1 and T3 (table 5.2) were relatively high (0.34 and 
0.25mg/mL respectively) for the group, that of LT6 was comparatively similar to others 
of the LT group (0.173mg/mL).  An increased synthesis during the APR could not 
explain the elevations in the monosaccharide because the analysis was performed on a 
common mass of AGP (50µg) as calculated from the levels isolated thus any difference 
could only be due to glycan expression.  Support of this concept was provided by the 
relatively consistent level of Man detected in all samples; the number of 
pentasaccharide cores should not change.   
 
Interestingly, the two oldest patients (LT4 and LT6 - 44 and 51 years old respectively) 
presented high levels of Gal (4.46±0.37 and 4.64±1.89 mol/mol AGP respectively) 
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compared to other members of the group (mean 3.51±0.91mol/mol AGP) however, the 
high standard deviation for LT6 demonstrated that the value was not necessarily as high 
as first suggested.  Only LT6 presented much higher than average GlcN levels 
(10.57±0.36 mol/mol AGP), in fact this was the highest value out of all the patients, that 
of LT4 was similar to the mean.   
 
Various teams have indicated the presence of altered glycosylation of AGP with age 
when individuals were considered healthy while others disagreed (Davis et al., 1985; 
Veering et al., 1990).  In those who suffer from inflammatory conditions, the incidence 
of which often increases with age, the appearance of alterations in the glycosylation are 
well documented (Smith et al., 1994; Rydén et al., 2001).  It was therefore unlikely that 
the alterations in AGP glycosylation suggested by HPAEC-PAD data were due to age, 
especially as most participants had levels of GlcN and Gal consistent with others from 
their respective treatment groups.  Moreover, a study with only two patients >40 years 
old does not provide enough data to ensure they are representative of this population. 
 
Similarities were found between the single patient receiving pure heroin as a 
replacement treatment and the ‘normal’ population, not only with respect to the level of 
AGP isolated but also in the level of all the monosaccharides constituting the glycans, 
and indicated that a change in type of drug administered may stimulate, or at least 
augment changes in AGP glycosylation.  H1 remained on a similar type of drug to that 
which was abused - the stresses associated with factors such as a new drug dosage 
regimen may have been more manageable and prevented the onset of an APR.  Also, the 
continuation with a similar drug, albeit in a more pure form, would not necessarily 
stimulate a reaction as the body had become accustomed to it over the duration of illicit 
drug use.  However it could only be speculated upon as H1 was the only patient 
undergoing such treatment.  Rostami-Hodjegan et al. (1999) reported that individuals 
abusing heroin had greater levels of AGP however these individuals were reported to be 
exhibiting withdrawal unlike patient H1.  Even if monosaccharide levels were similar, it 
did not necessarily signify a common structure, merely that the overall composition was 
analogous, the order and linkages binding the monomeric units could vary widely.  Such 
information could not be gathered using the technique described in this chapter.  
 
There are no known studies which have investigated the potential that AGP 
glycosylation may be altered in individuals undergoing opioid replacement therapy, 
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potentially affecting the efficacy of treatments.  Therefore it was not known if the data 
generated in this small preliminary study was representative of patients on the whole.  
The results from monosaccharide analysis in this study have indicated that although 
altered glycan composition of AGP did not appear to be associated with any particular 
treatment stage, all methadone patients had a demonstrable change in glycosylation 
hence there was potential that its subsequent ability to bind basic drugs like methadone 
may have been affected, altering its efficacy.  Prior determination of the glycosylation 
of patient AGP may be useful when considering the type of therapy to be administered.  
For example, if patient AGP expressed a high level of branching – as indicated by Gal 
and GlcNAc residues – and this was found to be associated with increased binding to 
methadone, it would be beneficial to consider an alternative therapy as high doses of 
methadone would be required to allow for inactivation by AGP, subsequently increasing 
the risk of toxicity.   
 
It was important to perform subsequent analysis of complete glycans as it is the whole 
structure which determines the ability of a glycoprotein to execute its functions. 
 
 
 
SUMMARY STATEMENT 
The monosaccharide composition of glycans cleaved from the polypeptide backbone of 
AGP differs significantly (in terms of Gal and GlcNAc content) between that isolated 
from ‘normal’ heparinised blood and from individuals undergoing various stages of 
opioid replacement therapy.  There was no significant difference between individuals 
receiving methadone as a substitute.  Results suggested an increase in branching 
therefore additional oligosaccharide profiling was required – as discussed in the 
following chapter. 
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Chapter 7 
AGP Oligosaccharide Analysis  
Results and Discussion 
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7.1 Introduction 
 
 
Understanding the close relationship between the specific structure of AGP glycans and 
the influence they have on the functions performed by the glycoprotein is paramount to 
the hypothesis of this study.   
 
HPAEC is a highly reliable method used in the detection and separation of glycans thus 
it was implemented to separate those generated upon cleavage of the isolated AGP 
samples by the enzyme PNGaseF.  Similar to monosaccharide compositional analysis, 
the separation of whole glycans relies upon the presence of weakly acidic sugars in a 
basic media (pH13) which undergo electrocatalytic oxidation when in contact with the 
gold electrode to form oxyanions.  The conditions required for its optimal performance 
differ slightly to account for the new analytes of interest.  Along with negatively 
charged terminal 9-carbon carboxylated SA residues (specifically N-acetylneuraminic 
acid, NeuAc), the negative charge contributed by component monosaccharides under 
alkaline conditions determine the strength with which the glycans interact with the 
stationary phase - a pellicular anion exchange resin (ammonium-bonded beads) 
ionically attached to large cation-exchange spheres.  In the late 1980s Townsend and 
colleagues demonstrated that glycans could be separated solely by the presence of SAs, 
using relatively acidic pHs as low as 4.6 (Townsend et al., 1988; 1989).  The formation 
of oxyanions under strongly alkaline conditions enhances separation, allowing isomers 
to be recognised as structurally distinct based on the differing pKa values of constituent 
monosaccharides (Lee, 1990).   
   
The sensitivity of HPAEC-PAD technology (shown to be 10-100pmol by Hardy and 
Townsend, 1988) owes itself to the detection and separation of glycan chains in addition 
to that of monosaccharide analysis.  Again, the introduction of pulsed amperometric 
detection (PAD) to HPAEC vastly improved the sensitivity of detection by ensuring 
periodic decontamination of the sugar oxide coating which formed on the electrode 
under the highly alkaline conditions.  Throughout the late 1980‘s and early 1990‘s, 
HPAEC was by far the most commonly used and sensitive technique available for 
glycan structural analysis after enzymatic or chemical release of the oligosaccharides 
from the underlying protein. One of the primary advantages of HPAEC-PAD was that 
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sensitivity does not require prior derivatisation to enhance hydrophobicity as is 
necessary in many other techniques such as MS (Lee, 1990).   
 
Removal of glycans bound to the anion-exchange resin requires an increasing linear 
gradient of a pushing agent, commonly sodium acetate (50-250mM NaOAc over 30min) 
which competes with the glycans for the column surface thereby displacing the 
oligosaccharide chains.  The gradient of NaOAc ensures that all structures are released, 
the most difficult being highly branched sialylated structures.  NaOH is used at 100mM 
to provide an alkaline pH.  There are two major forms of SA, N-glycolyl- and N-
acetylneuraminic acid, which differ by the presence or absence of a single -OH group.  
Despite this small difference, HPAEC-PAD can successfully separate them by more 
than ten minutes when the NaOAc gradient is used (Behan and Smith, 2010).  Without 
sodium acetate it would not be possible to dislodge the glycans from the column. 
 
If two similar oligosaccharide structures differing only in degree of sialylation were 
analysed, elution would occur in separate charge bands because the collative negative 
charge differs substantially (figure 7.1).  The size of the glycans subequently determine 
at what stage they elute within a given charge band; glycans with a greater 
monosaccharide composition elute later than glycans with the same sialylation but 
fewer monosaccharides.  Sugars with more carbon atoms have an increased number of   
-OH groups and negative charge, thus they are retained for longer (Paskach et al., 1991).  
For example, a mixture of bi-sialylated bi-antennary, tri-antennary and tetra-antennary 
structures would elute in this order within the bi-sialylated charge band because the 
structures increase in size and therefore in strength of interactions formed with the 
column.  By extension, it is possible for a highly branched, but incompletely sialylated, 
glycan to elute before a fully sialylated structure with fewer branches e.g. a bi-sialylated 
tetra-antennary glycan would elute earlier than a tri-sialylated tri-antennary structure. 
Such circumstances are relatively uncommon because the absence of SA at branch 
termini causes exposure of the Gal to which it is attached.  This would normally target 
the structure for degradation, unless another structure is expressed in its place. 
 
Townsend and colleagues (1988 and 1989) also indicated the possibility of separating 
oligosaccharide chains by manipulating the ability of Gal to bind the pentasaccharide 
core via a β(1, 4) or β(1, 3) linkage to GlcNAc.  The former elutes faster because the     
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-OH groups are less able to associate with the column surface when converted to 
oxyanions at pH 13 (Townsend et al., 1988; Townsend et al., 1989).  
 
It is also possible to distinguish glycans with a common degree of sialylation by the 
types of linkage existing within the chains.  NeuAc for example is capable of binding to 
the outer Gal residue through an α(2, 6) or α(2, 3) linkage; the greater the expression of 
the latter, the stronger is the interaction with the column (Townsend et al., 1988).  This 
is because α(2, 6) causes elimination of the oxyanion effect at the C6 –O- group of Gal 
(formed at the –OH group under alkaline conditions); it then becomes involved in the 
linkage to NeuAc. Therefore, the overall charge is decreased causing it to be more 
easily eluted by NaOAc than a similar structure expressing an α(2, 3) linkage which 
does not impede the interaction of the oxyanion group of C6 (Townsend et al., 1989).  
The two types of linkage can be detected using specific lectin conjugates and 
performing an ELISA; the relative level can thereby be investigated. 
 
 
7.2 Results 
 
 
7.2.1 HPAEC oligosaccharide analysis 
 
The generation of distinct peaks in the chromatograms is thought to be due to the 
absence of tautomerisation, epimerisation and other Lobry de Buyn-van Ekenstein 
transformations; reactions which carbohydrate structures may undergo at high pH 
subsequently interfering with chromatography.  However at room temperature and 
during the time-course of the chromatography, it is reported that these do not arise (Lee, 
1990; Dionex Corp., 1994). 
 
HPAEC-PAD firstly separated glycans into specific charge bands.  Those glycans 
expressing a single SA residue elute first (10-20 minutes), followed by bi-sialylated (20-
30minutes), tri-sialylated (30-40minutes) and finally tetra-sialylated, eluting between 
40-50 minutes.  Figure 6.1, demonstrates this with an oligosaccharide library containing 
bi-, tri- and tetra-sialylated chains; each group of peaks representing the different 
degrees of sialylation as labelled.  The library was used as a comparison trace for patient 
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samples, allowing identification of the sialylation of branches. Although 
monosaccharides can be easily quantified through the use of calibration curves, this was 
not possible for oligosaccharides because there was no similar availability of pure forms 
to use as reference material. 
 
A commercial AGP sample was run and compared to the library, generating peaks 
within the same charge bands however there was a reduction in the variability of tetra-
sialylated structures, indicated by fewer peaks (figure 7.2a).  Similar results were found 
for AGP isolated from ‗normal‘ heparinised blood samples (figure 7.2b).  Although 
some tetra-sialylated structures appeared to be present, favouritism was demonstrated 
for bi-sialylated forms.  There were fewer peaks than in commercial sample suggesting 
less variability.  
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Figure 7.1.   Oligosaccharide library trace generated during separation by HPAEC.  
Separation based on the charge of oligosacchiarde chains as measured using nano 
culons (nC). Degree of sialylation highlighted in purple.   
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a) 
 
b) 
  
Figure 7.2.  HPAEC chromatograms of oligosaccharide library versus a) 
commercially sourced AGP and b) AGP form ‘normal’ heparinised blood samples. 
Separation based on the charge of oligosaccharide chains as measured using nano 
culons (nC). Degree of sialylation highlighted in dashed boxes. ‗Normal‘ sample data 
represented the oligosacchairde profiles of AGP isolated from heparinised blood 
samples obtained from the Blood Transfusion Service. 
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Patient samples from the titration phase of therapy (n = 5) were analysed and each 
chromatogram generated during HPAEC was graphed alongside the library (figure 7.3).   
In general it could be seen that, when compared to the library, these glycans displayed a 
preference for the charge bands representing bi- and tri-sialylated structures with very 
few peaks in the tetra- sialylated region.  This appeared to be common with the ‗normal‘ 
and commercial samples of figure 7.2 suggesting the AGP of these individuals had low 
level branching.  However, all titration samples displayed some, albeit relatively few, 
peaks in the tetra-sialylated charge band.  The most noteworthy being T3 and the least 
T2.  Additionally, the chromatograms of T1 and T3 displayed higher levels of branhes 
terminated in three SA residues, with much larger distinct peaks compared to the other 
samples within the group; peaks were more comparable with those in the library. 
 
The two main peaks within the tri-sialylated charge band of T1 (34 and 35 minutes) 
were almost identical to the library in size and shape and probably represented similar 
structures, however they eluted slightly earlier.  Perhaps this could explain why the peak 
at approximately 42 minutes lay at the interface of the tri- and tetra-sialylated bands; it 
may be a tetra-antennary structure that eluted earlier than expected in line with the 
previous peaks.  A similar pattern was identified at this time point in the chromatogram 
of patient T2 but the remainder of the profile was composed of smaller peaks.  There 
was a novel peak at approximately 53 minutes in T3 AGP, unlike any of the other 
titration group samples where glycans tended to elute earlier in the tetra-siaylated region 
representing shorter chains.  HPAEC-PAD separation of T3 glycans also generated 
numerous peaks in the tetra-sialylated region, more so than any other titration pateint.   
 
There were also two small peaks (17-18minutes) in the chromatogram of patient T1 and 
a relatively large peak at approximately 16 minutes in that of T2 which may indicate the 
presence of monosialylated oligosaccharides.  This was unusual and unexpected 
because the absence of terminal SA residues causes the underlying Gal to be exposed 
which should cause its subsequent degradation.   
 
Overall the glycans expressed by AGP isolated from those in the titration phase of 
therapy appeared to show preference for branching of the bi- and tri-sialylated type, 
much like that in the ‗normal‘ and commercial samples (figure 7.2). 
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a)  
 
 
b)  
 
 
Figure 7.3.   Chromatograms of oligosaccharide library versus titration patients a) 
T1 and b) T2 (orange). Separation based on the charge of oligosaccharide chains as 
measured using nano culons (nC). Degree of sialylation highlighted in dashed boxes.  
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c) 
 
 
d)  
 
Figure 7.3 continued. Chromatograms of oligosaccharide library versus titration 
patients c) T3 and d) T4 (orange). Separation based on the charge of oligosaccharide 
chains as measured using nano culons (nC). Degree of sialylation highlighted in dashed 
boxes. 
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e) 
 
 
 
 
Figure 7.3 continued.   Chromatogram of oligosaccharide library versus titration 
patient e) T5 (in orange). Separation based on the charge of oligosaccharide chains as 
measured using nano culons (nC). Degree of sialylation highlighted in dashed boxes. 
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Figure 7.5 illustrates the HPAEC-PAD separation of AGP glycans from patients in the 
harm reduction (HR) scheme alongside that of an oligosaccharide library.  The only 
commonality between the chromatograms obtained for this group was that all displayed 
bi-sialylated structures.  Apart from this, the three samples representing the HR phase of 
opioid replacement therapy shared very few similarities with respect to their 
oligosaccharide profiles.   
 
HR1 displayed few peaks in any other charge band, with no discernable tetra-sialylated 
structures and limited evidence of tri-sialylated, although there was a small but broad 
peak at approximately 39 minutes which suggested there were some glycans terminated 
in three SA residues.  The large peak at 15 minutes followed by another smaller peak 
may represent a large number of mono-sialylated AGP glycans. 
 
Although there were few peaks spread throughout the chromatogram in pateints HR1 
and HR3, there were some in HR2, albeit much more broad than that of the library or 
patients from the other therapy groups, suggesting more of this particular glycan 
structure was expressed.  It should be noted that the chromatogram of sample HR3 may 
show more peaks if the scale was truncated; the peak in the tri-sialylated region was 
amost twice the height of the library therefore dwarfs the smaller peaks because the y-
axis scale accounted for the highest value.   
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a) 
  
b) 
 
Figure 7.4.  Chromatograms of oligosaccharide library versus harm reduction 
methadone patients a) HR1 and b) HR2 (in blue).  Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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c) 
 
Figure 7.4 continued.  Chromatograms of oligosaccharide library versus harm 
reduction methadone patients c) HR3 (in blue). Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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Subsequently, chromatograms generated during the HPAEC-PAD analysis of glycans 
cleaved from the AGP of long-term methadone therapy (LT) patients were graphed 
alongside the oligosaccharide library (figure 7.5).      
 
Like the AGP isolated from patients within the titration phase of opioid-replacement 
therapy, the glycans of LT patients appeared to be mainly bi- and tri-sialylated.  The 
peaks of LT1, LT3, LT5, LT9 and LT10 chromatograms were large and more distinct 
than in other members of this treatment group such as LT4, LT6 and LT7.  Dissimilar to 
the titration phase group however, the peaks representing tetra-sialylated structures in 
the chromatograms of some LT patients (for example LT4, LT9 and LT10) were more 
defined.  There was one main peak present in the chromatogram of LT1 within the tetra-
sialylated region eluting at approximately 43 minutes suggesting most tetra-antennary 
glycans existing in their AGP were of a common structure.  Comparison of LT9 and 
LT10 chromatograms suggested similar glycans were expressed, the main difference 
being that peaks in LT10 were generally much larger. 
 
LT1, LT3 and LT5 all expressed peaks in the latter region of the bi-sialylated charge 
band along with the early part of that corresponding to tri-sialylated structures, 
suggesting numerous long bi- and short tri-antennary structures were present.  The intial 
peaks detected in figure 7.4g (LT7) could represent mono-sialylated glycans 
(~17minutes).  
 
The chromatogram of patient LT8 had a high frequency of peaks, albeit small, in the tri-
sialylated region.  There appeared to be a preference for increased branching of the 
glycoforms of this AGP sample; very few peaks were recorded in the bi-sialylated 
region but some in the tetra-sialylated region. The glycans of AGP isolated from 
patients LT9 and LT10 were also predominantly tri-sialylated.  
 
Therefore, there were similarities with the titration, ‗normal‘ and commercial groups in 
that all appeared to have a high proportion of tri-sialylated structures however, within 
the LT, variations existed.  Some patients showed apparent preference for more highly 
branched structures (e.g. LT4 and LT10) while others for less branched (e.g. LT3). 
Those with peaks in the most highly charged band displayed more distinctive peaks than 
any in the titration phase where peaks were noted. 
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a) 
 
 
b)  
  
Figure 7.5. Chromatograms of oligosaccharide library versus long term methadone 
patients a) LT1 and b) LT2 (in green).  Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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c)  
 
 
d) 
 
Figure 7.5 continued.  Chromatograms of oligosaccharide library versus long term 
methadone patients c) LT3 and d) LT4 (in green). Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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e) 
 
 
 
f) 
 
Figure 7.5 continued. Chromatograms of oligosaccharide library versus long term 
methadone patients e) LT5 and f) LT6 (in green). Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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g) 
 
 
h) 
 
 
Figure 7.5 continued.  Chromatograms of oligosaccharide library versus long term 
methadone patients g) LT7 and h) LT8 (in green).  Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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i) 
 
 
j) 
 
 
Figure 7.5 continued.  Chromatograms of oligosaccharide library versus long term 
methadone patients i) LT9 and j) LT10 (in green).  Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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The remaining samples analysed from patients undergoing alternative therapies were 
graphed in figure 7.6. 
 
Patient B1 (receiving buprenorphine) displayed evidence of all types of sialylation as 
did B2. However the chromatograms differed widely with small peaks (B1) 
representative of strucutres eluting during the later stages of the bi-sialylated charge 
band and early on in the tri-sialylated band.  Sample B2 had large peaks at 
approximately 20, 25 and 30 minutes – suggesting two main bi-sialylated and one main 
tri-sialylated structure were expressed by this AGP.  The proflie of B1 was more 
comparable to B3, where peaks were of similar size in all charge bands suggesting 
similar levels of structures.  An exception was that AGP isolated from B1 appeared to 
display tetra-sialylated structures.   
 
Although the AGP isolated from pateint B1 and B4 expressed some tetra-sialylated 
glycans, the structures must vary because the peaks which represented them eluted at 
different stages within the charge band.  The chromatogram of B4 indicated structures 
were mainly tri-sialylated but all peaks were very small.  It was quite similar to that 
obtained for LT6 in figure 7.5f.  
 
The chromatogram generated upon HPAEC-PAD analysis of AGP isolated from the 
patient undergoing heroin therapy (H1), showed a large quantity of peaks throughout all 
charge bands.  Peaks in the bi-sialylated band were initially broad but as retention time 
increased, the peaks narrowed.  It would suggest that the AGP from this pateint 
displayed numerous different glycan structures terminated in various degrees of 
sialylation.  Most structures were bi- and tri-sialylated which was common with many 
samples analysed during this study.  Finally, patient D1 (receiving dihydrocodeine as a 
treatment) displayed peaks in the region preceeding the bi-sialylated charge band 
suggesting there may be some glycans terminated in SA at a single branch.  Although 
the trace displayed fewer peaks than H1, there were still examples of each type of 
sialylation.  
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a)  
 
 
b)   
 
Figure 7.6. Chromatograms of oligosaccharide library versus patients on 
alternative therapies a) B1 and b) B2 (in red).  Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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c) 
 
 
 
d)  
 
Figure 7.6. continued.  Chromatograms of oligosaccharide library versus patients 
on alternative therapies a) B3 and b) B4 (in red).  Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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e)  
 
 
f)  
 
Figure 7.6 continued.  Chromatograms of oligosaccharide library versus patients 
on alternative therapies e) D1 and f) H1 (in red).  Separation based on the charge of 
oligosaccharide chains as measured using nano culons (nC). Degree of sialylation 
highlighted in dashed boxes. 
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7.2.2 Siailic Acid ELISA 
 
SA residues present at the termini of glycan chains were investigated in more detail by 
performing an ELISA with specific lectin conjugates allowing the detection of α2,6- and 
α2,3- linked NeuAc.  The kit was developed by Galab primarily to analyse the sialic 
acid activity of milk and milk-derived samples but as the glycans of AGP are also 
terminated in these strucutres it was decided to perform the analysis and determine if the 
particular assay offered potential.  Not including the ‗normal‘ heparised blood sample 
control,  it was only possible to anaylse three AGP samples therefore data pertaining to 
the analysis was to be incomplete from the start.  However, as part of a preliminary 
study it was considered useful.  
 
The ELISA only generated useable absorbance data for α2,3 linkages therefore it was 
impossible to establish total SA content and compare to HPAEC analysis to determine if 
results were associated. The α2,6-linked SA experiment did not provide absorbance 
values that differed to that of the inhibition control or 100% signal i.e the inhibition 
control was erroneous. It was deemed useful to record and discuss the results of the α2,3 
data which is increasingly expressed in highly branched glycans (Bierhuizen et al., 
1988).  
 
The use of an inhibition control allowed the application of the assay to be gauged – 
sufficient glycoprotein should be used to out-compete the glycosylated plate surface 
thus providing absorbance values similar to the inhibition control (i.e. when inhibition is 
100%).  AGP was used at a concentration of 0.5mg/mL which was 10-fold lower than 
that suggested for the milk protein caseinomakropeptide (CMP) for which the assay was 
developed.  However, it was found that this concentration was capable of producing 
inhibition relatively similar to that of the control.  As the concentration of the 
glycoprotein decreased, there was less inhibition hence absorbance values became 
increasingly similar to the 0% inhibition control.  Values were recorded on addition of 
the enzyme conjugate and substrate after increasing incubation intervals to ensure data 
used in determining the relative α2,3-linked SA activity of each sample of glycans was 
the most efficient. 
 
Theoretically, the technique was based on the principle that the addition of AGP caused 
competition with the glycosylated plate suface for the lectin conjugate (specific to the 
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linkage type under investigation).  The removal of the lectin conjugate with AGP upon 
washing caused the reaction catalysed by the enzyme conjugate to be inhibited hence 
the inhibition was greatest when the glycoprotein of highest concentration was added.  
As the concentration decreased, more lectin was able to bind therefore the enzyme 
activity was increased. 
 
Figure 7.7 illustrates the relative signal intensity of SA recorded at 405nm over the 
range of AGP concentrations tested (to 0.5mg/mL) in the α2,3 assay.  It appeared that 
most α2,3 linkages were present in the T and LT sample. Even at the highest 
concentrations, the intensity of the HR AGP sample did not pass through 0.5 units 
which represents 50% inhibition and was necessary for the calculation of the SA activty.  
As shown in the bar chart of figure 7.8, there was a distinct lack of activity of the 
sample SA residues to the α2,3 lectin conjugate MAL which suggested this type of 
sialylation was too low to be detected thus α2,6 was perhaps more predominant 
however the inability to obtain data from the ELISA prevents this being supported 
experimetally.  Higher concentrations of the HR AGP may be required for detection.  
Conversely, there was clear activity in the T and LT samples, however only the LT 
sample demonstrated levels greater than the ‗normal‘ sample. Despite these apparent 
differences, the technique was only performed on few randomly selected samples 
therefore whether observations made were relatvie to all others in the study population 
could not be confirmed. 
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a) 
 
 
Figure 7.7.  Signal intensity at 405nm over a range of AGP concentrations.  The 
concentration of each sample at a signal intensity of 0.5 which represents 50% 
inhibition, was used to calculate sialic acid content – only when a declining linear trend 
was apparent.  Intensities which remained above 0.5 represented sample concentrations 
which did not cause sufficeint inhibition.  
b) 
    
  
 
Figure 7.8.  α2,3 – linked sialic acid activity.  A 2-D column graph representing the 
sialic acid activity of randomly selected samples from each methadone treatment group, 
calculated using the IC50 values from figure 7.7 i.e. the concentration at 50% inhibition 
of lectin binding. 
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7.3 Discussion 
 
 
The analysis of intact glycan structures expressed by glycoproteins first requires their 
release from an underlying polypeptide backbone; the structure must first be denatured 
(chapter 2).  Denaturing agents such as SDS could not be used as they destroy glycans 
(Hermentin et al., 1992).  Heat denaturation improves the subsequent hydrolytic 
cleavage by the endoglycosidase PNGaseF therefore it was utilised to denature AGP.  
The enzyme was used because it only cleaves the bond between the Asn residue of the 
denatured polypeptide backbone and the initial GlcNAc of the pentasaccharide core; 
generating complete glycan chains.  It ensured the release of all AGP glycans because 
the Asn residues to which they were attached were in turn linked to other amino acids 
(the consensus sequence) at each termini; a pre-requisite for the enzyme (Plummer et al., 
1984).  Deamination of the Asn residue forms aspartic acid, leaving the glycans 
unstable, subsequently becoming converted to a reduced structure.  Unlike the acidic 
conditions used to cleave component monosaccharides, the enzyme prevented 
desialylation of the glycan branches which was crucial to the HPAEC-PAD analysis 
utilised in this phase of the study; it relied on the presence of the negative charge of SA 
residues as a means of separating glycans. 
 
Figures 7.2 to 7.6 provided evidence that PNGase F was capable of cleaving glycan 
chains and that HPAEC-PAD separated them into charge bands based on the negative 
charge produced primarily by the SA content as labelled in the library trace (figure 7.1). 
As described above, the oligosaccharide chains were separated by HPAEC based upon 
their charge and size but also the constituting monosaccharides and linkages holding 
them together (Hardy and Townsend, 1988). Strong alkaline conditions (pH13) were 
required to induce oxyanion formation allowing improved resolution than that possible 
using SA expression alone – isomeric structures can be distinguished when oxyanions 
are generated. 
 
It has been shown that reducing glycan chains before analysis by HPAEC could 
improve the resolution of peaks however it required additional steps and may itself lead 
to the epimerisation and degradation of the structures if they are sensitive to the alkaline 
conditions utilised e.g. 0.5M Sodium borohydride (NaBH4) in 0.1M NaOH (Lee, 1996). 
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Chromatograms generated on analysis of isolated AGP samples were plotted with the 
library to aid identification of the degree of sialylation; charge bands could be easily 
distinguished.  Although it was possible to identify general features common to the 
oligosaccharide profiles generated for each AGP sample belonging to the individual 
study groups, selecting one to represent their respective groups was deemed 
inappropriate as variations were also clear.  Instead, comparisons were made between 
the general observations made in section 7.2.  As discussed previously, commercial 
AGP was not used to represent a ‗normal‘ trace because the isolation techniques 
implemented may have caused partial desialylation, rendering the HPAEC analysis 
inaccurate.  The chromatogram of commercial AGP (figure 7.2a) may support this as 
there were no detectable tetra-antennary peaks while the normal sample appeared to 
have some small peaks.  However, both were in agreement with previous studies 
(Kimura et al., 2006), where the branching of AGP appeared to favour bi- and tri-
antennary structures as demonstrated by the peaks in the corresponding charge bands.  
The general peak distribution was relatively consistent within the titration treatment 
group, generally displaying a large proportion of bi- and tri-sialylated structures.  
Preference for similar charge bands was displayed by the LT group. Chromatograms 
generated for the HR group differed considerably. Additionally, the ‗normal‘ AGP 
samples often displayed a peak prior to the bi-sialylated charge band which may 
represent glycans with only one branch terminated in a SA residue.  There are very few 
reports suggesting the AGP of healthy populations would express such structures, 
mainly because the absence of a SA residue causes the underlying Gal to become 
exposed.  This would normally act as a signal for the destruction or repair of the 
structure; targeted towards lysosomes or calnexin/calreticulin cycles respectively.  
 
If representative profiles are to be generated, further analysis must be undertaken.  A 
limitation of the current study was the restrictions on patient recruitment enforced by 
the NHS ethics board.  Preliminary investigations of a wide group of individuals have 
indicated the glycosylation of AGP may be altered in individuals undergoing opioid 
replacement therapy. The study would benefit from focussing interest on particular 
groups to investigate this further.  
 
In general, the glycosylation of AGP isolated from patients undergoing opioid 
replacement therapy showed preference for bi- and tri-sialylated branching.  Some 
patients demonstrated the presence of peaks in the tetra- and mono-sialylated regions 
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but, on the whole, it was less prevalent than other types.  Although AGP glycans 
isolated from ‗normal‘ heparinised blood also tended to express mostly bi- and tri-
sialylated glycans, data generated during monosaccharide (chapter 6) and 
oligosaccharide analysis has highlighted that the glycosylation of AGP in patients 
undergoing methadone therapy appears to differ.  Therefore, as all patients it was 
important to determine if functional changes occurred. 
 
The monosaccharide data (table 6.2) for the ‗normal‘ heparinised blood samples 
suggested there was a low degree of branching because the level of Gal and GlcN was 
low while Man was relatively constant – the number of core structures remained 
common as expected because comparable levels of AGP was analysed.  However, as the 
Gal and GlcN levels were far lower than the commercial AGP data, it would be 
expected that the chromatogram would show more peaks in the bi-sialylated charge 
band.  This was not the case and instead commercial AGP had more peaks in this area.  
Perhaps desialylation caused during isolation of the commercial sample resulted in the 
premature elution of glycans due to the reduction in negative charge - the degree of 
branching suggested in the profile may be misleading, instead the commercial sample 
may express higher levels of branching but without terminal SA residues.  The peaks 
corresponding to the glycans of commercial AGP were therefore expected to elute later 
in the charge bands due to the larger structures suggested by monosaccharide analysis 
however this was not the case, certainly within the tri-sialylated charge band.   
 
Interestingly the data obtained from monosaccharide analysis of many patient samples 
in chapter 6 was in agreement with the findings during glycan analysis i.e. a high 
content of Gal and GlcN, the monosaccharides present in glycan branches, often 
correlated with oligosaccharide profiles with peaks eluting in the tetra-sialylated charge 
band.  For example, patient T3 displayed significantly higher levels of GlcN and Gal 
compared to the ‗normal‘ heparinised sample suggesting highly branched structures.  T3 
recorded the highest level of GlcN (table 6.2) and a relatively similar level of Gal 
compared to other patients in the treatment group.  When the glycans were subsequently 
resolved using HPAEC-PAD, a higher degree of branching was evident; this patient was 
the only one to show a relatively large number of peaks in the tetra-sialylated region.  
Conversely, samples like LT2 which generated relatively ‗smooth‘ chromatograms 
more akin to the ‗normal‘ profiles of figure 7.2b than to others of their respective group 
also appeared to have low levels of Gal and GlcN; the levels did not show a significant 
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difference when compared to those for the ‗normal‘ population. It would have been 
useful to repeat oligosaccharide analysis of AGP glycans for said samples to determine 
whether the profiles were reproduced however limited sample availability rendered this 
impossible. 
 
It should be noted that Fuc was not detected in any patient samples and therefore it 
could not have been responsible for reducing the retention time of glycans as described 
by Pfeiffer et al. (1990).  Such modifications have been reported in diseases such as 
cancer or RA where fucosylation increased (Mackiewicz and Mackiewicz, 1995; Smith 
et al., 2002).  It is also known to be increased as a result of liver damage, like that which 
occurs during hepatitis or due to drug taking (Anderson et al., 2002).  There was no 
evidence suggesting this. 
 
Overall, HPAEC-PAD has been shown by this study and numerous others before to 
represent a useful sensitive technique in the analysis of glycan structures.  PAD detects 
only compounds with functional groups which are oxidised at the detection voltage.  
Similar to monosaccharide analysis, alterations in the structure of glycans were apparent 
in comparison to a normal population.   
 
The SA ELISA indicated that although the kit was produced to analyse the SA activity 
of milk and milk-derived proteins, it could be adapted for human AGP. The 
determination of SA was based upon a competitive lectin assay with the plate presenting 
sialylated structures which bind specific lectin conjugates – SNA and MAL for α(2,6) 
and α(2,3) respectively.  The sialylated glycoprotein AGP should inhibit this binding.   
 
Patients randomly selected from the T and LT phases of therapy were found to 
demonstrate α2,3 activity however only the LT AGP glycans had higher activity 
compared to the ‗normal‘ AGP.  Although the level of α2,6-linked NeuAc was not 
determined, the ELISA was useful as part of a preliminary study.  The data may 
correlate with that of HPAEC-PAD analysis of the oligosacchairdes, as the T and LT 
patients expressed a high level of branching however, with the lack of information 
regarding α2,6 SA activity and therefore total SA content, whether the ELISA truly 
mirrored the results of HPAEC-PAD analysis could not be determined. 
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Relatively high levels of α2,3 sialylation would be expected because the linkage is 
common to AGP glycans (Bierhuizen et al., 1988).  Its presence generally causes later 
elution of a glycan when compared to a similar structure but with α2,6 linkages because 
the latter has a lower collative negative charge due to the absence of the C6 oxyanion - 
this effect could not be clearly detected in the chromatograms generated.  However, it 
has been reported that an increased expression of α2,3-linked neuraminic acid residues 
is correlated with more highly branched structures, while α2,6 is more common to bi-
antennary glycans (Bierhuizen et al., 1988). This is in agreement with the 
oligosaccharide analysis by HPAEC-PAD, where the LT samples (figure 7.5) 
commonly demonstrated evidence of tetra-sialylated structures.   
 
Overall, HPAEC-PAD indicated that the glycosylation of AGP isolated from patients 
undergoing various stages of opioid-replacement therapy was different to that expressed 
by the AGP isolated from a ‗normal‘ heparinised blood sample.  For many patients the 
analysis supported, and had been supported by, data obtained during monosaccharide 
compositional analysis (chapter 6).   
 
 
 
SUMMARY STATEMENT 
The glycans of AGP isolated from heparinised ‗normal‘ blood and individuals 
undergoing opioid substitute therapies were shown to differ. All groups appeared to 
show a preference for bi- and tri-sialylated structures however tetra-sialylated structures 
were only found in AGP isolated from patients, most commonly in the LT group.  The 
results often provided support for the data generated during analysis of monosaccharide 
composition in chapter 6.  Whether these structural differences could alter the ability of 
the glycoprotein to bind drugs was therefore of interest. 
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Chapter 8 
Drug Binding 
Results and Discussion  
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8.1 Introduction 
 
 
Preceding chapters have focussed upon the structural analysis of successfully isolated 
AGP from patients undergoing opioid replacement therapy. In the present chapter the 
focus shifts towards a particular function performed by the glycoprotein, namely 
binding to basic drugs - primarily, to methadone.   
 
The magnitude of the role performed by AGP and other APPs in determining the level 
of active drug present in vivo is often incompletely appreciated during studies into a 
drug‘s effectiveness.  There are no known studies which have investigated the presence 
of the glycoprotein and more specifically the structure of its glycans in individuals 
undergoing opioid-replacement therapy.  Instead, those actually acknowledging AGP 
mainly concentrated on individuals administering heroin (e.g. Rostami-Hodjegan et al., 
1999) or those prescribed methadone for pain management (e.g. Abramson, 1982; 
Duché et al., 2000), however the studies did not considered altered glycosylation. 
 
Numerous techniques have shown use in the investigation of drug binding to the APPs 
like AGP. Equilibrium dialysis and ultrafiltration had been the most commonly 
implemented methods during the 1980s and 1990s, enabling the straightforward 
analysis of various in vitro and ex vivo systems (Oravcova et al., 1996).  The former 
relies upon the use of a permeable membrane (for low molecular weight structures) 
which separates two compartments - one containing the protein of interest and the 
second accommodating buffer.  The short analysis time and availability of commercial 
kits rendered ultrafiltration a useful technique in the clinical analysis of active drug 
levels.  Ultracentrifugation (Matsushita and Moriguchi, 2003), calorimetry (Aki and 
Yamamoto, 1994), liquid chromatography (Zhang et al., 2000), capillary 
electrophoresis (Jia et al., 2002) and fluorescence quenching analysis (Epps et al., 1999) 
are other valuable techniques.   
 
Increasingly implemented are forms of capillary electrophoresis (CE) - for example Jia 
and colleagues (2002) used pressure-assisted capillary electrophoresis (PACE) in 
conjunction with frontal analysis (FA).  The percentage of protein-bound drug can be 
ascertained based on the level of free drug which in turn is indicated by the frontal peak 
height.  Interest has also developed in chromatographic-based analysis e.g. HPLC (Hage, 
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2001) where immobilisation of the protein in columns is necessary to determine the 
retention of solute on the stationary phase and ascertain the percentage of drug which 
becomes bound.  CE has often been reported to allow greater throughput of samples 
however adsorption can occur at the capillary wall and it is generally considered less 
sensitive than HPLC - especially with the progress which has been made in reducing 
analysis time and the requirement of radio-labelled ligands (Oravcova et al., 1996; 
Rundlett and Armstrong, 2001).  Even more recent techniques were described in a paper 
by Xuan and Hage (2005) where AGP was immobilised onto columns to mimic the 
native form.  Such techniques have increased potential in the current climate because 
they are reusable unlike many of the column and membrane-based techniques; they 
have improved precision but still provide information regarding equilibrium and 
kinetics (Frostell-Karlsson et al., 2000).  In the current study however, it was decided to 
utilise intrinsic fluorescence techniques as reported by Parikh et al. (2000), although 
minor adaptations were required as described in more detail in chapter 3. 
 
The benefit of fluorescence-based studies over those above include its sensitivity, 
accuracy and ability to be used without prior separation of bound and unbound fractions 
(Epps et al., 1999).  Although not the most direct method to analyse binding interactions, 
only 30µg aliquots were required to perform triplicate analysis of AGP in the absence or 
presence of each drug concentration, therefore in this study less than 200µg was needed.  
Also, the methodology was preferred over dialysis techniques which risk the binding of 
hydrophobic drugs to the membrane thus reducing the accuracy of the method (Parikh et 
al., 2000).  The quick and simple fluorescence-based technique could also offer a basis 
on which to develop an assay with potential in a clinical setting.  As described in section 
3.4, intrinsic fluorescence studies detect the extent to which drugs bind proteins like 
AGP. Trp (and to a lesser extent Tyr) residues of the polypeptide backbone fluoresce 
when excited at 280nm.  The residues become masked upon the binding of a drug 
therefore causing a reduction in the florescence emitted i.e. it becomes ‗quenched‘.  
While HSA binds acidic drugs, AGP binds those basic or neutral in character, including 
methadone (Eap et al., 1990).  However, as indicated in section 1.3.4.2, caution must be 
applied as fluorescence resonance energy transfer (FRET) may occur in such studies, 
especially if the drug under investigation is known to absorb at wavelengths used in the 
analysis.  
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8.2 Results 
 
 
Previously in chapter 3 it was demonstrated using theophylline that the analysis of 
intrinsic fluorescence using a microtitre plate method adapted from the Parikh et al. 
(2000) study was useful in the investigation of drug binding to AGP.  A reduction in 
fluorescence of the Trp and Tyr residues was detected as the concentration of drug – 
and therefore binding – increased.  The method was subsequently repeated with 
methadone.  Advantageously, it required only 30µg of analyte to triplicate each AGP-
drug concentration analysis.  Therefore, all analyses were undertaken by excitation of 
the AGP and drug reaction components at 280nm, recording the emission at 340nm – 
the wavelength with which maximum fluorescence is correlated (refer to figure 3.1, 
section 3.1).  
 
Figure 8.1a indicates the reduction in fluorescence alongside increasing methadone 
concentration, thus illustrating that the level of quenching was increased but that it was 
not capable of completely quenching all fluorescence.  Figure 8.2 illustrated the effect 
the aforementioned methadone concentrations had on AGP isolated from ‗normal‘ and 
patient samples from the titration (T), harm reduction (HR), long-term methadone (LT), 
buprenorphine (B) and dihydrocodeine (D) treatment groups (figure 8.2a and 8.2b-f 
respectively).  All graphs were represented with the concentrations 50-200μM removed 
to allow a clearer representation of the effect low concentrations had on fluorescence.  It 
was discovered that in all individuals, the level of quenching was correlated with the 
concentration of methadone – quenching increased (i.e. fluorescence intensity decreased) 
as the glycoprotein samples were exposed to elevated concentrations of drug.  
Nonetheless, this effect on AGP isolated from the ‗normal‘ and patient blood samples 
attained a plateau at very high concentrations (> ~100μM) which was unlike the 
continual reduction in fluorescence detected when theophylline was used (refer to figure 
3.4, section 3.3.2).   
 
The fluorescence values recorded for AGP isolated from all available samples in the 
absence of methadone, with 1.07μM and with 250µM of the drug were summarised in 
Table 8.1 to highlight the similarity of samples (except D1) with ‗normal‘ AGP when 
analysed alone without the introduction of drug which was difficult to detect in the 
respective figures.  Reporting the values after the introduction of methadone at both a 
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low and high concentration showed there were differences in binding between the 
patient samples and ‗normal‘ AGP. 
 
The rate at which intrinsic fluorescence emitted by AGP isolated from patient samples 
declined was most pronounced at low concentrations, steadying after the introduction of 
22μM methadone.  There was therefore an indication that the binding sites available on 
AGP became saturated relatively quickly.  In spite of this, methadone did not bind all 
AGP binding sites – the continued detection of fluorescence in the presence of drug 
excess (e.g. 250μM) suggested binding sites remained available. 
   
The extent of reduction did not differ widely between patients within each group or 
between treatment groups (as illustrated in figure 8.3).  Nonetheless, the emission was 
generally lower upon the introduction of methadone than that of the ‗normal‘ (graphed 
alongside all samples) and 0.5mg/mL commercial sample (figure 8.1) suggesting that 
more binding occurred in individuals undergoing opioid-replacement therapy – 
fluorescence was quenched more effectively.   
 
Finally, analysis of AGP binding to another opioid - codeine (2.5-250μM) - was 
undertaken with commercial and normal serum AGP.  The drug was found to dissolve 
most effectively in the solvent DMSO.  Although insufficient patient AGP samples 
were available to undertake further drug binding studies, those performed using 
commercial AGP and a range of drug concentrations identical to that used previously 
for methadone and theophylline (25-2500µM) signified that the glycoprotein was 
unable to bind codeine (figure 8.4). 
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Figure 8.1. Intrinsic fluorescence at 340nm of 0.5mg/mL and 5mg/mL 
commercial AGP. AGP samples, alongside increasing concentrations of methadone 
(1.07-250μM), were excited at 280nm and the fluorescence emitted was recorded, the 
extent of reduction indicating the degree of binding. 
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a) 
 
 
b)  
 
 
Figure 8.2. Intrinsic fluorescence at 340nm of AGP isolated from ‗normal‘ 
individuals (a) and patients undergoing the titration phase of therapy (b) in the presence 
of methadone.   AGP samples, alongside increasing concentrations of methadone (1.07-
250μM), were excited at 280nm and the fluorescence emitted was recorded, the extent 
of reduction indicating the degree of binding.  
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c)  
 
 
d) 
 
 
Figure 8.2 continued. Intrinsic fluorescence at 340nm of AGP isolated from patients 
undergoing harm reduction (c) and long term methadone therapy (d) in the presence of 
methadone.  AGP samples, alongside increasing concentrations of methadone (1.07-
250μM), were excited at 280nm and the fluorescence emitted was recorded, the extent 
of reduction indicating the degree of binding. 
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e) 
 
 
f)
 
 
Figure 8.2 continued. Intrinsic fluorescence at 340nm of AGP isolated from 
patients undergoing buprenorphine (e) and dihydrocodeine therapy (f) in the presence 
of methadone.  AGP samples, alongside increasing concentrations of methadone (1.07-
250μM), were excited at 280nm and the fluorescence emitted was recorded, the extent 
of reduction indicating the degree of binding. 
Fl
u
o
re
sc
en
ce
 (
R
FU
) 
Concentration methadone (µM) 
Fl
u
o
re
sc
en
ce
 (
R
FU
) 
Concentration methadone (µM) 
199 
 
g)
 
 
 
 
Figure 8.3. Intrinsic fluorescence at 340nm of AGP isolated from ‘normal’ 
heparinised blood and opioid-replacement patients in the presence of methadone.  
AGP samples, alongside increasing concentrations of methadone (1.07-250μM), were 
excited at 280nm and the fluorescence emitted was recorded, the extent of reduction 
indicating the degree of binding. 
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Sample Fluorescence in the 
absence of methadone 
(RFU) 
Fluorescence in 
the presence of 
1.07µM 
methadone 
(RFU) 
Fluorescence in the 
presence of 250µM 
methadone (RFU) 
Commercial 
(Sigma) 
41636 38236 30620 
Normal 1 39943.5 39021 35476 
Normal 2 37784.5 37032 36138 
T1 39859 34006 30712 
T2 35992 33371 30840 
T3 36715 33020 30284 
T4 37571 31089 29182 
T5 38882 33959 29412 
HR1 39107 33280 29289 
HR2 38438 33215 29025 
HR3 33531 30023 27072 
LT1 31770 30775 27196 
LT2 33324 30252 28346 
LT4 38688 37189 31008 
LT5 39937 36241 31893 
LT6 39691 31681 27137 
LT7 38484 31538 28658 
B1 39862 30718 28227 
B2 38273 34872 31803 
B3 38492 31337 26303 
B4 37482 33940 28412 
D1 34608 32789 30363 
 
Table 8.1. Intrinsic fluorescence of AGP in absence and presence of 1.07µM 
and 250µM methadone. 
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Figure 8.4.  Intrinsic fluorescence at 340 nm of commercial AGP in the presence 
of codeine.  AGP samples, alongside increasing concentrations of codeine (2.5-250μM), 
were excited at 280nm and the fluorescence emitted was recorded, the extent of 
reduction indicating the degree of binding. 
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8.3 Discussion 
 
 
Methadone is an opioid substitute therapy implemented globally in the treatment of 
opioid dependencies and has been well documented as a favourable means of reducing 
crime and the spread of infectious disease (Ward et al., 1999). There is still 
disagreement over its success in terms of its ability to assist individuals in their quest to 
achieve complete drug abstinence.  Four years ago it was suggested that as few as 7% of 
patients may actually achieve this state annually in Scotland (McKeganey, 2006).  
Many more remain on methadone maintenance therapy long-term – their study did not 
consider this to signify those in which the treatment was successful. 
 
An explanation as to why the treatment has more success in certain individuals than 
others is essential if the therapy is to encourage and improve abstinence rates.  It is no 
easy task with numerous pharmacokinetic and pharmacodynamic factors fundamental in 
the determination of the drug‘s effect.  Differing rates of metabolism and elimination, 
which ultimately reduce the level of active drug in the blood, may be partly responsible 
for the variability in treatment success. For example, individuals expressing greater 
activity of cytochrome P450 enzymes (particularly CYP3A4) will possess lower levels 
of free active drug. 
 
Of interest to this study is the presence of in vivo drug-binding proteins such as AGP 
which forms predominantly hydrophobic interactions with basic and neutral drugs at a 
single binding site (Jia et al., 2002).  AGP binds methadone with a high affinity but low 
capacity at physiological pH.  Investigations into the binding of imipramine to AGP by 
Hervé and colleagues (1993) suggested that AGP may display variable numbers of 
binding sites, primarily determined by the variants expressed.  They reported that one 
high affinity site and two lower affinity binding sites may exist on the ORM-2A variant 
(the variant for which methadone expresses a high affinity at a single hydrophobic 
binding site).  The apparent correlation with the AGP variants expressed, suggests there 
is likely to exhibit interindividual variation in the binding of drugs like methadone to 
AGP.   
 
As many drugs reach their target site of action via the bloodstream, the presence of such 
proteins may have a significant effect on the availability of active drug; some becoming 
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bound upon contact, rendering it inactive.  The subsequent alteration of equilibrium 
between tissues affects other PK parameters including the volume of distribution (Vd) 
and elimination etc.  If binding is substantial, the level of active (unbound) drug may be 
insufficient to stimulate the pharmacological effect.  The concept has been widely 
studied for numerous drugs (for example Friedman et al., 1985; Paterson et al., 2003; 
Johnson and Smith, 2006 who studied chlorpromazine, tamoxifen and anti-tuberculosis 
drugs respectively).  It must also be remembered that the effectiveness of drugs which 
bind to AGP and other APPs will be affected during the APR to various physiological 
and pathophysiological conditions where synthesis is altered (Benedek et al., 1984) and 
atypical glycans may be expressed.  Increases in the methadone dose may be necessary 
to allow for enhanced AGP binding during the APR which, in the case of methadone, 
may prevent attainment of the MEC at the ORs causing the emergence of withdrawal 
symptoms. Upon termination of the APR, swift dosage adjustments must be made 
accordingly to prevent toxicity. 
 
It was hypothesised that alterations in the level and structure of this glycoprotein, shown 
to occur in chapters 5, 6 and 7, may enhance the affinity for methadone - inactivation of 
the drug would be exacerbated, rendering individuals susceptible to withdrawal and 
ensuing relapses.  AGP isolated from all patient blood samples did appear to bind more 
methadone, as shown by greater fluorescence quenching. Rostami-Hodjegan and 
colleagues (1999) reported that the levels of AGP in heroin dependent individuals with 
signs of opiate withdrawal were greater than in a drug free population and also showed 
a higher proportion binding to the glycoprotein when analysed ex vivo. There have 
however been no notable studies published which analysed the level and structure of 
AGP in patients undergoing opioid-replacement therapy.  Those in the initial weeks of 
titration therapy represent a study population similar to that central to the study by 
Rostami-Hodjegan and colleagues (1999); individuals commonly continue to co-
administer heroin at least until a maintenance dose of methadone is attained. 
 
As documented in chapter 5, the level of AGP isolated was greater in all patients 
compared to a ‗normal‘ population.  Fundamentally patients expressing the greatest 
levels of AGP would be expected to require the highest doses of methadone as binding 
would be expected to increase.  Instead, within the LT group, patients LT4 and 6 
demonstrated the greatest binding but were receiving 90 and 60 mg / day respectively, 
by no means the greatest doses.  One explanation could be that those with apparently 
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high levels of binding but receiving comparably low doses of methadone expressed 
fewer cytochrome P450 enzymes involved in its metabolism than those where binding 
was relatively similar but whom required much greater doses like LT2 and LT7 (150-
200mL).  The greatest reduction when comparing representative group members was 
found for LT2 and B1.  However, not all patients in these groups displayed such large 
reductions for example, LT4, LT6, and B2.   
 
Studies undertaken thus far have suggested that the glycosylation of AGP was altered in 
all patients however it was unspecific to a particular treatment group.  It was possible 
that these structural changes increased the affinity for methadone – in the absence of 
drug, fluorescence of Trp and Tyr residues of the polypeptide backbone was consistent 
with that of a ‗normal‘ AGP sample isolated from heparinised blood which suggested 
the structural alterations alone were not affecting fluorescence or location of Trp and 
Tyr therefore FRET was unlikely. Also, methadone does not absorb at wavelengths 
implemented in the intrinsic fluorescence studies so any reduction detected should be 
indicative of the binding of the drug to AGP and the effect altered glycosylation may 
have had. 
Additionally, the fluorescence reduction detected in all patients may be partly due to an 
increased expression of the ORM2A variant of AGP – the variant to which methadone 
is thought to exhibit preference (Eap et al., 1990).  As stated in the results, the reduction 
in intrinsic fluorescence was most pronounced at low concentrations suggesting 
relatively rapid uptake by the plasma protein with an apparent limit to the quenching 
effect, indicating saturation of the available binding sites.  There was very little 
variation in the extent of quenching between patients.  Unlike theophylline etc, the 
fluorescence was far from eradicated – this would have been expected had methadone 
been unspecific in its binding to the glycoprotein.  Binding sites must remain available 
otherwise the fluorescence would continue to be quenched, as shown for 
chlorpromazine and theophylline (refer to figures 3.1b and 3.4 respectively) which bind 
highly to AGP.  The relative proportions of AGP variants could not be determined for 
the patients due to insufficient samples but there was no reason not to conclude that the 
glycosylation changes which occur to this particular variant of AGP would increase its 
affinity for methadone.  The culmination of increased synthesis (as shown in chapter 5) 
and altered glycoform expression in vivo may cause substantial reduction in the active 
drug concentration in treatment groups thus necessitating dosage adjustments.  
205 
 
Selectivity is not only seen in terms of which AGP variants methadone binds but also in 
the chirality of the ligand (i.e. enantiomer) for which the glycoprotein exhibits 
preference (Muller, 1988), potentially contributing to the limitation of quenching when 
compared to that of theophylline and chlorpromazine.  Eap and colleagues (1990) have 
also documented that the enantiomers bind AGP genetic variants differently - similar to 
the traits of warfarin studied by Hervé et al (1998).  The (R) enantiomer of methadone 
expresses affinity for AGP.  However at concentrations of 250µM it is likely that there 
would be enough of the (R) enantiomer to cause a more significant decrease from the 
preceding 21µM which is approximately 10-fold lower.  In most countries, the (R) form 
of the drug is administered alongside the (S) enantiomer as a racemate which may 
partially explain why doses are so much higher (mg level) that the plasma level required 
to induce the pharmacological effect (ng level). 
 
Whether the single patient receiving dihydrocodeine was representative of all 
individuals receiving this treatment, was unknown.  Nonetheless, it was the only sample 
to have significantly different fluorescence to normal in the absence of drug suggesting 
that the structure of the molecule was altered or less was analysed.  Binding still 
occurred because the fluorescence reduced however not to the same degree as the other 
samples, again suggesting the binding site had lower affinity for the drug.   
 
It was seen that codeine was unable to bind AGP.  Although this opioid (a natural 
isomer of methylated morphine) is used in pain management and not usually in opioid-
replacement therapy for drug abuse due to its short duration of action of 2.51-3.15h 
(Yue et al., 1991), it was deemed of interest as it belongs to the same family and DHC 
could not be sourced (essentially codeine with two additional –H atoms and no double 
bond, making it more stable with greater metabolic resistance).  If considering the 
influence of AGP alone on the efficacy of methadone, a drug like codeine but with a 
longer half-life – if capable of reproducing the same effects such as withdrawal 
prevention – may be of use as an alternative treatment in those expressing high levels of 
AGP glycoforms with affinity for methadone.   
 
Finally, as reported by Parikh et al. (2000), the multi-well technique is well suited for 
high-throughput screening of drug binding at the binding site close to the integral Trp 
and Tyr residues.  The technique could be adapted for use in a clinical setting, allowing 
the clinician to perform a rapid binding assay without prior derivatisation or separation 
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of bound and unbound drug or genetic variants thus aiding in the determination of the 
likely effectiveness of the drug at doses under consideration. It may also offer use as a 
monitoring tool because it would be easy to detect alterations in the level of AGP. 
However, the technique would ultimately require adaptations for urine analysis, is likely 
to be expensive if specific structures are to be detected but also, there are likely to be 
many factors influencing the bioactive concentration of methadone including the 
expression of CYP450 enzymes involved in its metabolism thus further analysis needs 
to be undertaken regarding the interaction of all these factors if therapies are to be 
improved. 
 
 
 
SUMMARY STATEMENT 
Binding of methadone to AGP isolated from all sources was shown - using intrinsic 
fluorescence measurements - to increase with its concentration; the most apparent 
reduction in fluorescence was found at low concentrations of drug.  The degree of 
quenching was subsequently reduced at high concentrations suggesting binding sites on 
AGP became saturated.  There did not appear to be any clear interindividual variation in 
the binding of methadone to AGP isolated from patient blood samples however the 
quenching was greater than that for AGP isolated from heparinised ‗normal‘ blood.   
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Chapter 9 
Conclusions 
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9.1 Conclusions 
 
 
Opioid dependencies represent a worldwide problem not only in terms of the health of 
an abuser but to society as a whole due to associated illegal drug-seeking activities and 
unemployment.  Substitute drugs are commonly implemented in programmes targeted 
towards fighting these issues, aiding the achievement of abstinence through a safe and 
controlled manner while attaining a more stable lifestyle for the individual.  The use of 
orally administered substitute therapies also minimises the spread of potentially deadly 
blood borne viruses. 
 
Although numerous therapies are available, methadone remains that most commonly 
prescribed due to its low cost and long half-life.  The drug prevents the onset of 
withdrawal symptoms which would normally occur in the absence of the abused opioid 
and, as it belongs to the same family, it has many of the same effects as heroin therefore 
eliminating cravings and preventing the onset of withdrawal.  It does not similarly 
induce euphoria thus the ‗reward‘ associated with heroin is removed. 
 
The success of drug therapies relies on the presence of specific concentrations of its 
bioactive form (MEC) at the corresponding site of action.  Numerous factors determine 
whether this can be achieved, however often overlooked is the binding to plasma 
proteins.  Of interest to this study was AGP, a positive acute phase protein known to 
bind basic drugs including methadone (Kremmer et al., 1988).  During the APR the 
hepatic synthesis of this glycoprotein is known to increase 2-5 fold, which is well 
correlated with numerous pathological conditions including rheumatoid arthritis, 
inflammation and cancer (Fournier et al., 2000).  Alterations in its concentration are 
therefore not specific to a particular condition, unlike the glycosylation of AGP which 
may be uniquely altered.  Additionally, any structural change has the potential to affect 
the functions performed. 
 
The current preliminary study aimed to investigate whether AGP has a significant role 
in the determination of methadone activity. Of primary interest was whether the level 
and glycoform expression of AGP isolated from patients undergoing various stages and 
types of substitute therapy for opioid-dependence differed to a ‗normal‘ healthy 
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population.  It was supposed that alterations may correlate to variations in the binding of 
the glycoprotein to methadone.  Patients were recruited at the CDPS clinic in Edinburgh, 
including those undergoing titration, harm reduction, long-term methadone, 
buprenorphine, dihydrocodeine and heroin replacement.  It was hypothesised that AGP 
isolated from patients would exhibit higher levels and structural changes causing 
increased binding to methadone when compared to a ‗normal‘ AGP sample. Greater 
binding would at least partially explain why high doses of the drug are required – 
accounting for that which is bound and therefore inactivated. 
 
AGP was isolated using a two-column low-pressure chromatography technique that had 
been adapted from the methodology devised by Smith et al. (1994) to allow for low 
sample volumes and prevent degradation of the in vivo structure.  SDS-PAGE and a 
Western Blot were performed and indicated that the technique generated pure AGP.   
 
Similar to research undertaken by Rostami-Hodjegan et al. (1999), the current study 
detected increased levels of AGP expressed in individuals who displayed signs of 
withdrawal from heroin (represented by the titration group).  Recruitment of heroin-
dependent individuals who were not receiving substitute therapy was not possible.  The 
levels isolated from the patients in the remaining treatment groups – excluding the 
individual receiving heroin - were also greater than that isolated from the ‗normal‘ 
population.  An explanation may be that the presence of a xenobiotic, or the increase in 
DA release caused by the opioid agonist administered, deceives the body; causing 
stimulation of the APR or increased synthesis of AGP to aid in removal of methadone. 
 
The general hypothesis regarding heroin therapy is that maintaining the same drug in 
therapy as that abused - albeit in a more pure form, as was the case for patient H1 - may 
have prevented such a strong induction of the APR hence the low AGP level isolated 
compared to the other treatment groups.  However, the recruitment of a single patient 
was insufficient to determine whether it represented the whole group, therefore the 
accuracy of any conclusions made from the corresponding data could not be gauged.   
 
Although it is well understood that structural changes to AGP glycosylation can 
significantly affect the functions of the biomolecule, there is currently a paucity of 
research data pertaining to this effect in patients undergoing opioid-replacement therapy. 
It is well understood that AGP generally exhibits a degree of selectivity for the ligands 
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to which it binds and in terms of drugs, they are generally of the neutral or basic variety 
(Kremer et al., 1988).  If binding to methadone is altered by structural modifications to 
the glycan chains present on AGP, the free active concentrations and subsequent 
pharmacological effect could be changed.  A reduction in efficacy would become 
apparent when the affinity increases or vice versa if the affinity was reduced. 
 
The variability in the binding of methadone to AGP may partly explain why some 
individuals require more drug than others to produce the effect.  That is not to forget the 
roles of metabolism and elimination which display interindividual variability due to 
differences in gene expression.   
 
The analysis of glycan structure and composition initially required the most effective 
means of cleaving glycans into component monosaccharides to be identified.  Neutral 
monosaccharides became unstable in the presence of HCl and GlcNAc was less 
effectively cleaved by TFA, requiring instead a stronger acid.  Combining the acids, as 
performed by previous studies undertaken by the group (Smith et al., 2002; Mooney et 
al., 2006), did not provide adequate hydrolysis of the monosaccharides when analysed 
in this study therefore the methodology was adapted.  Optimal monosaccharide cleavage 
of the basic and neutral sugars was achieved by separating the use of HCl and TFA (and 
incubating for 6 and 4h respectively).  In order to detect the greatest levels of GlcN, 
hydrolysis with HCl was followed by washes with HPLC-grade water, the treated 
sample was not passed through a dowex cation-exchange column as it hindered the 
elution of the GlcN residues.  It was postulated that the additional negative charge 
displayed by the sugar after deacetylation, increased the interactions formed with the 
column.  The separate use of the acids TFA and HCl ensured the levels of Gal and 
GlcNAc were not compromised; these monosaccharides are correlated with glycan 
branching and therefore effective cleavage was important. 
 
The level of mannose remained constant which supported that differences detected in 
the other monosaccharide levels represented alterations in the structure of the chains.  
Mannose is only present in the core of complex N-linked glycans and should therefore 
remain constant when the same level of AGP from each patient was analysed; AGP 
expresses five complex N-linked glycans on the polypeptide backbone. Glycan 
structural analysis indicated that the composition of other monosaccharides was altered 
in the majority of patients.  Elevations in the level of Gal and GlcNAc in the AGP of all 
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patient groups (except D1 and H1) inferred an increase in branching occurred in the 
glycans of patient AGP.  Such an effect had not been documented previously therefore 
whether the results obtained represent other individuals undergoing similar stages and 
types of substitute therapy was unknown. 
 
There was no significant difference in the monosaccharide levels of glycans in patient 
AGP with respect to the commercial equivalent.  Nonetheless it was deemed more 
appropriate to use the ‗normal‘ heparinised blood samples as a control because 
commercially sourced AGP was isolated using a method that caused partial 
desialylation. The alternative - ‗normal‘ serum - was sourced from an elderly population 
of patients hence the expression of an APR was possible due to supplementary 
inflammatory conditions that were perhaps un-noted or undiagnosed and could therefore 
change the level and structure of AGP.   
 
Increased branching was supported in qualitative oligosaccharide analysis where the 
number of branches appeared to be higher in some AGP isolated from patients than in 
the ‗normal‘ AGP glycans.  A number of the glycans of patient AGP expressed tetra-
sialylated chains; this was not the case in the normal samples. The ELISA supported the 
finding to a degree, indicating greater SA expression for the LT patient than in the 
‗normal‘ population – the α2,3 linkage is associated with more highly branched 
structures.  However, the AGP isolated from patient HR1 did not provide sufficient 
activity to be detected and that of T1 was lower.  The level of α2,6 could not be 
ascertained therefore the complete SA content was not known.  The study indicated the 
possibility that such analytical kits could be adapted for AGP SA analysis but many 
more samples must be tested and the technique perfected. 
 
Drug binding analysis based on the methodology developed by Parikh and colleagues 
(2000) - exploiting intrinsic fluorescence on the microtitre plate scale -was shown to be 
effective.  In terms of patients, the binding increased in all when the concentration of 
methadone was increased.  The binding appeared to be enhanced when compared to a 
‗normal‘ sample however there was no clear difference between groups.  Additionally, 
in the absence of drug, fluorescence was relatively consistent to ‗normal‘ suggesting it 
was unlikely that the conformation of the binding site was altered by the presence of the 
different glycan structures. However, the fluorescence upon drug administration 
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decreased more substantially than in the ‗normal‘ sample suggesting that binding was 
affected by glycosylation.   
 
A useful comparative group would be heroin dependent individuals who are not 
receiving therapy; it may be possible to determine whether any effects seen in the 
patients were a direct result of therapy or perhaps due to underlying stresses associated 
with the illicit drug use. The apparent increase in glycan branching or length of 
branches already present may increase the affinity of AGP for the drug thereby 
explaining why some patients may require higher doses than others despite other 
pharmacokinetic parameters remaining constant.  
 
Currently treatment is based on a titration phase where individuals are given low doses 
of drug to allow for its slow accumulation.  Finally, a maintenance dose is determined.  
However, with investigations like these it may be possible to determine the relative 
level of glycoforms expressed by an individual‘s AGP to identify those where it is less 
likely to be effective or where higher doses will be required.  Also, assays may have 
potential in monitoring individuals to prevent relapses.  Therefore it may reduce the 
high risk of overdose often seen especially in the first two weeks of therapy.  However, 
any clinical test based on such analysis is likely to be expensive and potentially time-
consuming unless advances are made. The need for blood samples from which to isolate 
AGP would introduce difficulties; not only would it be invasive but a common 
consequence of i.v heroin use is collapsed veins, complicating venipuncture.  However, 
this preliminary study has shown that a potential correlation exists between the structure 
of AGP glycans and its ability to bind the basic drug methadone; although a larger 
patient population is required to address other influential factors and determine whether 
the interaction could significantly affect the efficacy of methadone in the treatment of 
opioid dependencies. 
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9.2 Future work 
 
The study presented within has highlighted the potential for the glycosylation of AGP to 
be altered in patients undergoing therapy for opioid dependence which can be correlated 
to an increased binding to methadone.  However, the study was limited by ethical 
approval as to the size of the patient cohort.  It has provided a useful preliminary study 
which could be expanded to determine if the accuracy of conclusions could be improved.  
Also, the study could be expanded in various ways to examine other aspects of the 
effect of AGP on treatment of opioid dependence. 
 
 Increase the patient population studied to determine if results from this 
preliminary study are supported. 
o Analyse female and male groups only to determine if the effect of gender 
is significant, few females were recruited as few were undergoing 
therapy. 
o Isolate AGP from a population of healthy individuals age-matched to the 
study sample to ensure all differences are due to the conditions of 
therapy. 
o Increase numbers from different therapies to determine if AGP plays a 
significant role in determining the levels of drug available. 
 Perform other forms of analysis for example Mass Spectrometry to compare the 
techniques perhaps gathering information about the peptide binding site. 
 Further in-depth analysis of the binding site conformation in the presence and 
absence of methadone to study the binding process.  
 Perform more drug binding studies using the scanning fluorescence mode to 
enable calculation of binding coefficients. 
 Drug binding studies with other treatments including dihydrocodeine alongside 
AGP isolated from all groups.  This will determine if those on methadone would 
actually benefit from another therapy because binding is less although should 
carry out studies with albumin etc to see if instead they bind to these proteins. 
 Isolate and separate the genetic variants of AGP and determine if binding greater 
to specific variant and if related to glycosylation of that variant. 
 Repeat the sialic acid ELISA with AGP samples isolated from a larger group of 
patients and determine the α(2,6) content. 
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Unfortunately in the current study it was not possible to recruit individuals whom had 
relapsed within the preceding 24 hours as they did not re-visit the clinic the following 
day.  Those that did were unwilling to participate in the study.  They had been 
considered a potentially interesting study group to determine whether the AGP level 
correlated with an increased risk of withdrawal when compared to that from individuals 
maintained long-term. 
 
Perhaps an ELISA could be developed similar to that utilised in this study to allow rapid 
determination of AGP concentration and relative branching of glycans using specific 
lectin conjugates, binding to multiwell plates.  However, no specific glycosylation 
patterns were determined for a particular treatment group thus perhaps it is most 
important to perform a drug binding assay like that described to attain information 
regarding how strongly the binds to the aberrant glycoprotein structures. 
 
This study determined the quantitative and qualitative changes in the glycosylation of 
AGP between normal and patient populations and their correlation with the degree of 
binding to methadone.  Although preliminary, results to date support the existence of a 
method of drug resistance linked to plasma protein binding and also may explain the 
often observed lack of response to methadone therapy.  Further research may aid in the 
development of improved treatment regimens to tackle the reportedly low success of 
current therapies. 
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Appendix 
The analysis of glycosylation: a continued
need for high pH anion exchange
chromatography
Jennifer L. Behan and Kevin D. Smith*
ABSTRACT: An appreciation of the structures of the oligosaccharide chains which become attached to biomolecules (the
process known as glycosylation), and their relevance to the biological function of the molecule concerned, has progressed
rapidly in recent years with developments in site-selective protein glycosylation, oligosaccharide synthesis and in vivo target-
ing of oligosaccharides. These developments have necessitated the parallel development of eﬀective analytical tools for the
determination of the structures of glycosylation. The conclusion of studies in the 1980s and 1990s was that high pH anion
exchange chromatography (HPAEC) was the most eﬀective HPLC mode for the analysis of glycosylation. It allowed the frac-
tionation of complex mixtures of monosaccharides or oligosaccharides, the latter in terms of charge, size, composition, ano-
merity and intra-chain linkages. This review reinvestigates whether HPAEC still appears to oﬀer the most eﬀective means of
analysing glycosylation. Copyright © 2010 JohnWiley & Sons, Ltd.
Keywords: HPAEC; glycosylation; biomarkers
Introduction
Glycosylation is a complex, ordered and energy-consuming
process that has become recognized as both functionally signiﬁ-
cant and responsible for presenting huge structural diversity.
Intra- and intermolecular properties such as circulatory lifespan,
immune modulation, solubility and conformation stability have
been shown to be dependent upon the expression of oligosac-
charides by glycoconjugates (Lis and Sharon, 1993; Varki, 1993).
Oligosaccharide chains are ordered structures comprising
various monosaccharides, primarily the hexoses, mannose (Man),
galactose (Gal), the deoxyhexose fucose (Fuc), and the hex-
osamines, glucosamine and galactosamine (formed by the addi-
tionof an aminogroupon carbon2of a hexose).Thehexosamines
are commonly N-acetylated to form N-acetylglucosamine
(GlcNAc) and N-acetylgalactosamine (GalNAc) respectively.
Finally,N-acetylneuraminic acid (NeuAc), a nine-carbon sialic acid,
with a formal negative charge, is commonly the terminal compo-
nent of oligosaccharide chains (Varki, 1992).
An oligosaccharide chain is synthesized by individual attach-
ment of monosaccharide components in speciﬁc sequences to
the protein or lipid biomolecule initially in the endoplasmic
reticulum (ER) lumen, then in the cis Golgi where the ﬁnal struc-
tural modiﬁcations occur (Kobata, 1992; Sasisekharan and
Myette, 2003). This synthesis andmodiﬁcation of oligosaccharide
structures is enzymatic in origin and is regulated by glycosyl-
transferases in the ER and Golgi apparatus (Rademacher et al.,
1988, Lis and Sharon, 1993).
Glycoproteins are classiﬁed by the mechanism of attachment
to the protein backbone. Glycans attached to the amide nitrogen
of asparagine (Asn) amino acids are termed N-linked structures.
This type of glycosylation only occurs when the Asn residue is
part of a consensus sequence Asn–X–Ser/Thr where X is never
proline because it hinders the formation of the important sec-
ondary structure: b turns (Avanov, 1991). O-linked glycosylation
occurs when the oligosaccharide chain is attached to the biomol-
ecule through the hydroxyl group of either a serine or threonine
amino acid. N-linked oligosaccharide chains all contain a
common pentasaccharide core (Man3GlcNAc2), as indicated in
Fig. 1. The monosaccharides attached to this can diﬀer, causing
the generation of three main families—high mannose, complex
and hybrid N-glycans (Kobata, 1992; Hashimoto et al., 2004).
O-linked glycans however are not restricted by the need for the
presence of a speciﬁc core structure; instead synthesis is com-
monly initiated in the Golgi by the transfer of GalNAc (catalysed
by an N-acetyl galactosaminyltransferase) to a Ser or Thr residue
of the peptide, followed by the action of speciﬁc transferases
which lead to the formation of various core structures. The
process does not require a preceding assembly pathway in the
ER, which is required during N-glycan synthesis (Hounsell et al.,
1996). The mucin-type O-glycans are thought to be the largest
group; GalNAc is the initiating sugar and there are six core oli-
gosaccharide structures possible (Van den Steen et al., 1998;
Sears and Wong, 1998).
One of the key sources of variability is the expression of glyco-
conjugates with the same protein or lipid structure but diﬀering
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oligosaccharide components (glycoforms). Their expression
promotes a high degree of heterogeneity which can be cell-,
organ- or tissue-speciﬁc and occurs prominently in disease. This
‘glycopathology’ (Kobata, 2000) is normally a result of alterations
to the transcription of genes encoding glycosyltransferases by
cytokines produced during the acute phase response to injury
and infection as part of the body’s defence system. Understand-
ing the potential for the expression of disease-speciﬁc glyco-
forms could be important in the development of future
treatments; perhaps oﬀering use as biomarkers for certain patho-
logical conditions.
HPLC of Glycosylated Structures
A consideration of the various HPLC stationary phases and mode
of detection has been the subject of numerous reviews including
two excellent papers in the tenth anniversary edition of this
journal (Davies and Hounsell, 1996; Lo-Guidice and Lhermitte,
1996). A further detailed consideration is outwith the scope of
this review and instead we intend to follow on from where the
latter articles concluded in that high pH anion exchange chroma-
tography (HPAEC) appeared to provide the most optimum and
eﬀectivemeans of resolving and detectingmonosaccharides and
oligosaccharides. As shown by Lee (1990), HPAEC is able to detect
sugars as low as the femtomole level and indeed pleas have been
made for lower levels of detection (Davies and Hounsell, 1996).
Recently, a major area of glycobiological research has been in
the evaluation of biomarkers or substances that can be indicative
of a biological state. HPAEC has shown great potential in high-
lighting alterations in oligosaccharide microheterogeneity which
may oﬀer use as prognostic and diagnostic biomarkers of disease
(Anderson et al., 2002; Mooney et al., 2006).
High pH Anion Exchange Chromatography
The accurate analysis of the glycosylation pattern of glycopro-
teins is essential when investigating potential disease-speciﬁc
changes and their subsequent evaluation as biomarkers of
disease diagnosis, prognosis and progression. HPAEC is capable
of providing information on both the monosaccharide and oli-
gosaccharide composition of N-linked oligosaccharides at a sen-
sitivity of 10–100 pmol (Hardy et al., 1988; Townsend et al., 1989;
Smith et al., 1997). A major advantage of the technique is that it
does not require prior derivitization or clean-up of carbohydrate
samples in order to allow quantiﬁcation (Lee, 1990).
The essence of HPAEC is a combination of a polymer-based
pellicular resin (the active component of which is a quaternary
ammonium ion), equilibrated by an alkaline mobile phase with
detection by pulsed amperometry. A large number of columns
are available containing speciﬁc modiﬁcations of the stationary
phase (Table 1) in order to impart a distinctive selectivity of analy-
sis. This stationary phase is a characterized by a high mechanical
and chemical stability. One of the ﬁrst columns developed, the
CarboPAc PA1® was a multipurpose column which could be used
for the analysis of monosaccharides, disaccharides and speciﬁc
oligosaccharides. Thereafter reﬁnements have resulted in
columns that are more sensitive for the analysis of monosaccha-
rides, disaccharides and sialic acids (CarboPAc PA10® and Carbo-
PAc PA20®), oligosaccharides (CarboPAc PA100® and CarboPAc
PA200®) and reduced monosaccharides and disaccharides
(CarboPAc MA1®).
Given that the eﬀectiveness of resolution and detection is
dependent upon the ionization of monosaccharides either indi-
vidually or as part of a larger moiety, the composition of the
mobile phase is critical to the sensitivity, selectivity and speed of
the technique. Normally the mobile phase is sodium hydroxide
a) 
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Figure 1. Simpliﬁed glycan structures. The pentasaccharide core of N-linked glycans (a) and an example
O-linked (b). Adapted from Hashimoto et al. (2004) and Lo-Guidice et al. (1994).
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with the exact concentration used being dependent on the
nature of the molecules being analysed. The analysis of oligosac-
charides and individual sialic acids, both of which interact more
strongly with the stationary phase, often requires the inclusion of
sodium acetate (or similar) which act as pushing agents to reduce
retention to the column. The inclusion of barium acetate in the
mobile phase is suggested to remove the need for column regen-
eration between runs and also eliminates carbonate formation
(Cataldi et al., 1999).
In terms of detection, the use of pulsed potentials is impor-
tant because it ensures that the gold electrode does not become
coated in, and therefore fouled by, oxides. Electrocatalytic oxi-
dation of weakly acidic sugars occurs when in contact with the
gold electrode. These oxidized sugars coat the electrode surface,
hindering detection; therefore they must be removed to ensure
reproducibility. The potential is increased and a layer of gold
oxide can form at the electrode surface thereby removing the
sugars. Upon lowering the potential, the coating is removed
because the oxide is reduced (LaCourse and Johnson, 1993). The
system consists of the application of a triple electrical pulse to
the surface of a gold electrode (Fig. 2). The ﬁrst pulse, of 0.5 s
duration (0.05 V) allows electrode equilibration which is fol-
lowed by 0.29–0.49 s of sampling time. The second pulse, 0.51–
0.6 s (0.6 V) causes full oxidation of the species on the electrode
surface to their most highly oxidized and most soluble forms,
allowing a ‘washing away’ of any contaminating species. Surface
oxidation of the electrode is inevitable for this process, thus
from 0.61–0.65 s a reducing potential is applied for the electrode
surface regeneration (-0.6 V). This ﬁnal pulse of three immedi-
ately precedes the electrode re-equilibration time of 0.0–0.29 s
(0.05 V).
HPAEC of Monosaccharides and
Oligosaccharides
Under alkaline conditions, the hydroxyl groups of a monosaccha-
ride, either individually or as part of a sequence, are ionized to
exist as negatively charged oxyanions. A monosaccharide pos-
sesses several potentially ionizable hydroxyl groups with the fol-
lowing descending hierarchy of acidity: 1-OH > 2-OH >> 6-OH >
3-OH > 4-OH. The varying location of the OH groups results in
slight diﬀerences in the pKa value (ranging from 12 to 14) of
individual monosaccharides under these conditions. The diﬀer-
ences in ionization are unique both with respect to individual
monosaccharides and also cumulatively; a sequence ofmonosac-
charides can be exploited chromatographically, using the anion
Table 1. Summary of column composition
Column Composition
CarboPAc PA1® 10 mm-diameter substrate (polystyrene 2% cross-linked with divinylbenzene) agglomerated with 500 nm
MicroBead quaternary ammonium functionalized latex (5% cross-linked)
CarboPAc PA10® 10 mm-diameter substrate (ethylvinylbenzene 55% cross-linked with divinylbenzene) agglomerated with
460 nm MicroBead™ difunctional quaternary ammonium ion (5% cross-linked)
CarboPAc PA20® 6.5 mm-diameter substrate (ethylvinylbenzene 55% cross-linked with divinylbenzene) agglomerated with
130 nm MicroBead difunctional quaternary ammonium ion (5% cross-linked)
CarboPAc PA100® 8.5 mm-diameter ethylvinylbenzene/divinylbenzene substrate (55% cross-linking) agglomerated with 275 nm
MicroBead™ quaternary amine functionalized latex (6% cross-linked)
CarboPAc PA200® 5.5 mm-diameter ethylvinylbenzene/divinylbenzene substrate (55% cross-linked) agglomerated with 43 nm
MicroBead quaternary amine functionalized latex (6% cross-linked)
CarboPAc MA1® 7.5 mm-diameter vinylbenzyl chloride/divinylbenzene macroporous substrate fully functionalized with an
alkyl quaternary ammonium group (15% cross-linked)
Figure 2. Pulsed electrochemical detection.
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exchange stationary phases and the electrochemical detector
based on pulsed potentials. The use of eluents with a pH of 12 or
higher stimulates electrocatalytic oxidation of weakly acidic
sugars when in contact with the gold electrode.
Monosaccharides
For a typicalmonosaccharide analysis, an alkaline environment of
0.03 M sodium hydroxide causes ionization and results in the for-
mation of oxyanions unique to individual monosaccharides
(Fig. 3). The interaction of the charged oxyanions with the strong
anion-exchange CarboPac™ column and the slight diﬀerences in
relative pKa values aids the chromatographic separation of indi-
vidual monosaccharides. The general rule is ‘the lower the pKa;
the longer it will be retained by the column’(Lee, 1990). Addition-
ally, a monosaccharide with an anomeric OH group, which is
more acidic than other OH groups, is less well retained than those
that do not contain anomeric OH groups, e.g. the inositols.
Typical conditions for the separation of monosaccharides
using HPAEC would be a Dionex 600™ HPAEC system (Dionex,
Camberley, UK) comprising a CarboPac PA-100 analytical 4 ¥
250 mm and guard 4 ¥ 50 mm columns, a GP50 gradient pump
and ED40 electrochemical detector (Johnson and Smith, 2006).
The pulsed potentials for the waveform are 0 s, 0.05 V; 0.29 s,
0.05 V; 0.49 s, 0.05 V; 0.5 s, 0.05 V; 0.51 s, 0.6 V; 0.6 s, 0.6 V; 0.61 s,
-0.6 V; 0.65 s, -0.6 V; and 0.66 s, 0.05 V, as shown in Fig. 2. A
typical separation of monosaccharide standards is shown in
Fig. 4, which was achieved using an isocratic separation of 0.03 M
sodium hydroxide.
In biomarker research, monosaccharide compositional analysis
has become a key tool for the rapid elucidation of changes in the
monosaccharide content of oligosaccharides or free oligosaccha-
rides that are associated with a disease or pathological condition.
Alterations in the oligosaccharide component of alpha-1-acid
glycoprotein (AGP) occur in a number of disease conditions
(Ceciliani and Pocacqua, 2007). In rheumatoid arthritis, HPAEC
monosaccharide compositional analysis has been utilized to
demonstrate that hyperfucosylation, hypersialylation and
increased chain branching of AGP glycans occur, diﬀering from
early acute stages when the content of biantennary chains is
increased (Elliott et al., 1997; Jørgensen et al., 1998). In other
studies by the same group, the determination of an increased
fucosylation of the oligosaccharide chains in rheumatoid arthritis
or burn injury either inhibited collagen ﬁbril formation (Yule
et al., 1999) or resulted in the atypical collagen deposition asso-
ciated with hypertrophic scarring (French et al., 2002). HPAEC
monosaccharide compositional analysis has proved that it is pos-
sible to distinguish individual liver diseases on the basis of their
AGP glycosylation, e.g. in hepatitis C the oligosaccharide chains
express more fucose (Fuc) residues in comparison to the other
liver diseases and also contain the rare monosaccharide
N-acetylgalactosamine (GalNAc) (Anderson et al., 2002; Mooney
et al., 2006). Further work has established not only that AGP in
chronic myeloid leukaemia has unique glycosylation that can be
correlated with severity and prognosis, but also that these alter-
ations inﬂuence the extent that AGP is able to bind to adminis-
tered drugs in the plasma and reduce their therapeutic eﬀect
(Jørgensen et al., 2002).
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Figure 3. An example of an oxyanion (mannose).
Figure 4. An example of HPAEC trace for separation of knownmonosaccharide stan-
dards. Fuc, fucose; IS, internal standard (2-deoxy-D-galactose); GalN, galactosamine;
GlcN, glucosamine. Gal, galactose; Glc, glucose; Man, mannose.
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Reduced Monosaccharides
Historically, the application of HPAEC to glycosylation analysis
faltered when the analyte of interest either existed, or was
released, in a reduced form. Recently Sim et al. (2009) have pro-
posed that the HPAEC determination of sorbitol could be a
screening tool to identify diabetic neuropathy. The author tested
four anion-exchange columns (CarboPac PA1, CarboPac PA20 and
CarboPac MA1 all from Dionex, and a MetrocepCarb1 from
Metrohm) and concluded that the MetrocepCarb1 column was
the most eﬃcient for the analysis of sorbitol. They also deter-
mined that the most eﬀective PAD waveform consisted of six
potentials.
Bardotti et al. (2000) used the CarboPac MA1 column to quan-
tify ribitol in a conjugate vaccine for Haemophilus inﬂuenzae type
b (Hib-CRM; PRP oligosaccharides linked to cross reacting mate-
rial of non-toxic diphtheria toxin variant) after TFA hydrolysis and
subsequent chromatographic separation. This analysis allowed
accurate monitoring of free saccharide in the formulated conju-
gate both alone and when combined with other vaccines—due
to the requirement of only nanomole levels.
Sialic Acids
Sialic acids are a group of sugars which terminate O-linked and
N-linked complex and hybrid glycan chains, two common to such
glycans areN-acetyl- andN-glycolyl-neuraminic acid, which diﬀer
only by the presence or absence of one hydroxyl (-OH) group.
These residues carry a formal negative charge which results in a
strong interaction with anion-exchange resins. The subsequent
removal from the strong charge interaction with the stationary
phase requires more robust conditions; an increasing sodium
acetate linear gradient is useful (50–250 mM over 30 min in addi-
tion to sodium hydroxide (100 mM). Such conditions are able to
separate N-acetyl- and N-glycolyl-neuraminic acid but not indi-
vidual N- or O-acetylated variants (Smith et al., 1997).
Oligosaccharides
In this instance, the alkaline environment created during HPAEC
allows the eﬃcient separation of oligosaccharide chains on the
basis of their size, formal charge, monosaccharide composition
and intra-chain linkages (Hardy and Townsend, 1988). The appli-
cation of oligosaccharide chains to an anion-exchange column
results in the negatively charged oligosaccharides binding
strongly to the positively charged beads of the column resin.
Subsequent removal from the column requires the addition of an
eluent that can compete with the oligosaccharides for the posi-
tively charged beads and displace them from the resin. The
strong interaction of the negatively charged NeuAcwith the qua-
ternary ammonium-bonded pellicular resin used in HPAEC
ensures that stronger elution conditions are required to displace
the charged molecules from the column (Smith et al., 1997).
This is achieved through the addition of a sodium acetate gradi-
ent; the greater the negative charge (greater the number of
NeuAc), the higher the sodium acetate concentration required to
displace the oligosaccharides from the column. It is possible for
the oligosaccharides to be separated at a lower pH (4.6) purely on
the basis of their NeuAc content (Townsend et al., 1988), but the
additional oxyanion charge at alkaline pH enhances resolution of
the oligosaccharide mixture by allowing separation of the chains
based on isomeric diﬀerences (Townsend et al., 1989).
Sialylated Oligosaccharides
The sialylated portion of the oligosaccharide allows separation of
the chains into distinct charge bands; the greater the number of
sialic acids, the greater the overall negative charge, resulting in a
longer retention time. Within these charge bands, the oligosac-
charides can be separated according to size with larger structures
demonstrating greater retention times. On this basis,
bi-antennary, bi-sialylated structures will elute earlier than tri-
antennary, bi-sialylated structures (Fig. 5). It is also possible for
this technique to detect and successfully separate structures
within charge bands which diﬀer in one linkage. NeuAc can be
linked either a (2, 6) or a (2, 3) to an outer galactose (Gal) residue.
The presence, or increased proportion, of a (2, 6) NeuAc-linked
chains results in a reduction in retention time (Townsend et al.,
1988). It is thought that, when NeuAc is added with a (2, 6), the
oxyanion eﬀect of the 6-OH of Gal is blocked, resulting in an
overall reduction in charge and a decrease in the retention time
when compared with a (2, 3)-linked NeuAc (Townsend et al.,
1989).
Figure 5. A standard HPAEC trace of AGP.
The analysis of glycosylation
Biomed. Chromatogr. 2010 View this article online at wileyonlinelibrary.comCopyright © 2010 John Wiley & Sons, Ltd.
Within each charge band, further separation based on the
neutral portion of the oligosaccharide can also be achieved. This
is demonstrated by the greater retention time of sialylated struc-
tures containing Galb (1,3) linked to GlcNAc compared with Galb
(1,4)-linked (Townsend et al., 1988, 1989). It was suggested that
this diﬀerence in retention time was due to the conformation of
theOHgroups in the Galb (1,3)-GlcNAc, allowing for greater inter-
action with the column. The presence of Fuc on an oligosaccha-
ride chain has also been shown to aﬀect retention time, reducing
it quite considerably. It is thought that this is due to a ‘masking’
eﬀect of the charges present on surrounding monosaccharides
and therefore a reduction in the overall charge of the oligosac-
charide (Hardy and Townsend, 1988; Lee, 1990).
In general the analysis of oligosaccharides by HPAEC is very
similar to monosaccharide analysis except with respect to the
mobile phase. The column is initially regenerated over two
20 min cycles using 50% 1 M NaOH and 50% HPLC-grade water
and then equilibrated for 10 min using 10% NaOH–5% 1 M
NaOAc–85% HPLC-grade water (v/v). The sample then separates
during a linear gradient over 45 minwhen the eluent proportions
are 10% NaOH–20% NaOAc–70% HPLC-grade water (v/v). The
column is regenerated over 10 minwith an eluent composition of
50% NaOH–50% HPLC-grade water (v/v). The ﬁnal equilibration
step, lasting 5 min, requires 10% NaOH–5% NaOAc–85% HPLC-
grade water (v/v) (Elliott et al., 1997; Smith et al., 1997).
Neutral Oligosaccharides
In 1988, Hardy and Townsend reported on the ability of HPAEC-
PAD to separate neutral oligosaccharides by their molecular size,
sugar composition and linkage type. Two identical pentasaccha-
ride chains, diﬀering only by one residue were resolved; one had
a glucose (Glc) residue and the other an N-acetylglucosamine
(GlcNAc). The Glc-containing chain eluted more slowly than its
GlcNAc-containing counterpart. They explained this by suggest-
ing that the 3-OH group of GlcNAc was less acidic than the 2-OH
of Glc, or perhaps the Glc group was able to interact with the
stationary phase more readily than GlcNAc. When an oligosac-
charide expressed more 1,6 linkages, it was suggested that its
increased rotational freedom allowed it to interact with the pel-
licular resin more strongly. It is possible using the HPAEC-PAD
technique to detect picomole levels of underivitized oligosaccha-
rides. Hardy and Townsend were able to separate positional iso-
meric oligosaccharides and glycopeptides, and also detect
reducing and non-reducing underivitized carbohydrates in the
pmol range. The use of an alkyl- or amine-bonded stationary
phase allows the separation of neutral oligosaccharides diﬀering
by one monosaccharide; however, if they diﬀer only in the posi-
tion of the linkage to a single monosaccharide, it is far harder to
separate eﬀectively (Dua and Bush, 1984; Tomiya et al., 1987;
Mellis and Baenziger, 1983; Blanken, et al., 1985).
Anumula and Taylor (1991) separated acidic (asialylated) and
neutral (asialo-complex and high-mannose) oligosaccharide
chains chromatographically, after cleavage from polypeptide
backbones using peptide N-glucosidase F, endo-b-N-
acetylglucosaminidase F and endo-b-N-acetylglucosaminidase
H. The separation required a polymeric anion-exchange column
HPIC-AS6/CarboPac PA-1 (Dionex), protected by a CarboPAc
guard column and 0.5 M NaOH and 3% acetic acid–NaOH pH 5.5
as eluents, producing a varied gradient when mixed with water.
The oligosaccharides were quantiﬁed—the technique sensitive
enough to detect <5 pmol—through the use of PAD.
When Fuc and GlcNAc are both present in amolecule, it is likely
that the hydrophobic methyl and acetyl groups, respectively,
prevent the interaction of the oligosaccharide anion with the
column matrix.
Routier et al. (1998) compared the use of chromatography and
lectin-based assays in the quantiﬁcation of oligosaccharides
released from IgGwhichwere puriﬁed from the serum of patients
suﬀering from rheumatoid arthritis. This was to determine the
percentage of glycoforms expressing no Gal, one Gal or two Gal.
In some experiments they used reverse-phase or normal-phase
columns for HPLC—after protease digestion and glycosamini-
dase A oligosaccharide release, or hydrazinolysis treatment
by exoglycosidases and a Biogel P4 chromatography of
2-aminobenzamide derivatives, or release of oligosaccharides
using PNGaseF and Biogel P4 chromatography of 2-AB deriva-
tives or HPAEC-PAD of native oligos. The change in glycosylation
proﬁle of IgG can be useful in developing a diagnostic test for the
rheumatic diseases.
The ability of HPAEC to resolve neutral oligosaccharides is per-
fectly demonstrated (McGuire et al., 1996) when applied to the
resolution of the asialylated and agalactosylated biantennary
present on immunoglobulin G (IgG).
McGuire et al. (1996) investigated the resolution of neutral oli-
gosaccharides in IgG by analysing the eﬀect of alterations to the
sodium acetate concentration gradient; the less extreme the gra-
dient, the better the resolution of the neutral oligosaccharides
(Fig. 6). The most eﬀective was an isocratic mixture of 25%
A–0.5% B–4.5% C (where A denotes 1 M sodium hydroxide, B is
1 M sodium acetate, and C is HPLC-grade water) for 40 min fol-
lowed by regeneration by elution with 50% A–50% C, which
enabled resolution of peaks indistinguishable under more severe
acetate conditions at a linear gradient, e.g. 10%A–2% B–88%C to
10% A–14% B–76% C over 57 min or 10% A–5% B–85% C to 10%
A–20% B–70% C over 40 min.
Glycoforms
When glycoproteins possess identical amino acid sequence but
diﬀerent glycan components, they are known as glycoforms. A
DNA Pac™ PA-100 column has been proposed that allows the
separation of glycoforms of the same glycoprotein which, like the
columns described for oligosaccharide and monosaccharide
analysis, is a pellicular anion-exchange column. Its ability to dis-
tinguish between diﬀerent levels of sialic acid expression is useful
in distinguishing sialylated glycoforms of glycoprotein and gly-
copeptides (Rohrer and Avdalovic, 1996; Rohrer, 1994). Those
with low sialylation are less well retained by the column and thus
elute earlier. The study by Rohrer (1994) indicated that glyco-
forms of fetuin can be separated by the structure of the sialylated
glycans attached.
It is also possible to resolve glycoforms with the same degree
of sialylation, but expressing the residues on diﬀerent branches.
The use of CarboPac™ PA-100 columns for the resolution of struc-
tures within a group of glycoforms is dependent on the diﬀering
sialylation. It is possible to initially separate sialylated glycoforms
with a DNA Pac™ PA-100 column and treat the fractions with
PNGaseF to release the oligosaccharides, resolving the sialylated
structures within the glycoform fraction (Townsend and Hardy,
1991; Rohrer et al., 1993).
This technique was applied to human serum transferrin glyco-
forms (Dionex application note 105) where they reported that,
after digested of fractions eluted from the DNA Pac™ PA-100
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column with PNGaseF, the sialylated oligosaccharides were
resolved by degree of sialylation, as seen by the retention times
of each peak. Neuraminidase was used to remove sialic acid resi-
dues fromPNGaseF F digestions to show that the peaks represent
sialylation of glycans during HPAEC-PAD analysis. The retention
times of sialylated glycans were reduced.
The Future
The development and emergence of high pH anion exchange
chromatography coupled with pulsed amperometry has revolu-
tionized the analysis of the glycosylated components of biomol-
ecules by oﬀering highly sensitive detection and eﬀective
separation without the need for derivitization. Even at the
present time of writing, more than 20 years after its introduction
and without any major change in the mechanisms of separation
or detection, the use of HPAEC is widespread and still competitive
with other techniques. A recent study (Adamo et al., 2009) con-
cluded that sensitivity of HPAEC inmonosaccharide and oligosac-
charide compositional analysis of IgGwas almost identical to, and
compared favourably with, both capillary electrophoresis–laser
induced ﬂuorescent detection and reverse-phase HPLC coupled
to electrospray mass spectrometry. The coupling of HPAEC with
mass spectrometry has been accomplished and utilized in several
studies (Okinaga et al., 1992; Barr et al., 1991); however, MS is still
usually undertaken oﬄine due the high salt concentration of the
mobile phase.
To date, HPAEC still appears to be the most commonly used
and sensitive technique available in the investigation of the oli-
gosaccharide chains of glycoconjugates after enzymatic or
chemical release. Not only has it revolutionized the analysis of
monosaccharides and oligosaccharides in general, but it has also
provided the technology required to investigate and identify
alterations in glycosylation that are diagnostically signiﬁcant as
biomarkers of disease processes.
Recently, a major area of interest for researchers seeking the
identiﬁcation of biomarkers for breast cancer has involved the
‘mapping’ of a tissue (Dwek and Alaiya, 2003). Although the pro-
teomic (mapping a tissue or cell according to the proteins it
expresses) approach to cancer biomarkers has yielded important
and fruitful results, recent research has also started to focus on
post-translational modiﬁcations of proteins, rather than protein
expression. Given that more than half of all proteins present in
serum are glycosylated and the same glycoprotein can exist as a
glycoformpopulation, there is a real requirement for an analytical
tool which is able to identify subtle but signiﬁcant alterations in
glycosylation consistent with the pathogenesis of a disease.
HPAEC satisﬁes this requirement both for the analysis of glycosy-
lation in general and in the investigation of disease biomarkers in
particular and the potential is still ongoing and appears positive.
References
Adamo M, Qiu D, Dick Jr LW, Zeng M, Lee A-H and Cheng K-C. Evaluation
of oligosaccharide methods for carbohydrate analysis in a fully
human monoclonal antibody and comparison of the results to the
monosaccharide composition determination by a novel calculation.
Journal of Pharmaceutical and Biomedical Analysis 2009; 49: 181–192.
Anderson NE, Pollacchi A, Hayes P, Therapondos G, Newsome P, Boyter A
and Smith KD. A preliminary evaluation of the diﬀerences in the gly-
cosylation of alpha-1-acid glycoprotein between individual liver dis-
eases. Biomedical Chromatography 2002; 16: 365–372.
Anumula KR and Taylor PB. Rapid characterization of asparagine-linked
oligosaccharides isolated from glycoproteins using a carbohydrate
analyzer. European Journal of Biochemistry 1991; 195: 269–280.
Avanov. Conformational aspects of glycosylation.Molecular Biology 1991;
25: 237–249.
Bardotti A, Ravenscroft N, Ricci S, D’Ascenzi S, Guarnieri V, Averani G and
Constantino P. Quantitative determination of saccharide in Haemo-
philus inﬂuenzae type b glycoconjugate vaccines, alone and in com-
bination with DPT, by use of high-performance anion-exchange
chromatography with pulsed amperometric detection. Vaccine 2000;
18: 1982–1993.
Barr JR, Anumula KR, Vettese MB, Taylor PB and Carr SA. Structural classi-
ﬁcation of carbohydrates in glycoproteins by mass spectrometry and
high-performance anion-exchange chromatography. Analytical Bio-
chemistry 1991; 192: 181.
Blanken WM, Bergh MLE, Koeppen PL and Van den Eijnden DH. High-
pressure liquid chromatography of neutral oligosaccharides: eﬀects
of structural parameters. Analytical Biochemistry 1985; 145: 322–330.
Cataldi TDR, Campa C, Angelotti M and Bufo SA. Isocratic separations of
closely-related mono- and disaccharides by high-performance anion-
exchange chromatography with pulsed amperometric detection
Figure 6. Separation of oligosaccharide chains from IgG. A, unknown; B, agalactosy-
lated fucosylated biantennary; C, agalactosylated, biantennary; D, monogalactosy-
lated biantennary (with bisecting GlcNAc); E, bigalactosylated biantennary (with
fucose and bisecting GlcNAc); F, bigalactosylated biantennary (with bisecting GlcNAc).
The analysis of glycosylation
Biomed. Chromatogr. 2010 View this article online at wileyonlinelibrary.comCopyright © 2010 John Wiley & Sons, Ltd.
using dilute alkaline spiked with barium acetate. Journal of Chroma-
tography A 1999; 855: 539–550.
Ceciliani F and Pocacqua V. The acute phase proteina1-acid glycoprotein:
a model for altered glycosylation during diseases. Current Protein and
Peptide Science 2007; 8: 91–108.
Davies MJ and Hounsell EF. Carbohydrate chromatography: towards yoc-
tomole sensitivity. Biomedical Chromatography 1996; 10: 285–289.
Dua VK and Bush CA. Resolution of some glycopeptides of hen ovalbumin
by reverse-phase high-pressure liquid chromatography. Analytical
Biochemistry 1984; 137(1): 33–40.
Dwek MV and Alaiya A. Proteome analysis enables separate clustering of
the normal breast, benign breast and breast cancer tissues. British
Journal of Cancer 2003; 89: 305–307.
Elliott MA, Elliott HG, Gallagher K, McGuire J, Field M and Smith KD. Inves-
tigation into the Concanavalin A reactivity, fucosylation and oligosac-
charide microheterogeneity of a1-acid glycoprotein expressed in the
sera of patients with rheumatoid arthritis. Journal of Chromatography:
Biomedical Applications 1997; 688: 229–237.
French D, Watson J, McCahill B, Taggart IM and Smith KD. A preliminary
evaluation of the functional signiﬁcance of alpha-1-acid glycoprotein
glycosylation on wound healing. Biomedical Chromatography 2002;
16: 412–419.
HardyMR and Townsend RR. Separation of positional isomers of oligosac-
charides and glycopeptides by high-performance anion-exchange
chromatography with pulsed amperometric detection. Proceedings of
the National Academy of Science 1988; 85: 3289–3293.
Hardy MR, Townsend RR and Lee YC. Monosaccharide analysis of glyco-
conjugates by anion exchange chromatography with pulsed ampero-
metric detection. Analytical Biochemistry 1988; 170: 54–62.
Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR,
Poland DCW, van Dijk W, Kuwano H, Kochibe N and Yazawa S. a1-Acid
glycoprotein fucosylation as a marker of carcinoma progression and
prognosis. Cancer 2004; 101: 2825–2836.
Hounsell EF, Davies MJ and Renouf D. O-linked protein glycosylation
structure and function. Glycoconj Journal 1996; 13(1): 19–26.
Johnson D and Smith KD. The eﬃcacy of certain anti-tuberculosis drugs is
aﬀected by binding to a-1-acid glycoprotein. Biomedical Chromatog-
raphy 2006; 20, 551–60.
Jørgensen HG, Elliott MA, Watson J and Smith KD. a1-Acid glycoprotein
derived from the human hepatoma cell line HepG2, and which over-
expresses fucose, can function as a ligand for E-selectin. Pharmaceu-
tical and Pharmacological Communications 1998; 4: 123–127.
Jørgensen HG, Elliott MA, Paterson S, Holyoake TL and Smith KD. Binding
of imatinib by a1-acid glycoprotein. Blood 2002; 100: 367–369.
Kobata A. Structures and functions of the sugar chains of glycoproteins.
European Journal of Biochemistry 1992; 209(2): 483–501.
Kobata A. A journey to the world of glycobiology. Glycoconjugate Journal
2000; 17: 443–464.
LaCourse WR and Johnson DC. Optimization of waveforms for pulsed
amperometric detection of carbohydrates based on pulsed voltam-
metry. Analytical Chemistry 1993; 65: 50–55.
Lee YC. High-performance anion-exchange chromatography for carbohy-
drate analysis. Analytical Biochemistry 1990; 189: 151–162.
Lis H and Sharon N. Protein glycosylation: structural and functional
aspects. European Journal of Biochemistry 1993; 218: 1–27.
Lo-Guidice J-M and Lhermitte M. HPLC of oligosaccharides in glycobiol-
ogy. Biomedical Chromatography 1996; 10: 290–296.
Lo-Guidice J-M, Wieruszeski J-M, Lemoine J, Verbert A, Roussel P and
Lamblin G. Sialylation and sulfation of the carbohydrate chains in
respiratory mucins from a patient with cystic ﬁbrosis. Journal of
Biology Chemistry 1994; 269(29) 18794–18813.
McGuire JM, Douglas M and Smith KD. The resolution of the neutral
N-linked oligosaccharides of IgG by high pH anion-exchange chroma-
tography. Carbohydrate Research 1996; 292(4): 1–9.
Mellis SJ and Baenziger JU. Size fractionation of anionic oligosaccharides
and glycopeptides by high-performance liquid chromatography.
Analytical Biochemistry 1983; 134(2): 442–449.
Mooney P, Hayes P and Smith KD. The putative use of a-1-acid glycopro-
tein as a non-invasive marker of ﬁbrosis. Biomedical Chromatography
2006; 20: 1351–1358.
Okinaga T, Ohashi Y and Hoshi M. A novel saccharide structure, Xyl 1→3
Gal 1→ (SO3-)3, 4 Fuc→, is present in acrosome reaction-inducing
substance of the starﬁsh, Asterias amurensis. Biochemistry and Bio-
physics Research Communications 1992; 186(1): 405–410.
Rademacher TW, Parekh RB and Dwek RA. Glycobiology. Annual Reviews
of Biochemistry 1988; 57: 785–838.
Rohrer J. Improved fractionation of sialylated glycopeptides by pellicular
anion-exchange chromatography. Journal of Chromatography A 1994;
667: 75–83.
Rohrer J and Avdalovic N. Separation of human serum transferrin iso-
forms by high-performance pellicular anion-exchange chromatogra-
phy. Protein Expression and Puriﬁcation 1996; 7: 39–44.
Rohrer JS, Cooper GA and Townsend RR. Identiﬁcation, quantiﬁcation,
and characterization of glycopeptides in reversed-phase HPLC sepa-
rations of glycoprotein proteolytic digests. Analytical Biochemistry
1993; 212: 7–16.
Routier FH, Housell EF, Rudd PM, Takahashi N, Bond A, Hay FC, Alavi A,
Axford JS and Jeﬀeris R. Quantitation of the oligosaccharides of
human serum IgG from patients with rheumatoid arthritis: a critical
evaluation of diﬀerent methods. Journal of Immunological Methods
1998; 213: 113–130.
Sasisekharan R and Myette JR. The sweet science of glycobiology. The
American Scientist 2003; 91: 432–441.
Sears P and Wong C-H. Enzyme action in glycoprotein synthesis. Cellular
and Molecular Life Science 1998; 54: 223–252.
Sim H-J, Jeong J-S, Kwon H-J, Kang TH, Park HM, Lee Y-M, Kim SY and
Hong S-P. HPLC with pulsed amperometric detection for sorbitol as a
biomarker for diabetic neuropathy. Journal of Chromatography B
2009; 877: 1607–1611.
Smith KD, Hounsell EF, McGuire JM, Elliott MA and Elliott HG. Structural
elucidation of the N-linked oligosaccharides of glycoproteins using
high pH anion-exchange chromatography. In Advances in Macromo-
lecular Carbohydrate Research, Volume 1, Sturgeon RJ (ed.). Elsevier:
Amsterdam, 1997.
Tomiya N, KuronoM, Ishihara H, Tejima S, Endo S, Arata Y and Takahashi N.
Structural analysis of N-linked oligosaccharides by a combination of
glycopeptidase, exoglycosidases, and high-performance liquid chro-
matography. Analytical Biochemistry 1987; 163(2): 489–499.
Townsend RR and Hardy MR. Analysis of glycoprotein oligosaccharides
using high-pH anion exchange chromatography. Glycobiology 1991;
1: 139–147.
Townsend RR, Hardy MR, Hindsgaul O and Lee YC. High-performance
anion-exchange chromatography of oligosaccharides using pellicular
resins and pulsed amperometric detection. Analytical Biochemistry
1988; 174: 459–470.
Townsend RR, Hardy MR, Cumming DA, Carver JP and Bendiak B. Separa-
tion of branched sialylated oligosaccharides using high-pH anion-
exchange chromatography with pulsed amperometric detection.
Analytical Biochemistry 1989; 182: 1–8.
Van den Steen P, Rudd PM, Dwek RA and Openakker G. Concepts and
principles of O-linked glycosylation. Critical Reviews in Biochemistry
and Molecular Biology 1998; 33(3): 151–208.
Varki A. Diversity in the sialic acids. Glycobiology 1992; 2: 25–40.
Varki A. Biological roles of oligosaccharides: all of the theories are correct.
Glycobiology 1993; 3: 97–130.
Yule FSB, Watson J and Smith KD. In-vitro eﬀects of a1-acid glycoprotein
on collagen ﬁbril formation in rheumatoid arthritis. Pharmaceutical
and Pharmacological Communications 1999; 5: 507–510.
J. L. Behan and K. D. Smith
Biomed. Chromatogr. 2010View this article online at wileyonlinelibrary.com Copyright © 2010 John Wiley & Sons, Ltd.
